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Obesity is closely associated with insulin resistance, which is a pathophysiologic condition 
contributing to the important co-morbidities of obesity, such as the metabolic syndrome 
(MetS) and type 2 diabetes mellitus (T2DM). However, not all obese subjects develop insulin 
resistance. In obese subjects, adipose tissue is characterized by inflammation with 
macrophage infiltration and increased expression of signalling peptides (adipocytokines) 
counteracting insulin action, as well as decreased expression of insulin-sensitizing molecules. 
Increased liver fat accumulation, without excessive alcohol consumption or other known 
causes of liver disease, is also associated with obesity and insulin resistance. The latter 
condition is defined as non-alcoholic fatty liver disease (NAFLD). It is unknown whether and 
how insulin resistance is associated with altered expression of adipocytokines in adipose 
tissue, and whether adipose tissue inflammation and NAFLD coexist independent of obesity. 
Genetic factors could explain variation in liver fat independent of obesity but the heritability 
of NAFLD is unknown. 
 
The present studies were undertaken to determine whether acute regulation of adipocytokine 
expression by insulin in adipose tissue is altered in obesity. The studies also aimed to 
investigate the relationship between adipose tissue inflammation and liver fat content 
independent of obesity. In addition, heritability of serum alanine aminotransferase (ALT) 
activity, a surrogate marker of liver fat, was assessed. 
 
A total of 55 normal-weight and obese non-diabetic and healthy volunteers were recruited for 
studies I-IV. For study V, 313 healthy individual twins were recruited from a large 
population-based cohort. In studies I and II, subcutaneous adipose tissue biopsies were 
obtained for measurement of gene expression before and during 6 hours of euglycemic 
hyperinsulinemia. In studies III and IV, liver fat content was measured by proton magnetic 
resonance spectroscopy (1H-MRS), and adipose tissue inflammation was assessed by gene 
expression, immunohistochemistry and lipidomics analysis. In study V, genetic factors 
contributing to serum ALT activity were determined by statistical heritability modeling. 
 
Studies I and II demonstrated that during in vivo insulin infusion the expression of genes 
related to insulin sensitivity remains unchanged, while the expression of genes related to 
insulin resistance and inflammation increases in obese and insulin-resistant subjects compared 
to insulin-sensitive subjects. Studies III and IV demonstrated that adipose tissue inflammation 
is associated with liver fat content independent of obesity. Adipose tissue of subjects with 
high liver fat content is characterized by increased number of macrophages and increased 
expression of inflammatory genes, as well as by increased concentrations of ceramides and 
long-chain triacylglycerols (TAG) when compared to equally obese subjects with normal liver 
fat. Study V verified significant heritability for serum ALT activity. 
 
In conclusion, the effects of insulin infusion on adipose tissue gene expression in obese and 
insulin-resistant subjects are not only characterized by hyporesponse of insulin sensitivity 
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genes but also by hyperresponse of insulin resistance and inflammatory genes. This suggests 
that in obesity, the impaired insulin action contributes or self-perpetuates alterations in 
adipocytokine expression in adipose tissue. Adipose tissue inflammation, defined by 
increased infiltration of macrophages and expression of inflammatory genes, is increased in 
subjects with high liver fat compared to equally obese subjects with normal liver fat content. 
Ceramides, the putative mediators of insulin resistance, are also the most upregulated lipid 
species in lipidomics analysis of adipose tissue in subjects with high liver fat. In addition, 
genetic factors contribute significantly to variation in serum ALT activity, a surrogate marker 
of liver fat. These data imply that adipose tissue inflammation and increased liver fat content 





Obesity is closely associated with increasing insulin resistance, which is an important 
pathophysiologic condition contributing to clinically important co-morbidities of obesity, 
such as the MetS and T2DM (Kahn and Flier 2000). However, not all obese subjects are 
insulin-resistant or develop the MetS, and the reasons for this are poorly understood. 
 
Adipose tissue is not merely a passive depot for storage of excess energy mainly in the form 
of TAG, but also a metabolically active endocrine organ secreting numerous peptides called 
adipocytokines (Kershaw and Flier 2004). Adipose tissue has been shown to be inflamed and 
infiltrated by inflammatory macrophages in obese mice and humans compared to lean 
counterparts (Weisberg et al. 2003, Xu et al. 2003b). The expression and production of 
proinflammatory adipocytokines, such as tumor necrosis factor α (TNFα), interleukin 6 (IL-6) 
and monocyte chemoattractant protein 1 (MCP-1), by adipose tissue have been shown to be 
increased in obese and insulin-resistant subjects. Adipose tissue inflammation and 
adipocytokines may cause both local and systemic insulin resistance. On the other hand, in 
vitro studies and animal models have suggested that regulation of some genes may retain 
sensitivity to insulin action even under insulin-resistant states (Sartipy and Loskutoff 2003). 
To date, the triggers of adipose tissue inflammation and mechanisms by which adipose tissue 
inflammation relates to whole body insulin resistance in humans are incompletely understood. 
 
Accumulation of excess fat in the liver (i.e. steatosis), not caused by alcohol or other known 
causes of liver disease, is defined as NAFLD (Neuschwander-Tetri and Caldwell 2003). The 
fatty liver in NAFLD is insulin-resistant and produces excess amounts of both glucose and 
very low-density lipoproteins (VLDL) (Ryysy et al. 2000) leading to hyperglycemia, 
hyperinsulinemia and hypertriglyceridemia (Seppälä-Lindroos et al. 2002, Adiels et al. 2006). 
NAFLD is closely related to all components of the MetS independent of obesity (Kotronen 
and Yki-Järvinen 2008). The increased release of free fatty acids (FFA) and uncontrolled 
production of adipocytokines by inflamed and insulin-resistant adipose tissue may contribute 
to liver fat content. However, it is unknown whether adipose tissue inflammation and fat 
accumulation in the liver are related independent of obesity. Concerning causes of liver fat 
accumulation in NAFLD, acquired and environmental factors, such as changes in body 
weight, have been shown to contribute. Studies assessing the effects of genetic factors on 
variation in liver fat content are limited. 
 
The present studies aimed to assess the acute effects of insulin on adipose tissue expression of 
genes associated with insulin sensitivity, insulin resistance and inflammation in healthy 
insulin-sensitive and insulin-resistant subjects. The aim was also to determine whether 
adipose tissue inflammation is related to liver fat content independent of obesity and whether 
there are differences in infiltration of macrophages and gene expression in adipose tissue 
between equally obese subjects with normal or high liver fat content. In addition, the 
heritability of serum ALT activity, a surrogate marker of liver fat, was determined in healthy 
young adult twins. 
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REVIEW OF THE LITERATURE 
1. Lipid and glucose metabolism under normal physiological 
conditions 
1.1. Adipose tissue 
Adipose tissue is, in addition to skeletal muscle and the liver, one of the three main insulin 
target tissues (Yki-Järvinen 1993). The key function of adipose tissue is the storage of excess 
energy in the form of triacylglycerols (TAG), and when needed, mobilization of TAG for 
delivery to other tissues, such as skeletal muscle and the liver, for energy production. 
Depending on the nutritional state, TAG stores are increased or mobilized. Insulin is the key 
regulator of metabolism of fatty acids (FA) in adipose tissue (Duncan et al. 2007). In addition, 
adipose tissue functions as an autocrine, paracrine and endocrine organ secreting 
adipocytokines that mediate inflammation and regulate insulin action (Kershaw and Flier 
2004). 
1.1.1. Triacylglycerol storage and release 
The fasting state. In the fasting state (i.e. in the postabsorptive phase), circulating 
concentrations of glucose and insulin are low. Lipoprotein lipase (LPL) is an enzyme located 
on the luminal side of endothelial cells of adipose tissue capillaries catalyzing lipolysis of 
VLDL and chylomicrons (Scow et al. 1980). During this intravascular lipolysis, part of the 
hydrolyzed FFA are released directly into the blood stream (Frayn et al. 1995), a phenomenon 
called FFA spillover (Miles and Nelson 2007, Ruge et al. 2009). Activity of LPL is regulated 
by insulin and is low in the fasting state. Low insulin concentration, on the other hand, allows 
hormone sensitive lipase (HSL), the major intracellular lipolytic enzyme inside adipocytes 
(Frayn et al. 2003), to hydrolyze adipocyte TAG stores together with adipose triacylglycerol 
lipase (ATGL). Part of the FA released from intracellular TAG stores is rapidly re-esterified 
within adipocytes, but this activity is low during fasting (Frayn et al. 1994). Thus, there is a 
net release of FFA from adipose tissue in the fasting state. Glycerol kinase activity that 
converts free glycerol into glycerol-3-phosphate for synthesis of TAG, is low to negligible in 
human adipose tissue. Free glycerol is released by adipose tissue and mainly utilized by the 
liver and kidneys that possess glycerol kinase activity (Guo and Jensen 1999). 
 
Postprandial state. After ingestion, dietary fat is hydrolyzed and packed in bile acid-
containing micelles in the gut and taken up by the enterocytes. FA are incorporated as TAG in 
chylomicrons that then enter the systemic circulation via the thoracic duct. Chylomicrons 
contain, in addition to TAG (the major lipid), apolipoprotein(apo) B-48, phospholipids, 
cholesteryl esters and free cholesterol (DeFronzo et al. 2004). Circulating chylomicrons are 
hydrolyzed mainly in adipose tissue via the action of LPL, the activity of which is upregulated 
by insulin postprandially (Sadur and Eckel 1982, Frayn et al. 1994). Both in the fasting and 
postprandial state, FFA are taken up by adipose tissue through diffusion down a concentration 
gradient and with the help of fatty acid transport and binding proteins (Stahl 2004). 
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Remaining circulating chylomicron-remnant particles are removed by the liver (Frayn 2001) 
majorily via the function of LDL receptors and LDL receptor-related proteins (Cooper 1997). 
Also the blood flow in adipose tissue increases postprandially (Ruge et al. 2009), and in 
addition to increased LPL activity, insulin stimulates re-esterification of FA in adipocytes 
(Frayn et al. 1994, Coleman and Lee 2004) and decreases FFA spillover (Frayn et al. 1995). 
After ingestion, the net release of FFA in adipose tissue converts to net trapping and there is a 
rapid fall in total circulating FFA concentration (Bickerton et al. 2007). 
 
Other factors regulating lipid storage and breakdown in adipose tissue. In addition to insulin, 
lipolysis is regulated by catecholamines that stimulate HSL activity during fasting and under 
other conditions, such as aerobic exercise (via β1- and β2-adrenergic receptors). Other 
physiological stimulators of lipolysis include TNFα and growth hormone (Coppack et al. 
1994, Lafontan and Langin 2009). 
 
During fasting, HSL activity and the rate of lipolysis is enhanced by the action of the protein 
perilipin located on the surface of TAG droplets (Sztalryd et al. 2003, Tansey et al. 2004, 
Brasaemle 2007). Both HSL and perilipin action are stimulated by protein kinase A (PKA)-
mediated phosphorylation. Under postprandial conditions, perilipin restricts the function of 
lipases and suppresses TAG breakdown. Positive staining for perilipin has also been used as a 
marker of viable adipocytes in immunohistochemical sections of both mouse and human 
adipose tissue (Cinti et al. 2005). 
 
ATGL is another enzyme capable of TAG hydrolysis with high specificity for TAG (Jenkins 
et al. 2004, Zimmermann et al. 2004). The generated diacylglycerol (DAG) in turn appears to 
be the main substrate of HSL (Haemmerle et al. 2002, Kraemer and Shen 2002). In addition, 
the third enzyme in the TAG hydrolytic cascade, monoacylglycerol lipase (MGL), is 
expressed in adipose tissue and is required to complete lipolysis by hydrolyzing 
monoacylglycerols into FA and glycerol (Fredrikson et al. 1986). 
 
Another lipase/transacetylase is adiponutrin that is expressed in both adipose tissue and the 
liver (Wilson et al. 2006). The exact function of adiponutrin is unknown but it has been 
suggested to participate in both lipolysis and lipogenesis. Its expression is positively 
associated with obesity (Johansson et al. 2006) and decreased during fasting but increased 
after re-feeding both in mice and humans (Liu et al. 2004). Recently, genetic variation in 
adiponutrin gene has been closely associated with liver fat content in humans (discussed in 
section 4. in DISCUSSION). 
1.1.2. Glucose metabolism 
Adipocytes are highly responsive to insulin and thus in normal subjects even small increases 
(~5-15 mU/l) in circulating insulin concentration are sufficient to decrease significantly serum 
FFA concentration (Nurjhan et al. 1986, Bonadonna et al. 1990, Groop et al. 1992). In 
adipose tissue, insulin stimulates glucose uptake, LPL activity and lipogenesis. Glucose 
uptake is mediated by facilitated glucose transporter member 4 (GLUT-4) and subsequent 
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glycolysis is responsible for glycerol-3-phosphate supply for FA re-esterification and TAG 
synthesis in adipose tissue (Frayn et al. 2006). Adipose tissue accounts for less than 5 % of 
whole body glucose uptake as determined by early tracer studies (Björntorp et al. 1971, Mårin 
et al. 1987), and approximately 8 % when measured with a more recent technique using 
positron emission tomography (PET) and labeled glucose and water during euglycemic 
hyperinsulinemia (Virtanen et al. 2002). 
1.1.3. Adipocytokines 
Cytokines are signalling peptides acting in an autocrine, paracrine or endocrine fashion 
(Cannon 2000). Chemokines are cytokines with chemotactic properties regulating migration 
of cells (Charo and Ransohoff 2006). Adipocytokines are cytokines secreted from adipose 
tissue. The definition of adipocytokine varies. Some define them as secretory products 
exclusively of adipocytes or pre-adipocytes, while others accept also non-fat cells in adipose 
tissue as a source. These non-fat cells include macrophages, fibroblasts, endothelial cells, 
lymphocytes and smooth muscle cells and they constitute the stromal vascular fraction (SVF) 
of adipose tissue (Frayn et al. 2003, Kershaw and Flier 2004). One adipocytokine can 
originate from several different cell types. In the following text, the term adipocytokine 
denotes cytokines, chemokines and peptides secreted by any cell type present in adipose 
tissue. 
 
Adipocytokines constitute a wide spectrum of factors that regulate body weight, insulin 
sensitivity, glucose and lipid metabolism, and inflammation (Rasouli and Kern 2008). 
Selected adipocytokines identified in human adipose tissue, their expression and serum 
concentrations in insulin-resistant states are listed in Table 1. Some adipocytokines play a role 
in normal physiology. For example, based on studies in genetically engineered mice, 
adiponectin is an anti-atherogenic adipocytokine that has both insulin-sensitizing and anti-
inflammatory effects (discussed in section 2.3. in REVIEW OF THE LITERATURE). In 
humans, lean and insulin-sensitive subjects have higher plasma concentration and adipose 
tissue expression of adiponectin compared to obese and insulin-resistant subjects. Another 
example is leptin that is shown to be responsible for normal food intake, energy expenditure 
and adipose tissue mass (Friedman 2009). Many other adipocytokines are mainly included in 
inflammation and insulin resistance (discussed in section 2.3. in REVIEW OF THE 
LITERATURE). 
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1.2. The liver 
1.2.1. Glucose metabolism 
After an overnight fast, the liver produces glucose (endogenous glucose production, EGP) at a 
rate of approximately 2 mg/kg⋅min in normal subjects (Bondy et al. 1949, DeFronzo et al. 
1981, DeFronzo and Ferrannini 1987, Consoli 1992). The liver accounts for most of this via 
glycogenolysis and gluconeogenesis (GNG) (Ekberg et al. 1999). GNG accounts for ~50 % of 
hepatic glucose production after an overnight (14 hours) fast and for almost all (~95 %) after 
a 42-hour fast (Rothman et al. 1991, Landau et al. 1996, Chandramouli et al. 1997). 
 
Hepatic glucose production is suppressed at lower insulin concentration than what is required 
for stimulation of glucose uptake in skeletal muscle (Rizza et al. 1981, Yki-Järvinen et al. 
1987b). These effects on the liver by insulin are mediated directly through both hepatic 
insulin receptors and downregulation of gluconeogenetic enzymes (Sutherland et al. 1996) 
and indirectly through effects on pancreatic α-cells, adipose tissue and skeletal muscle (Girard 
2006). In addition, studies in mice suggest that inhibition of hepatic glucose production could 
be partly mediated via neural pathways activated in response to insulin action in the brain 
(Obici et al. 2002). In normal subjects, complete suppression of hepatic glucose production is 
achieved at insulin concentration of ~50-60 mU/l and half-maximal suppression at an insulin 
concentration of ~30 mU/l (Rizza et al. 1981). Hyperglycemia under normoinsulinemic 
conditions also suppresses hepatic glucose production (DeFronzo et al. 1983). In addition to 
insulin, glucagon is also an important regulator of hepatic glucose production, particularly in 
the fasting state. Glucagon counteracts insulin action by stimulating both hepatic GNG 
(Chiasson et al. 1975) and glycogenolysis (Magnusson et al. 1995). In addition to glucagon, 
other insulin counterregulatory hormones include cortisol, adrenalin and noradrenalin. 
 
After ingestion of oral glucose or a mixed meal, increases in insulin and glucose 
concentrations, and a decrease in glucagon concentration, suppress hepatic glucose production 
almost completely (Taylor et al. 1996, Singhal et al. 2002). Concerning disposition of an oral 
glucose load (1 g/kg body weight), splanchnic tissues take up approximately 30 % during 5 
hours (Kelley et al. 1988). Hyperglycemia stimulates splanchnic glucose uptake also 
independent of insulin concentration (DeFronzo et al. 1983). 
1.2.2. Lipid metabolism 
Origin of intrahepatic TAG. The uptake of FFA and secretion of lipids in the form of VLDL 
by the liver also depends on the nutritional state (Frayn et al. 2006). In the fasting state, the 
majority of circulating FFA that are taken up by the liver, originate from adipose tissue 
lipolysis and these FFA are also the main source (~80 %) of FA incorporated in VLDL. In the 
fasting state less than 5 % of intrahepatocellular TAG in normal subjects originates from 
hepatic de novo lipogenesis (DNL) (Barrows and Parks 2006). Other sources of 
intrahepatocellular TAG during fasting include FA delivered to the liver in the form of 
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VLDL-remnants and spillover of FFA from intravascular lipolysis in peripheral tissues 
(Donnelly et al. 2005, Goldberg and Ginsberg 2006). 
 
In the postprandial state, adipose tissue lipolysis is suppressed by insulin but still accounts for 
the majority (~45 %) of FA used for hepatic VLDL synthesis while DNL accounts only for a 
small fraction (~8 %) of the FA incorporated in intrahepatic TAG (Barrows and Parks 2006). 
Uptake of chylomicron remnants and the spillover pathway also account for a small part (~5-
15 %) of VLDL-TAG assembly (Barrows et al. 2005). Lipid stores of the liver are dynamic, 
since 13C-labeled FA in a lipid mixture ingested along with normal breakfast, showed peak 
incorporation in hepatic TAG stores after 6 hours when measured with 13C-MRS (magnetic 
resonance spectroscopy) in normal subjects (Ravikumar et al. 2005). Labeled FA were also 
rapidly replaced by non-labeled FA in the subsequent mixed meal. 
 
Fate of FA in the liver. In the liver, FA can be directed in oxidation, ketone body formation, 
TAG storage or phospholipid synthesis, or they can be incorporated into VLDL. Under 
fasting conditions, low insulin and high glucagon concentrations favor mitochondrial FA 
oxidation and VLDL synthesis over storage (Frayn et al. 2006, Tessari et al. 2009). On the 
other hand, dietary FA are rapidly incorporated into the liver TAG stores (Ravikumar et al. 
2005) instead of VLDL synthesis (Gibbons et al. 2004) in the postprandial state. In normal 
subjects, insulin decreases apoB-100 and VLDL-TAG production under hyperinsulinemic 
normoglycemic conditions (Malmström et al. 1997, Julius 2003). This results from direct 
suppression of apoB-100 synthesis and VLDL assembly by insulin and from suppression of 
hepatic uptake of FFA via the antilipolytic effect of insulin (Havel et al. 1970, Lewis et al. 
1995, Ginsberg et al. 2005). 
1.3. Skeletal muscle 
1.3.1. Glucose metabolism 
After an overnight fast, whole body glucose uptake averages approximately 2 mg/kg⋅min and 
is mostly insulin-independent. The brain takes up approximately 50% of this glucose, while 
skeletal muscle accounts for only approximately 10 % of whole body glucose uptake in the 
fasting state (Yki-Järvinen 1993). However, skeletal muscle is the major tissue for insulin-
stimulated glucose extraction in vivo (DeFronzo et al. 1985), and under intravenously 
maintained hyperinsulinemic normoglycemic conditions, glucose replaces FFA as the main 
fuel for skeletal muscle (Kelley et al. 1988, Kelley et al. 1990). Muscle glucose uptake 
increases 8-fold under hyperinsulinemia (DeFronzo et al. 1981, Yki-Järvinen et al. 1987b, 
Nuutila et al. 1992) and after ingestion of a normal mixed meal (Ruge et al. 2009). Of an oral 
glucose load (1 g/kg body weight) or after a mixed meal containing ~80 g glucose, skeletal 
muscle takes up approximately 30 % of the glucose during 5- to 6-hour period. Most glucose 
(~50 %) taken up by skeletal muscle is oxidized for energy, while the rest is stored as 
glycogen and glycolyzed into lactate, pyruvate and alanine (Kelley et al. 1988, Woerle et al. 
2003). The maximal effective concentration of insulin to stimulate glucose uptake in skeletal 
muscle in normal insulin-sensitive subjects is ~200 mU/l, while the half-maximal 
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concentration is ~80 mU/l (Yki-Järvinen et al. 1987a). However, in everyday life in normal 
insulin-sensitive subjects the circulating concentration of insulin rarely exceeds 50 mU/l. 
 
Concerning the mechanisms of insulin-stimulated glucose uptake in muscle (and in adipose 
tissue), insulin first binds to the insulin receptor and induces its autophosphorylation (Kasuga 
et al. 1982). This leads to several intra-cellular phosphorylation-dephosphorylation cascades 
(White 2003) including insulin-receptor substrate proteins 1 and 2 (IRS-1/2), 
phosphatidylinositol 3-kinase (PI3K) and Akt/protein kinase B (PKB) that are the most 
important links between insulin receptor binding and intracellular effects of insulin (Saltiel 
and Kahn 2001). These cascades lead to the translocation and fusion of the insulin-sensitive 
GLUT-4 from intracellular vesicles to the cell membrane (Klip and Paquet 1990, Guma et al. 
1995) that launches the anabolic effects in glucose, lipid and protein metabolism. Insulin also 
regulates the intracellular enzyme hexokinase (Mandarino et al. 1995) that phosphorylates 
transported glucose into glucose-6-phosphate (G6P), which is used for glycogen synthesis and 
glycolysis. 
1.3.2. Lipid metabolism 
In the fasting state, circulating FFA are the major oxidative substrates for skeletal muscle 
(Andres et al. 1956, Baltzan et al. 1962). FFA originate from plasma albumin-bound FFA or 
from LPL-catalyzed intravascular VLDL-TAG lipolysis in adipose tissue. There is almost no 
extraction of VLDL-TAGs in muscle, while postprandially the extraction of FA from 
chylomicrons by LPL is quite efficient. Nevertheless, most of dietary FA from chylomicrons 
are diverted into adipose tissue. FA can be stored as TAG in adipocytes between muscle 
fibers or inside myocytes as intramyocellular lipid (IMCL) (Frayn et al. 2006). Only 
approximately 5 % of postprandial whole body TAG storage occurs in muscle tissue 
(Ravikumar et al. 2005). IMCL content is inversely related to insulin sensitivity in normal and 
obese sedentary subjects (Krssak et al. 1999, Boden et al. 2001). However, IMCL is 
paradoxically increased and positively associated with insulin sensitivity in aerobic 
endurance-trained athletes for reasons, which are incompletely understood (Thamer et al. 
2003). 
 
Exercise affects muscle fuel selection (Henriksson 1995). At rest, FFA are the dominant 
energy source and only a minor part of muscle fuel derives from plasma glucose. During 
prolonged low to moderate intensity exercise FFA (from both circulation and IMCL) still play 
an important role as energy source, but during initial period and with high-intensity exercise 
the use of muscle glycogen stores and plasma-derived glucose dominate as fuel (Ahlborg et 
al. 1974). 
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2. Insulin resistance in adipose tissue 
Growing evidence links low-grade inflammation in adipose tissue with obesity and insulin 
resistance. This inflammation is characterized by increased infiltration of macrophages and 
increased expression of pro-inflammatory adipocytokines in adipose tissue (Rasouli and Kern 
2008). However, the sequence of events leading to inflammation and the mechanisms that link 
adipose tissue inflammation to insulin resistance are still poorly understood. 
2.1. Defects in in vivo insulin action in adipose tissue 
Insulin resistance and fasting serum insulin concentration tend to increase with increasing 
obesity, but not all obese subjects are insulin-resistant (Bogardus et al. 1985, Abate et al. 
1995). In adipose tissue, insulin is responsible for increasing glucose uptake, LPL activity and 
lipogenesis and, on the other hand, for decreasing HSL activity and adipocyte TAG lipolysis. 
The classic hallmark of insulin resistance in adipose tissue is the defective antilipolytic effect 
of insulin that leads to increased circulating FFA concentration (Coppack et al. 1994). 
 
Adipose tissue FFA release and circulating FFA concentration, under both fasting and 
postprandial conditions, are increased in obese and insulin-resistant compared to normal 
weight and insulin-sensitive subjects (Opie and Walfish 1963, Baldeweg et al. 2000). 
Lipolysis and the release of FFA by adipose tissue measured by labeled 2H5-glycerol and 
14C-
palmitate respectively, are suppressed by insulin in both lean and obese subjects in a dose-
dependent manner under euglycemic hyperinsulinemic conditions (Campbell et al. 1994). 
However, in obese subjects, insulin doses that decrease FFA release by adipose tissue are 
significantly higher compared to lean subjects. Several studies using euglycemic 
hyperinsulinemia have also shown that the suppression of FFA release by insulin is defective 
in obese and insulin-resistant subjects (Yki-Järvinen and Taskinen 1988, Jensen et al. 1989, 
Groop et al. 1992, Virtanen et al. 2005). Some studies, however, found no statistically 
significant difference in the antilipolytic effects of insulin between obese and lean subjects 
under hyperinsulinemic conditions (Howard et al. 1984, Zuniga-Guajardo et al. 1986). 
 
In everyday life, insulin resistance of adipose tissue lipolysis is especially important under 
postprandial conditions (Frayn 2001). During fasting, obese subjects show decreased 
clearance of VLDL-TAG in adipose tissue compared to lean subjects (Potts et al. 1995). After 
a standard mixed meal, the normal stimulation of LPL and suppression of HSL activity are 
blunted in obese compared to lean subjects, and adipose tissue continues to release FFA in 
obese but not in lean subjects (Coppack et al. 1992, Frayn et al. 1996). In addition, after a 
mixed meal, adipose tissue extraction of FFA from TAG-rich chylomicrons and VLDL is 
decreased in obese compared to lean subjects (Potts et al. 1995). Glucose uptake in adipose 
tissue is also resistant to insulin action in obese and insulin-resistant subjects compared to 
non-obese counterparts (Virtanen et al. 2001). The quantitative contribution of adipose tissue 
to whole body glucose uptake, however, is small (less than ~5 %) even in the obese subjects 
(Björntorp et al. 1971, Mårin et al. 1987, Virtanen et al. 2002) and thus unlikely contributes to 
decrease in glucose disposal in insulin resistance. 
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Although the visceral (i.e. intra-abdominal) fat depot constitutes ~10-20 % of the total body 
fat mass in humans (Ross et al. 1993, Abate et al. 1995), it is suggested to be more harmful 
compared to subcutaneous fat concerning the risk of insulin resistance, T2DM and 
cardiovascular diseases (CVD) (Montague and O'Rahilly 2000, Mathieu et al. 2009). Visceral 
fat is considered metabolically more active than subcutaneous fat in both lipid and glucose 
metabolism, and in unfavorable cytokine secretion (Després and Lemieux 2006). Lipolysis 
and FFA release and insulin-stimulated glucose uptake are increased in visceral compared to 
subcutaneous adipose tissue (Arner 1995, Lafontan and Berlan 2003, Nielsen et al. 2004, 
Virtanen et al. 2005). In both normal weight and morbidly obese subjects, the number of 
macrophages, measured by immunohistochemical staining, is increased in visceral compared 
to subcutaneous adipose tissue (Bornstein et al. 2000, Cancello et al. 2006). In addition to 
body mass index (BMI) that represents general adiposity, waist circumference and waist-to-
hip ratio (W/H) are strongly associated with overall mortality in a large prospective study 
(Pischon et al. 2008). Waist circumference represents mainly visceral and upper-body obesity. 
Upper-body subcutaneous fat depot is the major source of FFA release in whole body 
(Koutsari and Jensen 2006), although the FFA released by visceral adipose tissue possess a 
direct route to the liver via the portal vein (Björntorp 1990). 
2.2. Inflammation 
Experimental animal models have proposed strong evidence of the important role of 
inflammatory pathways in the pathophysiology of insulin resistance (Hotamisligil et al. 1993, 
Yuan et al. 2001, Arkan et al. 2005). Causality is difficult to prove in human studies but there 
is evidence of a relationship between inflammation and insulin resistance. For example, the 
expression of pro-inflammatory cytokines, such as TNFα, and tissue infiltration of 
inflammatory cells, are increased in adipose tissue of obese subjects (De Luca and Olefsky 
2008). 
 
In 2003, two groups reported that obesity and insulin resistance are associated with increased 
macrophage accumulation and chronic low-grade inflammation in adipose tissue in mice and 
humans (Weisberg et al. 2003, Xu et al. 2003b). Macrophages are suggested to be major 
contributors to the inflammatory changes observed in adipose tissue. Expression of 
macrophage marker gene Cluster of differentiation 68 (CD68) is significantly higher in 
adipose tissue of obese when compared to lean subjects. Adipocyte cell size is closely 
correlated to BMI and insulin resistance and also to macrophage infiltration (Hirsch and 
Batchelor 1976, Coppack 2001, Weisberg et al. 2003). Transplantation studies suggested that 
the adipose tissue macrophages are bone marrow-derived monocytes infiltrating the site of 
inflammation (Weisberg et al. 2003) rather than preadipocytes differentiating into 
macrophage-like cells (Charriere et al. 2003). Other studies have confirmed the increased 
infiltration of adipose tissue macrophages in obese or insulin-resistant subjects by assessing 
the gene expression or immunohistochemical staining of macrophage markers (Cinti et al. 
2005, Di Gregorio et al. 2005, Pietiläinen et al. 2006, Coenen et al. 2007). In contrast to 
inflamed adipose tissue, human skeletal muscle shows almost no macrophage infiltration in 
obese insulin-resistant subjects (Bruun et al. 2006). The relationships between adipose tissue 
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inflammation and macrophage infiltration with liver fat content, and with whole body insulin 
sensitivity have not been previously determined in humans in vivo. 
 
In addition to CD68 (Holness and Simmons 1993, Weisberg et al. 2003), also other gene 
markers for macrophage tissue infiltration have been used. A disintegrin and metallopeptidase 
domain 8 (ADAM8) (Xu et al. 2003b) and epidermal growth factor module-containing mucin-
like hormone receptor 1 (EMR1) (McKnight and Gordon 1998) are monocyte- and 
macrophage-specific proteins, and integrin α M (ITGAM) is a leukocyte surface adhesion 
molecule found in monocytes, macrophages, neutrophils and NK cells (Solovjov et al. 2005). 
All these genes show absent or only minor expression in human adipocytes (Khazen et al. 
2005, Lee et al. 2005). 
 
The mechanisms underlying macrophage infiltration in adipose tissue remain unresolved. It 
has been suggested that the increase in adipocyte cell size could promote adipocyte cell 
dysfunction, cell death and necrosis (Cinti et al. 2005). Expansion of adipose tissue may lead 
to hypoxia and activation of the intracellular inflammatory pathways leading to increased 
expression and secretion of inflammatory and chemoattractant adipocytokines (Wang et al. 
2007, Pasarica et al. 2009). Endoplasmic reticulum (ER) stress can also activate inflammatory 
pathways and adipocytokine expression (Ozcan et al. 2004, Zhang and Kaufman 2008) and is 
associated with initiation of inflammation and insulin resistance (Schenk et al. 2008). ER 
stress and dysfunction can be triggered by hypoxia and chronic overflow of FFA that also 
characterize obesity (Gregor and Hotamisligil 2007, Boden et al. 2008). 
 
In both obese mice and men, using immunohistochemistry and electron microscopy, 
macrophages have been shown to form crown-like structures (CLS) consisting of several 
macrophages surrounding necrotic, perilipin-negative, adipocytes (Cinti et al. 2005). These 
structures scavenge the cell debris, and at the same time actively secrete cytokines and recruit 
more macrophages, thereby maintaining the inflammatory reaction in adipose tissue. 
Adipocyte cell size strongly predicts the number of macrophages and CLS in adipose tissue, 
even independent of total fat mass (Cinti et al. 2005). In human adipocytes in vitro, large 
hypertrophic cells presented a proinflammatory cytokine secretion profile compared to 
smaller cells (Skurk et al. 2007). In morbidly obese subjects, histologically determined 
macrophage number correlated positively with adipocyte cell size in both visceral and 
subcutaneous adipose tissue (Cancello et al. 2006). Thus, it has been suggested that in obesity 
adipocytes reach a critical cell size after which the function of the cell and whole tissue 
changes into an inflammatory direction (Cinti 2009). This is characterized by increased 
expression of inflammatory adipocytokines, infiltration of macrophages, as well as impaired 
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Concerning the mechanisms by which inflammation in adipose tissue could be linked to 
insulin resistance, inhibitor of IκB (IKK-β) and C-Jun amino-terminal kinase (JNK) are 
suggested to play a role (Schenk et al. 2008). IKK-β is an important coordinator of cellular 
inflammatory responses via inhibiting IκB that, in turn, inhibits activation of nuclear factor 
κB (NFκB), an inflammatory transcription factor. JNK is another important intracellular 
modulator of inflammatory pathways, also associated with insulin resistance (Hirosumi et al. 
2002). Both IKK-β and JNK are serine kinases capable of inhibiting the function of IRS-1 and 
thereby insulin signaling. Interestingly, in knock-out (KO) studies where IKK-β or JNK were 
depleted specifically from myeloid cells (monocytes, macrophages, neutrophils, lymphocytes) 
but not from adipose tissue, the liver or skeletal muscle, mice were protected from whole 
body insulin resistance (Arkan et al. 2005, Solinas et al. 2007). In intervention studies using 
salicylates, inhibitors of IKK-β, insulin resistance was ameliorated in both rodents and 
humans (Kim et al. 2001, Hundal et al. 2002). TNFα-deficient myeloid cells also show 
enhanced insulin sensitivity (De Taeye et al. 2007). 
 
Circulating monocytes and macrophages can be divided into two major subsets with 
heterogenic properties (Gordon and Taylor 2005). Proinflammatory, or classically activated, 
M1-macrophages show increased reactivity to lipopolysaccharide (LPS), whereas anti-
inflammatory, or alternatively activated, M2-macrophages are suggested to associate with 
normal adipocyte function and insulin sensitivity, and to show increased IL-10 expression 
(Lumeng et al. 2007). In obese mice and humans, M1/M2 ratio in adipose tissue is increased 
and with high-fat feeding in mice, the phenotype of macrophages changes from M2 into M1 
contributing to insulin resistance (Lumeng et al. 2007, Aron-Wisnewsky et al. 2009). The 
proinflammatory switch may originate from bone marrow-derived monocytes that are shown 
to be in proinflammatory state in obese subjects (Ghanim et al. 2004) or by changes in 
adipose tissue microenvironment that favors inflammation (Stout et al. 2005). Also different 
growth factors (granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage 
colony-stimulating factor (M-CSF)) may determine the phenotype and inflammatory 
properties of differentiated macrophages (Waldo et al. 2008). In humans, weight loss after 
bariatric surgery decreased M1/M2 ratio in subcutaneous adipose tissue (Aron-Wisnewsky et 
al. 2009). LPS-stimulated inflammatory gene expression responses in human monocyte-
derived macrophages and possible differences between insulin-resistant and sensitive subjects 
have not been previously studied. 
2.3. Adipocytokines and insulin resistance 
Monocyte chemoattractant protein 1 
MCP-1 (also known as CCL2) is a mononuclear cell-specific chemokine and the C-C motif 
chemokine receptor 2 (CCR2) is its specific receptor. MCP-1 is expressed in many cell types 
including adipocytes but other cells in adipose tissue, especially macrophages, have been 
proposed to be its predominant source (Murao et al. 1999, Bruun et al. 2005, Fain and Madan 
2005). MCP-1 and CCR2 have been suggested to be crucial in macrophage recruitment, 
adipose tissue inflammation and insulin resistance (Neels and Olefsky 2006). 
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In ob/ob mice, expression of MCP-1 in the liver is less than 10 % of that in adipose tissue 
(Sartipy and Loskutoff 2003). MCP-1 induces insulin resistance and decreases expression of 
GLUT-4, LPL and nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) in 
adipocytes in vitro. In genetically obese db/db-mice or in wild-type (WT) mice with high-fat 
diet-induced obesity, the adipose tissue expression and serum concentration of MCP-1 are 
increased compared to controls (Kanda et al. 2006). Overexpression of MCP-1 selectively in 
adipose tissue in mice markedly increases serum MCP-1 concentration, macrophage 
infiltration in adipose tissue, insulin resistance and hepatic fat accumulation. Obese MCP-1-
KO mice, on the other hand, are protected from these changes when compared to equally 
obese WT mice, according to some (Kanda et al. 2006) but not all (Inouye et al. 2007, Kirk et 
al. 2008) studies. Overexpression of MCP-1 in adipose tissue also increases adipose tissue 
expression of TNFα and IL-6, and plasma concentration of FFA (Kamei et al. 2006). CCR2-
KO mice have also been suggested to exhibit reduced macrophage infiltration and 
inflammatory responses, and increased adiponectin expression in adipose tissue. These mice 
show decreased insulin resistance and hepatic steatosis (Weisberg et al. 2006). Similar results 
were not found, however, in a previous study (Chen et al. 2005a). 
 
In obese humans, expression of MCP-1 and CCR2 are increased in both subcutaneous and 
visceral adipose tissue compared to lean subjects (Christiansen et al. 2005, Dahlman et al. 
2005, Huber et al. 2008). Gene expression of MCP-1 is also associated with that of 
macrophage marker CD68 in both adipose tissue depots in humans. MCP-1 protein secretion 
by cultured human adipose tissue is increased in obesity and is higher in visceral than in 
subcutaneous adipose tissue (Bruun et al. 2005, Dahlman et al. 2005). Data of circulating 
concentration of MCP-1 have been variable. Some studies found no difference in serum 
MCP-1 concentration between obese and lean subjects or in venous blood draining 
subcutaneous adipose tissue (Dahlman et al. 2005), while others found increased serum MCP-
1 concentration in obese compared to lean subjects, and also a correlation between adipocyte 
MCP-1 expression, serum MCP-1 concentration and BMI (Christiansen et al. 2005, Kim et al. 
2006). 
 
Concerning regulation of MCP-1 in humans, weight loss induced by hypocaloric diet (Bruun 
et al. 2006) or by bariatric surgery (Cancello et al. 2005) decreases macrophage infiltration 
and MCP-1 gene expression in subcutaneous adipose tissue. Pioglitazone treatment for 10 
weeks decreases macrophage number and expression of CD68 and MCP-1 in subcutaneous 
adipose tissue, while metformin had no such effects (Di Gregorio et al. 2005). In human 
adipose tissue in vitro, TNFα, IL-1β and IL-6 increase MCP-1 secretion (Bruun et al. 2005). 
Data of regulation of MCP-1 by insulin are inconsistent. In humans under euglycemic 
hyperinsulinemic conditions, adipose tissue gene expression of MCP-1 has been reported to 
increase only in lean subjects (Murdolo et al. 2007). In the latter study, neither obese nor lean 
subjects showed change in serum MCP-1 concentration. Adipose tissue interstitial MCP-1 
concentration, on the other hand, is increased in both obese and lean subjects under 
hyperinsulinemic conditions (Murdolo et al. 2007, Siklova-Vitkova et al. 2009). The acute 
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effects of insulin in vivo on adipose tissue expression and serum concentration of MCP-1 have 
not been compared in insulin-sensitive and insulin-resistant subjects. 
Macrophage inflammatory protein 1α 
Macrophage inflammatory protein 1α (MIP-1α, also known as CCL3) is secreted by 
preadipocytes, mature adipocytes and activated macrophages and has chemotactic and 
proinflammatory effects (Gerhardt et al. 2001, Maurer and von Stebut 2004). Macrophages 
from human subcutaneous and visceral adipose tissue show higher expression of MIP-1α than 
isolated adipocytes (Curat et al. 2006). LPS, TNFα and IL-1 stimulate MIP-1α production 
while IL-10 and dexamethasone have the opposite effect (Maurer and von Stebut 2004). 
Macrophage-conditioned medium increases MIP-1α secretion by human visceral adipocytes 
in vitro (Bassols et al. 2009). Studies on MIP-1α in humans in vivo are scarce and gene 
expression in adipose tissue in insulin-resistant and sensitive subjects is unknown. 
Tumor necrosis factor α 
TNFα is an important and extensively studied proinflammatory cytokine capable of inducing 
and mediating insulin resistance in different cell lines and animal models (Hotamisligil et al. 
1993, Hotamisligil et al. 1994, Liu et al. 1998). LPS-stimulated TNFα production is more 
abundant by whole human adipose tissue than by isolated adipocytes (Sewter et al. 1999). 
Macrophages are suggested as the predominant source of TNFα in adipose tissue (Weisberg et 
al. 2003, Fain et al. 2004a, Di Gregorio et al. 2005). However, it is unclear whether merely 
the number, or also the location and properties of TNFα-secreting macrophages, differ in 
obesity and insulin resistance. 
 
Adipose tissue expression of TNFα is increased in obese and insulin-resistant mice and 
associates positively with adiposity (Hotamisligil et al. 1993). TNFα decreases IRS-1 and 
GLUT-4 expression in 3T3-L1 adipocytes and thereby inhibits insulin-stimulated glucose 
uptake (Peraldi et al. 1997). TNFα also inhibits expression of PPARγ that is important in 
adipocyte differentiation and the target for anti-diabetic agents, thiazolidinediones (also 
known as glitazones). TNFα decreases LPL activity and stimulates intracellular lipolysis in 
adipocytes (Zhang et al. 2002). In obese mice, TNFα-KO protects from insulin resistance, 
decreases circulating FFA concentration and improves insulin signaling in muscle and 
adipose tissue (Uysal et al. 1997). 
 
In human adipocytes, treatment with TNFα decreases IRS-1 and PI3K activity with a 
simultaneous decrease in glucose uptake (Liu et al. 1998) and decreases the expression of 
adiponectin (Bruun et al. 2003). Adipose tissue gene expression of TNFα is increased in obese 
compared to lean subjects (Hotamisligil et al. 1995, Kern et al. 1995, Pietiläinen et al. 2006). 
Adipose tissue expression and serum concentration of TNFα correlate with liver-derived acute 
phase protein C-reactive protein (CRP) in obese subjects (Maachi et al. 2004). Recently in a 
large cohort study, serum TNFα concentration correlated significantly with homeostasis 
model insulin resistance (Hivert et al. 2008). On the other hand, some studies found no 
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correlation between adipose tissue TNFα expression and obesity or insulin sensitivity (Frittitta 
et al. 1997, Montague et al. 1998, Koistinen et al. 2000). In obese T2DM patients, 4-week 
treatment with recombinant-engineered human TNFα-neutralizing antibody did not affect 
whole body insulin sensitivity (Ofei et al. 1996) while this was effective previously in mice 
(Hotamisligil et al. 1993). A subsequent study, however, suggested that chronic, instead of 
acute, anti-TNFα treatment could improve insulin sensitivity in humans (Yazdani-Biuki et al. 
2004). Additionally, the endocrine effects of TNFα on systemic insulin resistance in humans 
have been questioned by adipose tissue arteriovenous difference studies that show no 
significant secretion of TNFα by subcutaneous adipose tissue (Mohamed-Ali et al. 1997). 
This suggests primarily autocrine/paracrine function for TNFα in human adipose tissue. 
 
Human adipose tissue TNFα expression decreases markedly after weight reduction 
(Hotamisligil et al. 1995, Kern et al. 1995, Bruun et al. 2006) while acquired obesity increases 
adipose tissue TNFα and CD68 expression (Pietiläinen et al. 2006)., The results of acute 
regulation of adipose tissue expression of TNFα by insulin in humans are not completely 
coherent. Some studies show no effect of insulin on TNFα expression in vitro (Sewter et al. 
1999) while others represent increased expression in healthy subjects in vivo (Krogh-Madsen 
et al. 2004). Interestingly, in human monocyte cell line and monocyte-derived human 
macrophages in vitro, insulin has been shown to stimulate expression of TNFα more than any 
other gene (Iida et al. 2001). Differences in adipose tissue TNFα expression in non-diabetic 
insulin-sensitive and resistant subjects and acute effects of hyperinsulinemia on TNFα 
expression have not been previously assessed. 
Interleukin 6 
IL-6 is a cytokine of the immune system and the main cytokine involved in acute phase 
reaction and associated with insulin resistance (Feve and Bastard 2009). In humans, 
significant amounts of IL-6 are secreted by adipose tissue into the circulation, in contrast to 
TNFα (Mohamed-Ali et al. 1997). Intra-abdominal adipose tissue seems to secrete more IL-6 
than subcutaneous depot and adipocytes have been suggested to account for only ~10 % of 
total IL-6 secretion in adipose tissue, and thus, the SVF (mainly macrophages) primaly 
contributes to IL-6 production (Fried et al. 1998, Weisberg et al. 2003, Fain et al. 2004b). 
 
In vitro, IL-6 decreases IRS-1, GLUT-4 and adiponectin expression in 3T3-L1 adipocytes 
(Fasshauer et al. 2003b, Rotter et al. 2003). Mice with IL-6-KO unexpectedly showed 
increased whole body fat mass, impaired glucose tolerance (IGT), dyslipidemia and leptin 
insensitivity (Wallenius et al. 2002). However, these results were not reproduced in a later 
study with a similar design (Di Gregorio et al. 2004). Overexpression of IL-6 selectively in 
skeletal muscle in mice, results in decreased body weight, but also in hyperinsulinemia, 
impaired glucose uptake in muscle, and inflammatory changes in the liver (Franckhauser et al. 
2008). 
 
In humans, circulating IL-6 concentration and adipose tissue IL-6 protein content and 
secretion are positively associated with obesity and insulin resistance (Mohamed-Ali et al. 
REVIEW OF THE LITERATURE 
27 
1997, Vozarova et al. 2001, Bastard et al. 2002, Maachi et al. 2004). Adipose tissue gene 
expression of IL-6 is correlated to adipocyte cell size (Sopasakis et al. 2004), and is increased 
in insulin-resistant compared to sensitive subjects, independent of body weight (Rotter et al. 
2003). Circulating IL-6 is also associated with serum FFA concentration (Bastard et al. 2002) 
and IL-6 have been shown to stimulate lipolysis in vivo in healthy subjects (Lyngso et al. 
2002). IL-6 downregulates adiponectin and PPARγ gene expression in adipose tissue in vitro. 
Interestingly, interstitial concentration of IL-6 in human subcutaneous adipose tissue appears 
~100 times higher than that in serum (Sopasakis et al. 2004), and human adipocytes also 
express IL-6 receptors (Bastard et al. 2002). These data suggest both endocrine and auto or 
paracrine effects for this adipocytokine. IL-6 is also the main stimulator of hepatic acute 
phase protein production (Gabay and Kushner 1999). Thus, serum concentration of IL-6 and 
concomitant IL-6-dependent CRP, amyloid A and fibrinogen concentrations are increased in 
subjects with IGT and T2DM compared to healthy control subjects (Müller et al. 2002). 
 
Some studies suggest no relationship between circulating IL-6 and deteriorated insulin-
stimulated glucose disposal and propose even insulin-sensitizing effects for IL-6 (Carey et al. 
2006). In skeletal muscle during acute exercise, production of IL-6 increases and circulating 
IL-6 concentration increases 100-fold (Febbraio and Pedersen 2002). In muscle, the present 
evidence suggests, that IL-6 may increase rather than decrease insulin sensitivity (Glund et al. 
2007). 
 
Glucocorticoids inhibit and catecholamines and TNFα stimulate expression of IL-6 in adipose 
tissue (Fried et al. 1998, Vicennati et al. 2002, Fasshauer et al. 2003a). IL-6 secretion is 
increased dose-dependently by insulin in adipocytes in vitro (Vicennati et al. 2002). Under 
euglycemic hyperinsulinemic conditions in humans, both subcutaneous adipose tissue gene 
expression and plasma concentration of IL-6 increase (Krogh-Madsen et al. 2004). In the 
latter study, no change in human skeletal muscle IL-6 expression was observed. In another 
study under hyperinsulinemic conditions, simultaneous infusion of human recombinant IL-6 
increased, rather than decreased, whole body glucose disposal with no effect on hepatic 
glucose production (Carey et al. 2006). Weight loss induced by hypocaloric diet in humans 
decreases both serum concentration and adipose tissue gene expression of IL-6 (Bastard et al. 
2000). 
 
Thus, despite strong relationship with inflammation, the contribution of IL-6 to insulin 
resistance is under vivid debate and more in vivo studies in humans are warranted. 
Adiponectin 
Adiponectin was identified by four research groups in the mid-1990s (Scherer et al. 1995, Hu 
et al. 1996, Maeda et al. 1996, Nakano et al. 1996) and was shown to be exclusively produced 
by mature adipocytes. Two adiponectin receptors, AdipoR1 and AdipoR2, mediating the 
effects of adiponectin have been characterized in the liver, skeletal muscle (Yamauchi et al. 
2003) and in adipose tissue (Rasmussen et al. 2006). 
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Adiponectin has been suggested to function as an insulin-sensitizing and anti-inflammatory 
adipocytokine (Kadowaki et al. 2006). In human hepatic cell line in vitro, biosynthesis and 
secretion of anti-atherogenic high-density lipoprotein (HDL) are increased by adiponectin 
(Matsuura et al. 2007). Mice deficient of adiponectin gene expression show notable insulin 
resistance and atherosclerosis in vivo (Kubota et al. 2002) and are characterized by increase in 
both adipose tissue expression and circulating concentration of TNFα (Maeda et al. 2002). 
Lipoatrophic mice deficient of subcutaneous adipose tissue show absent circulating 
adiponectin and insulin resistance, and infusion of adiponectin in these mice decreases insulin 
resistance (Yamauchi et al. 2001). Overexpression of adiponectin prevents diabetic phenotype 
of obese ob/ob mice (Kim et al. 2007). In addition, macrophage infiltration and TNFα 
expression in adipose tissue, circulating IL-6 concentration and liver fat content are decreased 
in these mice overexpressing adiponectin. Injections of adiponectin in mice decrease body 
weight and circulating FFA, glucose and insulin concentrations (Fruebis et al. 2001), and 
decrease glucose production by the liver (Combs et al. 2001). Adiponectin infusion also 
decreases liver fat content in both lipoatrophic (Yamauchi et al. 2001) and obese mice (Xu et 
al. 2003a). 
 
In human endothelial cells in vitro, beneficial cellular effects of adiponectin are suggested to 
involve inhibition of TNFα-mediated activation of NFκB (Ouchi et al. 2000). Also in human 
adipose tissue SVF cells and in monocyte-derived human macrophages in vitro, adiponectin 
incubation has been suggested to increase the anti-inflammatory M2-phenotype over 
proinflammatory M1-phenotype (Ohashi et al. 2009). In humans in vivo, adiponectin gene 
expression in adipose tissue is decreased in obese compared to lean subjects (Hu et al. 1996, 
Bruun et al. 2003). Also circulating concentration of adiponectin decreases in obesity (Arita et 
al. 1999), T2DM (Weyer et al. 2001) and in the MetS (Trujillo and Scherer 2005). Circulating 
adiponectin also correlates negatively with serum insulin concentration and positively with 
insulin sensitivity, as measured using the euglycemic hyperinsulinemic clamp technique 
(Weyer et al. 2001). Plasma adiponectin concentration correlates inversely with hepatic 
glucose production (Bajaj et al. 2004) and with expression and secretion of TNFα and IL-6 in 
adipose tissue (Bruun et al. 2003, Kern et al. 2003). A recent meta-analysis suggests a 
correlation between a higher circulating adiponectin concentration and a lower risk of T2DM 
in different ethnic groups independent of gender and BMI (Li et al. 2009). 
 
Concerning regulation of adiponectin in humans, treatment with TNFα and IL-6 with its 
soluble receptor (IL-6sR) decrease expression of adiponectin in adipose tissue in vitro (Bruun 
et al. 2003). Treatment with glitazones increases both plasma and adipose tissue expression of 
adiponectin in normal, obese and T2DM subjects without changes in body weight (Maeda et 
al. 2001, Yu et al. 2002b, Tiikkainen et al. 2004). Glitazone-induced decrease in liver fat 
content inversely correlates with concomitant increase in plasma adiponectin in T2DM 
patients (Tiikkainen et al. 2004). Weight loss in obese non-diabetic subjects increase plasma 
adiponectin concentration and this increase correlates with enhanced insulin sensitivity (Yang 
et al. 2001, Bruun et al. 2003, Esposito et al. 2003a). 
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Insulin stimulates adiponectin secretion in visceral but not in subcutaneous human adipocytes 
in vitro (Motoshima et al. 2002). In vivo studies in humans show no effect of up to 3 hours of 
euglycemic hyperinsulinemia on subcutaneous adipose tissue expression of adiponectin in 
healthy insulin-resistant (Lihn et al. 2003) or T2DM subjects (Koistinen et al. 2004). Longer, 
5-hour euglycemic hyperinsulinemia, however, was suggested to decrease plasma adiponectin 
in lean, obese and T2DM subjects, with no differences between the groups (Yu et al. 2002b). 
This discrepancy warrants further in vivo studies in humans to clarify the acute effects of 
insulin on adipose tissue expression of adiponectin. 
Plasminogen activator inhibitor 1 
Plasminogen activator inhibitor 1 (PAI-1) is the physiological rapid acting inhibitor of 
fibrinolysis and involved in the atherothrombotic process (Skurk and Hauner 2004). Adipose 
tissue is an important site of expression and secretion of PAI-1 in humans (Alessi et al. 1997). 
Other PAI-1 producing tissues include the liver, endothelium and thrombocytes. In adipose 
tissue, SVF has been suggested to be the predominant cell fraction of PAI-1 secretion 
(Bastelica et al. 2002). 
 
Mice deficient of PAI-1 expression show resistance to high-fat diet-induced obesity, have 
increased insulin sensitivity and adipose tissue PPARγ and adiponectin expression, and 
decreased muscle and hepatic lipid content compared to WT mice (Ma et al. 2004). Obese 
ob/ob mice with PAI-1-KO show decreased expression and secretion of TNFα in adipose 
tissue compared to obese mice expressing PAI-1 (Schafer et al. 2001). On the contrary, mice 
overexpressing PAI-1 have been suggested to exhibit reduced adipose tissue mass, lower 
fraction of stromal vascular cells in adipose tissue and lower fasting insulin concentration 
after high-fat diet-induced obesity compared to WT mice (Lijnen et al. 2003). 
 
In humans, circulating PAI-1 concentration is increased in subjects with insulin resistance, 
abdominal obesity and T2DM compared to healthy subjects (Juhan-Vague et al. 1989, 
Pannacciulli et al. 2002). Circulating concentration of PAI-1 and adiponectin are inversely 
correlated in obese women, independent of BMI and visceral adiposity (Mertens et al. 2005). 
In severely obese subjects, plasma PAI-1 concentration and activity correlate with 
histologically determined liver fat content (Alessi et al. 2003). In addition, in subjects with 
non-alcoholic fatty liver, circulating PAI-1 concentration is higher compared to subjects 
without steatosis (Targher et al. 2005). Consistent with data of circulating PAI-1, its gene 
expression in adipose tissue is increased in obese compared to lean subjects (Alessi et al. 
1997, Mavri et al. 2001). 
 
TNFα increases the expression and secretion of PAI-1 in both subcutaneous and visceral 
human adipose tissue in vitro (Cigolini et al. 1999). Also IL-6 induces PAI-1 production by 
human adipocytes (Rega et al. 2005). Weight loss induced by bariatric surgery or by 
hypocaloric diet in obese subjects decreases significantly both plasma concentration and 
adipose tissue expression of PAI-1 (Primrose et al. 1992, Mavri et al. 2001). In humans, 
contrary to mice and cell cultures (Samad and Loskutoff 1996), insulin appears to have no 
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effect on PAI-1 secretion in subcutaneous or visceral adipose tissue in vitro (Halleux et al. 
1999). Further, in vivo euglycemic hyperinsulinemia does not have an effect on plasma PAI-1 
concentration in normal subjects (Vuorinen-Markkola et al. 1992) or on adipose tissue 
interstitial PAI-1 concentration in obese subjects (Siklova-Vitkova et al. 2009). 
Resistin 
Resistin was first found in 3T3-L1 and mature mouse adipocytes and suggested to associate 
with obesity and to mediate insulin resistance in mice (Steppan et al. 2001, Rajala et al. 2003). 
Obese resistin-KO mice show decreased insulin resistance in the liver (Banerjee et al. 2004), 
muscle and adipose tissue (Qi et al. 2006), and decreased hepatic steatosis and VLDL 
production (Singhal et al. 2008) compared to WT mice. Overexpression of resistin results in 
hepatic and systemic insulin resistance (Satoh et al. 2004). 
 
In humans, the role of resistin in obesity and insulin resistance is less certain (Arner 2005). 
The predominant cell type of resistin production appears to be monocytes and macrophages 
with no expression in myocytes or adipocytes (Savage et al. 2001, Patel et al. 2003). In 
humans, resistin increase IL-6, IL-8 and MCP-1 gene expression in adipose tissue (Nagaev et 
al. 2006) and TNFα, IL-1 and IL-6 expression in monocytes in vitro (Bokarewa et al. 2005, 
Silswal et al. 2005). Some in vivo studies in humans suggest relationship between circulating 
resistin concentration and obesity (Degawa-Yamauchi et al. 2003), insulin resistance (Hivert 
et al. 2008) and T2DM (Youn et al. 2004). Many, if not the most, of the relevant studies 
show, however, no such relationships (Furuhashi et al. 2003, Lee et al. 2003b, Chen et al. 
2005b, Utzschneider et al. 2005). Interestingly, concentration of resistin in synovial fluid of 
inflamed joints is increased in patients with rheumatoid arthritis compared to patients with 
non-inflammatory joint diseases (Bokarewa et al. 2005). 
 
In human macrophages, TNFα, IL-6 and LPS significantly increase gene expression and 
secretion of resistin while resistin expression is inhibited by glitazones and salicylates through 
inhibition of NFκB (Kaser et al. 2003, Lehrke et al. 2004). Also LPS-induced endotoxemia in 
humans increases circulating concentration and monocyte expression of resistin in vivo 
(Lehrke et al. 2004). Glitazones also decrease circulating resistin concentration in T2DM 
patients, and this decrease is associated with decrease in hepatic steatosis and insulin 
resistance (Bajaj et al. 2004). Weight loss of ~5 % by orlistat or sibutramine decreases 
resistin, and increase adiponectin serum concentrations (Valsamakis et al. 2004). Thus, 
although the role of resistin in human obesity and insulin resistance remains controversial, a 
relationship between resistin expression, macrophage infiltration and inflammation exists. 
This justifies further in vivo studies in humans. 
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2.4. 11β-hydroxysteroid dehydrogenase 
In most peripheral tissues, two isozymes of 11β-hydroxysteroid dehydrogenase, type 1 and 2 
(11β-HSD-1/2), are responsible for interconversion of hormonally inactive cortisone and 
active cortisol (Seckl and Walker 2001). 11β-HSD-1 converts cortisone into cortisol and 11β-
HSD-2 vice versa. Isozyme type 2 is mainly expressed in the kidneys while the liver and 
adipose tissue express 11β-HSD-1. 
 
In rodent adipose tissue, both adipocytes and SVF express 11β-HSD-1 (Napolitano et al. 
1998). Obese rats show selective increase in 11β-HSD-1 activity in adipose tissue, and 
decrease in the liver (Livingstone et al. 2000). Selective inhibition (Alberts et al. 2003) or 
11β-HSD-1-KO in mice (Kotelevtsev et al. 1997) enhances hepatic insulin sensitivity and 
protects from obesity. 11β-HSD-1-KO mice also have decreased gene expression of resistin 
and TNFα in adipose tissue compared to WT mice (Morton et al. 2004). Overexpression of 
11β-HSD-1 selectively in adipose tissue in mice, essentially results in hyperlipidemia, 
visceral obesity, hepatic lipid accumulation, insulin resistance and diabetes (Masuzaki et al. 
2001). 
 
In humans, 11β-HSD-1 is expressed in both adipocytes (Bujalska et al. 2002) and mature 
monocyte-derived macrophages (Thieringer et al. 2001). Expression and activity of 11β-HSD-
1 in adipose tissue are associated with BMI, waist circumference and measures of insulin 
resistance in most (Paulmyer-Lacroix et al. 2002, Lindsay et al. 2003, Wake et al. 2003, 
Kannisto et al. 2004) but not all (Tomlinson et al. 2002) studies. Activity of 11β-HSD-1 
correlates with adipocyte cell size and appears higher in visceral compared to subcutaneous 
adipose tissue in humans (Bujalska et al. 1997, Veilleux et al. 2009). In spite of alterations in 
adipose tissue 11β-HSD-1 activity in obesity, circulating free cortisol concentration is 
comparable between obese and lean subjects (Strain et al. 1980). In healthy men, treatment 
with the non-selective inhibitor of 11β-HSD-1, carbenoxolone, increases whole body insulin 
sensitivity measured by euglycemic hyperinsulinemic clamp technique (Walker et al. 1995). 
 
In human adipose tissue SVF cells in vitro, TNFα increases the activity and expression of 
11β-HSD-1 while simultaneous insulin treatment inhibits these effects (Handoko et al. 2000). 
In human monocyte-derived macrophages in vitro, expression of 11β-HSD-1 is increased by 
LPS treatment (Thieringer et al. 2001). Both cortisol and insulin stimulate adipocyte 
differentiation during adipogenesis (Hauner et al. 1987). TNFα and different interleukins, 
such as IL-1 and IL-6, increase 11β-HSD-1 activity and/or gene expression in human 
adipocytes in vitro (Tomlinson et al. 2004). In humans in vivo, a 3-hour euglycemic 
hyperinsulinemia shows no effect on adipose tissue 11β-HSD-1 gene expression in healthy or 
T2DM subjects (Koistinen et al. 2004). Weight loss in obese subjects induced by hypocaloric 
diet, significantly decreased 11β-HSD-1 gene expression in subcutaneous adipose tissue 
(Purnell et al. 2009). Expression of 11β-HSD-1 in human monocyte-derived macrophages in 
obese and non-obese subjects has not been studied and the relationship between adipose tissue 
expression of 11β-HSD-1 and liver fat content is unknown. 
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2.5. Peroxisome proliferator-activated receptor γ 
Peroxisome proliferator-activated receptors α, δ (or β) and γ (PPARα/δ/γ) are nuclear 
receptors that regulate transcription of vast array of genes (Lee et al. 2003a). PPARα is 
mainly expressed in the liver regulating FFA uptake and oxidation, and functions as a receptor 
for PPARα-agonist drugs, such as fibrates. PPARδ increases glucose uptake and insulin action 
in human muscle and its protein expression in muscle is upregulated in response to exercise 
(Fritz et al. 2006). PPARγ is mainly expressed in adipose tissue and macrophages with low 
expression in the liver, muscle and β-cells (Vidal-Puig et al. 1997, Semple et al. 2006). 
PPARγ plays an important role in adipocyte differentiation (Tontonoz et al. 1994) and in 
regulation of genes involved in FFA uptake and TAG synthesis. 
 
Homozygous PPARγ-KO in mice is lethal but adipose tissue-specific KO results in adipocyte 
necrosis, decreased adipose tissue mass, compensatory increased adipocyte cell size (He et al. 
2003) and infiltration of inflammatory cells (macrophages, lymphocytes) in adipose tissue 
(Imai et al. 2004). Additionally, these mice show increased FFA and TAG concentrations, 
decreased adiponectin and leptin concentrations in plasma, increased susceptibility to diet-
induced fatty liver and insulin resistance in adipocytes and in the liver. Macrophage-specific 
PPARγ-KO in normal and lean mice has been shown to result in glucose intolerance, insulin 
resistance in skeletal muscle and in the liver and to blunted insulin-sensitizing effects of 
glitazones (Hevener et al. 2007). 
 
The discovery of the glitazone class of insulin-sensitizing drugs that are selective agonists of 
PPARγ, has made it possible to study effects of PPARγ (Lehmann et al. 1995). Pioglitazone 
and rosiglitazone are currently available for treatment of hyperglycemia in T2DM. Glitazones 
lower circulating glucose and insulin concentrations both in the fasting and postprandial 
states, decrease circulating FFA concentration and ameliorate insulin sensitivity in adipose 
tissue, skeletal muscle and in the liver (Yki-Järvinen 2004). Beneficial effects on gene 
expression and secretion of adipocytokines (TNFα, IL-6, adiponectin, PAI-1, MCP-1), 
redistribution of visceral fat to subcutaneous depot, increased FFA uptake and TAG storage 
by adipose tissue and decreased hepatic and muscle fat content contribute to insulin-
sensitizing actions of glitazones (Sharma and Staels 2007). 
 
Data of PPARγ gene expression in human adipose tissue are controversial while different 
studies suggest decreased, unchanged or increased expression in obese compared to lean 
subjects (Auboeuf et al. 1997, Vidal-Puig et al. 1997, Sewter et al. 2002, Giusti et al. 2003). 
In human adipose tissue in vitro, PPARγ agonist decreases MCP-1 secretion (Bruun et al. 
2003). In addition, in subjects with IGT pioglitazone decreases the number of histologically 
determined macrophages and expression of CD68 and MCP-1 in adipose tissue with 
concomitant increase in insulin sensitivity (Di Gregorio et al. 2005). Also in T2DM patients, 
glitazone treatment increases adiponectin and decreases TNFα, MCP-1, FFA and glucose 
plasma concentrations. In addition, glitazones increase adipose tissue expression of PPARγ 
and both whole body and hepatic insulin sensitivity in subjects with T2DM (Miyazaki et al. 
2004, Tiikkainen et al. 2004). 
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Concerning regulation, fasting and experimental insulin-deficiency decreases, while high-fat 
diet and insulin administration increases adipose tissue expression of PPARγ in mice (Vidal-
Puig et al. 1996). TNFα and IL-6 decrease expression of PPARγ in 3T3-L1 adipocytes (Rotter 
et al. 2003). In humans, insulin stimulates PPARγ expression in adipose tissue and adipocytes 
in vitro (Vidal-Puig et al. 1997), and 3-hour in vivo euglycemic hyperinsulinemia increases 
PPARγ expression in subcutaneous adipose tissue with no differences between control, obese 
or T2DM patients (Rieusset et al. 1999). 
2.6. PPARγ coactivator 1α 
The PPARγ coactivator 1α (PGC-1α) is a transcriptional cofactor that modulates 
transcriptional activity of PPARγ (Puigserver et al. 1998). PGC-1α is expressed mainly in the 
liver, brown adipose tissue, skeletal and heart muscles, but also in white adipose tissue. PGC-
1α universally induces mitochondrial oxidative metabolism with additional tissue-specific 
effects (Handschin and Spiegelman 2006). 
 
In humans, PGC-1α gene expression increases during preadipocyte differentiation and 
adipose tissue expression of PGC-1α correlates with that of IRS-1 and GLUT-4, and also with 
in vivo insulin action measured by euglycemic hyperinsulinemic clamp technique 
(Hammarstedt et al. 2003). Adipose tissue expression of PGC-1α is decreased in morbidly 
obese and insulin-resistant compared to lean and insulin-sensitive subjects (Hammarstedt et 
al. 2003, Semple et al. 2004). In T2DM patients, skeletal muscle PGC-1α expression is also 
decreased compared to healthy subjects (Patti et al. 2003). In the liver, fasting stimulates 
PGC-1α function and induces gluconeogenetic activity. The effects of acute regulation of 
PGC-1α expression by insulin in human adipose tissue in insulin-resistant and sensitive 
subjects have not been previously studied. 
2.7. Lipid mediators of insulin resistance 
2.7.1. Free fatty acids 
The serum concentration of FFA in the fasting and postprandial states is increased in obese 
insulin-resistant compared to lean insulin-sensitive subjects (see section 2.1. in REVIEW OF 
THE LITERATURE). In humans, increase of serum FFA concentration induces whole body 
and muscle insulin resistance (Nuutila et al. 1992) in a dose-dependent and reversible manner 
(Boden and Chen 1995, Belfort et al. 2005). Acute elevation in circulating FFA concentration 
under insulin-deficient, but not under well-insulinized conditions, stimulates hepatic glucose 
production in vivo in normal subjects (Ferrannini et al. 1983). Increased FFA concentration 
also blunts suppression of hepatic glucose production by insulin in humans (Homko et al. 
2003). In normal subjects after 16 to 24 hours of fasting, neither decrease nor increase in 
serum FFA by an antilipolytic drug, nicotinic acid, has an effect on EGP (Chen et al. 1999b). 
On the other hand, reduction of circulating FFA under hyperinsulinemic conditions by 
acipimox, an analog of nicotinic acid, augments the suppressive effect of insulin on hepatic 
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glucose production (Saloranta et al. 1991). An acute decrease in serum FFA concentration, 
induced by overnight administration of acipimox, enhances whole body insulin sensitivity in 
both obese non-diabetic and diabetic individuals (Santomauro et al. 1999). 
 
Randle with colleagues were the first to suggest a biochemical mechanism for the FFA-
induced defect in insulin-stimulated glucose uptake in muscle. The mechanism was studied 
using isolated heart and diaphragm muscles of rats and was called the glucose-fatty acid or 
Randle’s cycle (Randle et al. 1963). The studies showed that oxidation of glucose and FA in 
muscle was reciprocally regulated, and the hypothesis was that FA oxidation results in 
mitochondrial accumulation of acetyl-coenzyme A (-CoA) that directly inhibits pyruvate 
dehydrogenase (PDH) and increases citrate concentration. Citrate inhibits 
phosphofructokinase (PFK) leading to cytosolic accumulation of G6P that can be used for 
glycogen synthesis but is also an inhibitor of hexokinase that is responsible for glucose 
phosphorylation in the initial irreversible step of glycolysis. PFK and PDH, on the other hand, 
are the essential enzymes in the later steps of glycolysis. Thus, the oxidation of glucose would 
be suppressed during increased oxidation of FA. This hypothesis prevailed long until it was 
questioned by in vivo studies in humans showing that increase in circulating FFA 
concentration increases neither citrate, G6P nor glucose concentrations in muscle cells (Boden 
et al. 1991, Roden et al. 1996, Dresner et al. 1999). 
 
In rats, high-fat diet for 3 days increases fasting serum FFA concentration resulting in fatty 
liver and hepatic insulin resistance that could be attributed to increased activity of protein 
kinase C (PKC) and JNK and decreased activity of IRS-1 and -2 (Samuel et al. 2004). 
Another study on rat liver showed that increase in circulating FFA concentration activates 
PKC and NFκB in the liver and increases hepatic expression of TNFα and IL-1β and serum 
concentration of MCP-1 (Boden et al. 2005). MCP-1 may provide a link between expanding 
adipose tissue, inflammation and insulin resistance (see section 2.3. in REVIEW OF THE 
LITERATURE). Activation of PKC and NFκB can induce insulin resistance and inflammation 
in both muscle and the liver (Petersen and Shulman 2006). Also in 3T3-L1 adipocytes, FFA-
induced insulin resistance was mediated by activation of IKK-β and PKC and by inhibition of 
IRS-1 (Gao et al. 2004). In mice, long-chain FFA induce activation of JNK and increase 
expression of IL-6 and TNFα in macrophages, while specific JNK-KO in bone marrow-
derived cells (e.g. monocytes, macrophages) protects from high fat diet-induced insulin 
resistance and inflammation (Solinas et al. 2007). In addition, obesity and increased 
circulating FFA concentration induce ER stress that is accompanied with inflammatory 
responses and insulin resistance (Gregor and Hotamisligil 2007). In humans, increase in 
serum FFA concentration suppresses IRS-1 and PI3K activity in muscle cells decreasing 
GLUT-4 translocation and glucose transport (Dresner et al. 1999). 
 
Thus, FFA have multiple metabolic effects beyond inhibition of glucose oxidation via 
substrate competition. The effect of intravenous high dose FFA to induce insulin resistance 
takes approximately 3 hours to develop (Boden et al. 1991), and different metabolites of FA 
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have been suggested to account for the defect in insulin action. These include DAG and 
ceramides that are discussed in detail in the following sections. 
2.7.2. Diacylglycerols 
After uptake into the cell, FA can be metabolized, depending on FA composition and the 
energy need of the cell, through three different pathways. FA are first esterified to fatty acyl-
CoA and can then be β-oxidized in mitochondria, stored as TAG or metabolized into 
sphingolipids, such as ceramides (Holland et al. 2007b). DAG is formed de novo by 
combining two FA with glycerol-3-phosphate or by breakdown of phospholipids or TAG. 
DAG and ceramides are both able to inhibit insulin signaling, although the mechanisms are 
incompletely understood. HSL is considered crucial and rate-limiting lipolytic enzyme in 
DAG breakdown, since HSL-KO mice show accumulation of DAG in adipose and muscle 
tissue and decrease in stimulated lipolysis and glycerol release (Haemmerle et al. 2002). 
 
Studies in animal muscle in vitro and in vivo suggest that increased serum FFA concentration 
increases intramyocellular accumulation of fatty acyl-CoA and DAG leading to inhibitory 
serine phosphorylation of IRS-1 by PKC (Yu et al. 2002a). This results in decreased PI3K 
activity and GLUT-4-mediated glucose uptake. In human muscle in vitro, treatment with 
saturated FA blunts insulin-stimulated glucose uptake and increases PKC activity (Montell et 
al. 2001). In addition, saturated FA tend to incorporate into DAG fraction. 
 
In humans in vivo, expression and activity of muscle DAG kinase, an enzyme responsible for 
depleting DAG amount in cells, is decreased in T2DM patients compared to healthy subjects, 
thus suggesting a relationship between DAG and insulin resistance (Chibalin et al. 2008). In 
normal subjects, simultaneous euglycemic hyperinsulinemia and lipid (Intralipid) plus heparin 
infusion increased DAG content in muscle compared to insulin infusion alone (Itani et al. 
2002). In the latter study, the increase in muscle DAG was accompanied by decreased amount 
of IκB and increased activity of PKC in muscle and decrease in whole body glucose disposal. 
These data suggest that DAG regulates insulin signaling and inflammation, which both 
contribute to insulin resistance. 
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2.7.3. Ceramides 
Ceramides are sphingolipids with two FA of variable length linked to a sphingosine base. 
Ceramides can be synthesized in muscle and in the liver either de novo from saturated FA or 
from breakdown of sphingomyelin by sphingomyelinases (SMPD) (Holland and Summers 
2008). De novo synthesis is heavily dependent on the supply of long-chain saturated FA that 
participate to the initial and rate-limiting step in the synthesis pathway (Merrill 2002). 
Ceramides function also as precursors for more complex sphingolipids (Figure 2). 
 
Figure 2. Flow chart of ceramide synthesis both de novo and from breakdown of 
sphingomyelin. Numbers indicate enzymes participating in sphingolipid metabolism; 1) 
Serine palmitoyltransferase, 2) 3-Ketosphinganine reductase, 3) Dihydroceramide 
synthase, 4) Dihydroceramide desaturase, 5) Sphingomyelinase, 6) Sphingomyelin 
synthase, 7) Ceramidase, 8) Ceramide kinase, 9) Glucosylceramide synthase. Modified 
from Holland and Summers 2008. 
Although a minor component of all lipids (Kotronen et al. 2009c), ceramides function as 
bioactive lipid metabolites mediating insulin resistance and inflammation (Holland et al. 
2007a) by inactivating Akt/PKB (Powell et al. 2003). Ceramides decrease GLUT-4 (Long and 
Pekala 1996) and increase TNF-α, MCP-1, PAI-1 and IL-6 (Samad et al. 2006) gene 
expression in 3T3-L1 adipocytes. Several studies show relationships between ceramides and 
different inflammatory pathways including TNFα-activated JNK/NFκB pathway and also toll-
like receptor pathway that mediates the effects of LPS and stimulates inflammatory cytokine 
expression (Holland and Summers 2008) (Figure 3). 




Figure 3. Regulation of cellular metabolism by ceramide. Arrows with (+) indicate 
stimulatory effect and lines with (-) indicate inhibitory effect. Modified from Summers 
2006. 
In muscle in vitro, insulin signaling is inhibited and ceramide formation increased by long-
chain saturated FFA, but not by short-chain or unsaturated FFA (Chavez and Summers 2003). 
In rats, infusion of saturated lipids increases muscle ceramide content and whole body insulin 
resistance while infusion of unsaturated lipids results in insulin resistance independent of 
muscle ceramide accrual (Holland et al. 2007a). In cell cultures, TNFα stimulates both de 
novo and SMPD pathway of ceramide synthesis (Dbaibo et al. 2001). In animal models, 
inhibition of serine palmitoyltransferase (SPT), the essential enzyme regulating de novo 
ceramide synthesis, prevents the accumulation of ceramides in the liver and muscle and the 
decrease in insulin-stimulated glucose disposal in obesity or after lipid infusion (Holland et al. 
2007a). 
 
In humans, serum ceramides are carried in lipoproteins, mostly (~80 %) in VLDL and low-
density lipoprotein (LDL) particles (Lightle et al. 2003, Kotronen et al. 2009c). After LPS-
induced acute systemic inflammation in healthy subjects, concentration of ceramides in serum 
and in VLDL and LDL increased significantly. These results were reproduced in mice and, in 
addition, animal studies showed increased SPT activity in the liver and increased SMPD 
activity in serum suggesting that LPS-induced changes in lipoprotein ceramide content are 
due to increased de novo synthesis in the liver and increased breakdown of sphingomyelin in 
LDL particles (Lightle et al. 2003). 
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In human muscle, concentration of ceramides is increased in obese and insulin-resistant 
subjects compared to lean and insulin-sensitive subjects (Adams et al. 2004). Muscle 
ceramide content is also positively correlated with circulating FFA concentration. In healthy 
subjects, total ceramide content in muscle is, independent of BMI and serum FFA 
concentration, negatively correlated with insulin sensitivity measured with euglycemic 
hyperinsulinemic clamp technique (Straczkowski et al. 2004). In the latter study, lipid 
(Intralipid) plus heparin infusion increased ceramide content and SMPD activity in muscle 
and decreased whole body insulin sensitivity. Another study reported no differences in muscle 
ceramide content between T2DM or insulin-resistant subjects and insulin-sensitive subjects 
(Skovbro et al. 2008). Another study found no change in ceramide concentration in human 
skeletal muscle after 6 hours of lipid (Intralipid) infusion or acipimox treatment (Serlie et al. 
2007). 
 
In recent years, advances in lipidomics methodology (described in section 5. in METHODS) 
that combines ultra performance liquid chromatography, mass spectroscopy and data 
processing have enabled characterization and quantitation of numerous lipid species, such as 
TAG, DAG, FFA, ceramides and other phospholipids. FFA chain length and degree of 
saturation can also be determined. This method has not been previously used to study human 
adipose tissue. 
3. Insulin resistance in the liver 
3.1. Non-alcoholic fatty liver disease and insulin resistance 
3.1.1. Definition 
Sites of lipid deposition outside adipose tissue include the liver, skeletal muscle, heart muscle 
and the pancreas. NAFLD refers to increased (>5-10 % fat as determined by histology) liver 
fat content that is not due to excess alcohol consumption or any other known causes of liver 
disease (hepatitis B or C, toxic or autoimmune liver disease, hemochromatosis, Wilson’s 
disease, hypobetalipoproteinemia) (Neuschwander-Tetri and Caldwell 2003). If assessed by 
non-invasive 1H-MRS, liver fat of 5.6 % (55.6 mg of TAG/g of liver tissue) is the upper limit 
of normal. The latter threshold corresponds to the 95th percentile of liver fat distribution in 
healthy non-obese subjects (n=345) without a history of liver disease, excessive alcohol 
consumption or diabetes and with normal serum ALT activity in the Dallas Heart Study 
(Szczepaniak et al. 2005). NAFLD covers a spectrum of liver conditions from simple steatosis 
to non-alcoholic steatohepatitis (NASH) and cirrhosis. The diagnosis of NASH requires a 
biopsy (Angulo 2009) and liver histology is characterized by lobular inflammation and 
hepatocellular ballooning in addition to steatosis. 
3.1.2. Prevalence and significance 
NAFLD is the most common cause of elevated serum aminotransferase activities (Clark et al. 
2003). The prevalence estimates for NAFLD vary considerably depending on the methods and 
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population studied (Clark 2006). When liver fat was measured by 1H-MRS in Caucasian, 
African American and Hispanic subjects (n=2349) in the population-based Dallas Heart 
Study, ~30-35 % had hepatic steatosis (Szczepaniak et al. 2005). The prevalence of NAFLD 
is even higher in obesity and T2DM (Angulo 2002). In morbidly obese patients (n=551) 
undergoing bariatric surgery, in whom liver biopsies where histologically analyzed, 86 % had 
steatosis, 24 % mild inflammation or NASH, and 2 % cirrhosis (Marceau et al. 1999). A 
normal serum ALT activity does not exclude steatosis since ~79 % of subjects with NAFLD 
have normal serum ALT (Browning et al. 2004). 
 
NAFLD has been shown to predict CVD and T2DM in several prospective studies 
independent of obesity (Targher et al. 2007, Kotronen and Yki-Järvinen 2008). Simple 
steatosis can progress into more serious NASH with mild to moderate fibrosis in 
approximately 10-20 % of cases (Day 2006). Of these, ~5-15 % will develop severe fibrosis 
and of these, up to ~10 % cirrhosis over 15 years. The risk of hepatocellular carcinoma is also 
increased (Angulo 2002). It has been suggested that NASH might be the most common cause 
of liver transplantation by the year 2020 in the United States (Charlton 2004). 
3.1.3. The metabolic syndrome and hepatic insulin resistance 
The MetS, originally known as syndrome X (Reaven 1988), is a cluster of metabolically 
interrelated risk factors for CVD and T2DM. The prevalence of the MetS in adults in the 
United States and Europe is approximately 20-30 % (Grundy 2008). The MetS increases the 
risk of CVD events and death approximately 2-fold and the likelihood of developing T2DM 
5-fold. Many previous definitions of the MetS exist and the most recent joint interim 
statement by several international organizations include five criteria: elevated waist 
circumference (≥94 cm in Europid males, ≥80 cm in females), elevated TAG (≥1.7 mmol/l) 
and glucose (≥5.6 mmol/l) concentrations, elevated blood pressure (systolic≥130 mmHg or 
diastolic≥85 mmHg) and reduced HDL-cholesterol concentration (<1.0 mmol/l in males, <1.3 
mmol/l in females) (Alberti et al. 2009). In addition to defined thresholds, specific drug 
treatment for the four latter criteria is also sufficient to fulfill the criteria. To have the MetS, a 
subject has to have any three of the five risk factors (Alberti et al. 2009). 
 
The prevalence of fatty liver is increased in obesity (Wasastjerna et al. 1972) and liver fat is 
significantly increased in subjects with the MetS (Alberti et al. 2005) than without. Liver fat 
content correlates closely with all components of the MetS and these correlations remain 
significant even after adjusting for BMI, age and gender (Kotronen et al. 2007b). In addition, 
other markers of insulin resistance, such as the intra-abdominal fat mass, and insulin and C-
peptide concentrations, correlated positively with liver fat content (Westerbacka et al. 2004). 
Serum insulin and C-peptide concentrations are more closely related to liver fat content than 
to hepatic transaminase activities or components of the MetS (Kotronen et al. 2007b). These 
data imply that the non-alcoholic fatty liver is the hepatic manifestation of the MetS and it 
may help to distinguish the subjects who develop insulin resistance and the MetS, from those 
who do not. 
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Liver fat content correlates positively with hepatic insulin resistance that, in turn, plays a 
central role in the relationship between fatty liver and the MetS. When excess TAG deposits 
in the liver, the normal inhibitory action of insulin on hepatic glucose production is impaired 
(Ryysy et al. 2000, Seppälä-Lindroos et al. 2002) which, in turn, stimulates a compensatory 
secretion of insulin. This results in normal or mild hyperglycemia and hyperinsulinemia. 
Increased liver fat content also impairs hepatic insulin clearance that contributes to 
hyperinsulinemia (Kotronen et al. 2007a). Normally, insulin also inhibits secretion of TAG-
rich VLDL by the liver (Malmström et al. 1997). Once the liver becomes fatty, this inhibition 
is blunted (Adiels et al. 2006) resulting in overproduction of VLDL and consequent 
hypertriglyceridemia, low serum HDL-cholesterol concentration and small dense LDL 
particles. This atherogenic lipid triad characterizes both the MetS and T2DM (Adiels et al. 
2008). 
3.1.4. Causes of liver fat and hepatic insulin resistance 
Acquired causes. Obesity is associated with whole body and hepatic insulin resistance and 
liver fat, but the variation in liver fat content at any given BMI or waist circumference is 
considerable (Yki-Järvinen 2005, Kotronen et al. 2007b). Acquired obesity in monozygotic 
(MZ) twins is associated with increased liver fat content (Pietiläinen et al. 2005). Even a 
single mixed meal can rapidly increase liver fat content in normal subjects (Ravikumar et al. 
2005). Fast food-based overfeeding in healthy subjects for 4 weeks resulted in ~9 % weight 
gain, 2- to 3-fold increase in liver fat content and 4- to 5-fold increase in serum ALT activity 
(Kechagias et al. 2008). Fatty liver is associated with increased intake of total and, especially, 
saturated fat (Tiikkainen et al. 2003, Pietiläinen et al. 2005). Weight loss decreases liver fat 
content (Luyckx et al. 2000, Petersen et al. 2005) and the decrease in hepatic TAG is 
relatively faster and greater than that from other sites in the body (Tiikkainen et al. 2003). 
Excess consumption of carbohydrates, especially fructose, has been associated with 
hypertriglyceridemia, insulin resistance and increased DNL in humans (Faeh et al. 2005, 
Havel 2005). In normal subjects, ingestion of fructose stimulates hepatic DNL more than 
glucose alone (Parks et al. 2008). Thus, increased consumption of refined sugars could 
contribute to the development of a fatty liver and the MetS. Concerning treatment of NAFLD, 
PPARγ agonists decrease liver fat content and increase hepatic insulin sensitivity in patients 
with T2DM, while metformin only ameliorates hepatic insulin sensitivity but does not appear 
to change liver fat content (Tiikkainen et al. 2004, Yki-Järvinen 2009). 
 
Inherited causes. Family studies (Willner et al. 2001) and comparison between different 
ethnic groups (Browning et al. 2004, Petersen et al. 2006) suggest that genetic factors 
contribute to NAFLD. Studies comparing genotypes of different candidate genes, until the 
recent discovery of variation in adiponutrin gene (Romeo et al. 2008), have not provided 
conclusive evidence of an exclusive role of any gene. The heritability of liver enzymes has 
previously been assessed in adolescent or elderly twins but it is unclear whether these subjects 
had NALFD (Bathum et al. 2001, Middelberg et al. 2007). 
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Sources and composition of intrahepatocellular TAG. The sources of FA in 
intrahepatocellular TAG include adipocyte lipolysis, spillover of FFA from intravascular 
lipolysis of chylomicrons, hepatic uptake of chylomicron and VLDL remnants and DNL (see 
section 1.2.2. in REVIEW OF THE LITERATURE). Although DNL is increased in human 
NAFLD (Donnelly et al. 2005), lipolysis of stored TAG in adipose tissue accounts for the 
major part of hepatic FA delivery. FA appear to originate mainly from peripheral tissues since 
even in markedly abdominally obese subjects, splanchnic lipolysis accounts only for up to 
~30 % of hepatic FA delivery (Nielsen et al. 2004). The FA composition of 
intrahepatocellular TAG is characterized by increased amount of saturated and decreased 
amount of unsaturated FA (Kotronen et al. 2009b). 
 
Role of adipose tissue in the pathogenesis of NAFLD. Adipose tissue is inflamed in obese 
subjects (Weisberg et al. 2003) and inflammation may induce insulin resistance in adipocytes 
that results in blunted antilipolytic effect of insulin (see sections 2.1 and 2.2. in REVIEW OF 
THE LITERATURE). Adiponectin is secreted exclusively by adipocytes and suggested to 
possess anti-inflammatory and insulin-sensitizing effects and to decrease liver fat. 
Concentration of adiponectin in both serum and adipose tissue is decreased in obese and 
insulin-resistant subjects, and PPARγ agonist-induced decrease in liver fat content and 
increase in serum adiponectin concentration are closely interrelated in humans (see 
Adiponectin in section 2.3. in REVIEW OF THE LITERATURE). Thus, inflammation in 
adipose tissue and increased release of FFA and decreased production of adiponectin are 
likely to regulate liver fat and hepatic insulin sensitivity (see Figure 1 in section 2.2. in 
REVIEW OF THE LITERATURE). Human studies assessing the relationship between adipose 
tissue inflammation and NAFLD are scarse. In one study, the number of macrophages in 
omental, but not subcutaneous, adipose tissue was shown to be related to liver fat content in 
morbidly obese subjects (Cancello et al. 2006). Whether subcutaneous adipose tissue 
inflammation is associated with liver fat content in humans in vivo independent of obesity, is 
unknown. 
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AIMS OF THE STUDY 
The present studies were performed to answer the following questions: 
 
1) How does insulin in vivo acutely regulate expression of selected ”insulin resistance genes” 
(IL-6, TNFα, 11β-HSD-1, MCP-1, MIP-1α) and ”insulin sensitivity genes” (GLUT-4, 
PPARγ, PGC-1α, adiponectin) in subcutaneous adipose tissue of insulin-sensitive and insulin-
resistant subjects (studies I and II)? 
 
2) Is adipose tissue inflammation (i.e. infiltration of macrophages, expression of inflammatory 
genes) related to hepatic fat accumulation independent of obesity (studies III and IV)? 
 
3) Are there differences in adipose tissue inflammation between equally obese groups of 
subjects with high compared to normal liver fat content (study IV)? 
 
4) What are the relative roles of genetic and environmental factors on interindividual variation 
in serum ALT activity, a surrogate marker of liver fat content, in young adult MZ and 
dizygotic (DZ) twins (study V)? 
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SUBJECTS AND STUDY DESIGNS 
1. Subjects 
 
Baseline characteristics of the study subjects in studies I-V are shown in Table 2. The 
participants in studies I-IV were Caucasian women (total number of 55) who were recruited 
based on the following criteria: 1) age 18-60 years, 2) no known acute or chronic disease 
other than obesity determined by medical history, physical examination and standard 
laboratory tests (blood counts, sedimentation rate, electrolytes, glucose, creatinine, thyroid-
stimulating hormone, electrocardiogram), 3) stable weight (±5kg) during the preceding 6 
months, 4) alcohol consumption less than 20 grams (i.e. two drinks) per day assessed by 
interview and questionnaire, 5) no treatment with drugs that may alter glucose tolerance, 6) no 
pregnancy. Elevated serum liver enzyme activities (ALT; aspartate aminotransferase, AST; γ-
glutamyl transferase, γGT) were not exclusion criteria. 
 
For study V, subjects were recruited based on the same criteria as in studies I-IV from a 
population-based longitudinal study (FinnTwin16) of five consecutive birth cohorts (1975-
1979) of Finnish twins, their siblings and parents through the National Population Registry of 
Finland (Kaprio et al. 2002). The subjects in study V were MZ and same-sex DZ twin pairs 
(total of 313 subjects) recruited based on their body weight, height and BMI at the last follow-
up in the FinnTwin16 study (mean age 27.3±0.2 years, range 23.2-32.2). The aim was to 
cover the full BMI range of both normal-weight and obese subjects. The BMI in the present 
study subjects (mean 24.1±0.2 kg/m2, range 17.6-42.9 kg/m2) matched with that of the whole 
cohort (22.9±0.1 kg/m2, 14.0-44.2 kg/m2). Intrapair differences in liver fat content between 13 
MZ twin pairs discordant for obesity (mean intrapair BMI difference 5.0±0.5 kg/m2) was also 
separately determined. 
 
The nature and potential risks of the studies were explained to all subjects before obtaining 
their written informed consent. The present studies adhere to the principles of the Declaration 
of Helsinki, and the Ethics Committee of Helsinki University Central Hospital approved the 
protocols. 
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2. Study designs 
The specific design and measurements of the individual studies I-V are listed below. 
 
Studies I and II. A total of 21 non-diabetic women were divided into insulin-sensitive and 
insulin-resistant groups based on their median whole body insulin sensitivity that was 
determined by euglycemic hyperinsulinemic clamp technique. Gene expression of GLUT-1, 
GLUT-4, PPARγ, PGC-1α, 11β-HSD-1, TNFα, adiponectin, IL-6, CD68, EMR1, ITGAM, 
ADAM8, MCP-1 and MIP-1α was measured in needle aspiration biopsy of abdominal 
subcutaneous adipose tissue using semi-quantitative real-time polymerase chain reaction (RT-
PCR) technique. Biopsy was taken after an overnight fast and repeated after 3 and 6 hours of 
euglycemic hyperinsulinemia. In addition, adipose tissue protein concentration of MCP-1 and 
serum concentration of MCP-1 and MIP-1α were measured using enzyme-linked 
immunosorbent assay (ELISA) in study II. Body weight, height and BMI, as well as waist and 
hip circumference were measured. Percent body fat was determined with bioelectrical 
impedance analysis. Fasting blood sample for measurement of glucose, insulin, C-peptide and 
blood lipid concentrations was obtained. 
 
Study III. A total of 20 non-diabetic women were divided into non-obese and obese groups 
based on their median BMI. Insulin sensitivity and adipose tissue gene expression after an 
overnight fast were measured as in studies I and II. Liver fat content was measured non-
invasively using 1H-MRS. Another group of 14 women was similarly divided into non-obese 
and obese groups and fasting blood sample was obtained for isolation and differentiation of 
circulating monocytes into macrophages in vitro. Gene expression of TNFα, 11β-HSD-1 and 
resistin in macrophages was measured both basally and after 3 and 6 hours of LPS-stimulation 
with RT-PCR. In all subjects, fasting blood sample was obtained and body fat and 
anthropometric measures were determined as in studies I and II. 
 
Study IV. A total of 20 non-diabetic obese women were divided into two groups based on 
their median liver fat content measured by 1H-MRS. Both groups were equally obese and of 
same age. Body fat composition (subcutaneous and visceral fat) was measured using magnetic 
resonance imaging (MRI). A surgical biopsy of abdominal subcutaneous adipose tissue was 
obtained after an overnight fast. Part of the biopsy was used for measurement of fat cell size 
by collagenase digestion and for quantification of inflammatory and macrophage marker gene 
expression with RT-PCR. Another part of the biopsy was used for immunohistochemical 
staining to assess the actual number of macrophages and necrotic adipocytes and their 
relations. Adipose tissue MCP-1 concentration was determined as in study II. To assess the 
numerous individual lipid species (such as ceramides, DAG and long-chain FA) in adipose 
tissue, a lipidomics analysis was performed using ultra-performance liquid chromatography 
and mass spectrometry. Fasting blood sample was obtained and anthropometric measures 
were determined as in studies I and II. 
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Study V. A total of 313 MZ (n=120) and same-sex DZ (n=193) twins participated in the study. 
Zygosity was confirmed by 10 informative genetic markers. Heritability of serum ALT 
activity and insulin concentration was estimated by heritability model fitting using Mx 
statistical package. To validate the use of ALT and insulin as surrogate markers of liver fat, 
1H-MRS was used to measure liver fat content in a subgroup of 66 subjects (46 MZ, 20 DZ 
subjects). The intrapair differences in liver fat content between MZ twin pairs (n=13) 
discordant for obesity (mean intrapair difference 5.0±0.5 kg/m2) were also determined. 
Statistical analyses were corrected for clustered twin data. Fasting blood sample for 
measurement of liver enzyme activities and of insulin and glucose concentrations was 
obtained, and percent body fat was measured using DEXA. Anthropometric measures were 





1. Whole body insulin sensitivity 
1.1. Euglycemic hyperinsulinemic clamp (studies I-III) 
Whole body insulin sensitivity was measured using the euglycemic hyperinsulinemic clamp 
technique (DeFronzo et al. 1979). The study started at 07:30 after an overnight fast. Two 18 
gauge catheters (Venflon, Viggo-Spectramed, Helsingborg, Sweden) were first inserted. One 
in an antecubital vein for infusion of insulin and glucose, and another retrogradely in a heated 
dorsal hand vein to obtain arterialized venous blood for measurement of plasma glucose 
concentration every 5 min and serum insulin concentration every 30 min. Regular human 
insulin (Insulin Actrapid, Novo Nordisk, Bagsvaerd, Denmark) was infused in a primed-
continuous fashion. The rate of the continuous insulin infusion was 1 mU/kg⋅min for 6 hours. 
Normoglycemia was maintained by adjusting the rate of a 20 % glucose infusion based on 
plasma glucose measurements. Whole body insulin sensitivity (M-value) was determined 
from the glucose infusion rate required to maintain normoglycemia (DeFronzo et al. 1979) 
between 30 and 360 min in studies I and II and between 30 and 120 min in study III. Glucose 
infusion rate is corrected for glucose pool size and the M-value is expressed as mg/kg fat free 
mass (FFM)⋅min. 
2. Liver fat content 
2.1. Proton magnetic resonance spectroscopy (studies I-V) 
Localized single voxel (2x2x2 cm) proton spectra were acquired using a 1.5 T whole body 
system (Magnetom Vision, Siemens, Erlangen, Germany) that consisted of a combination of 
whole body and loop surface coils for radiofrequency transmitting and signal receiving. T1-
weighted high-resolution MRI scans were used for localization of the voxel of interest. 1H-
MRS measurements of the liver fat were performed in the middle of the right lobe of the liver 
at a location that was individually determined for each subject avoiding vascular structures 
and subcutaneous fat tissue. Subjects lay on their stomachs on the surface coil that was 
embedded in a mattress to minimize abdominal movement due to breathing. The single voxel 
spectra were recorded using the stimulated-echo acquisition mode sequence with an echo time 
of 20 msec, a repetition time of 3000 msec, a mixing time of 30 msec and 1024 data points 
over 1000 kHz spectral width with 32 averages. Water-suppressed spectra with 128 averages 
were also recorded to detect weak lipid signals. A short echo time and long repetition time 
were chosen to ensure a fully relaxed water signal that was used as an internal standard. 
Chemical shifts were measured relative to water at 4.80 parts per million (ppm). The signal 
from methylene groups that represents intracellular TAG was measured at 1.4 ppm. Signal 
intensities were quantified by using an analysis program (VAPRO-MRUI, 
http://www.mrui.uab.es/mrui/). The spectroscopic intracellular TAG content (liver fat) was 
expressed as a ratio of the area under the methylene peak to that under the methylene and 
water peaks (×100=percent liver fat). This measurement has been validated against 
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histologically determined lipid content (Longo et al. 1993, Thomsen et al. 1994), and against 
estimates of fatty degeneration or infiltration by x-ray computer-assisted tomography by our 
group (Ryysy et al. 2000) and others (Thomsen et al. 1994). All spectra were analyzed by 
physicists who were unaware of the clinical data. The reproducibility of repeated 
measurements of liver fat in non-diabetic subjects studied on two occasions in our laboratory 
is 11 % (Sutinen et al. 2002). 
3. Adipose tissue gene and protein expression and 
immunohistochemistry 
3.1. Adipose tissue biopsy, fat cell size and total RNA and cDNA preparation 
(studies I-IV) 
A needle aspiration (studies I-III) or surgical (study IV) biopsy of abdominal subcutaneous 
adipose tissue was taken under local anesthesia after an overnight fast (Yki-Järvinen et al. 
1986). In studies I-III, the aspiration biopsy was repeated after 3 and 6 hours of 
hyperinsulinemia and each biopsy was obtained from a different location in the left, middle 
and right lower abdominal region. Part of the fresh basal sample was incubated with 
collagenase to isolate adipocytes and to measure cell size with light microscope (Hirsch and 
Gallian 1968). All other samples were immediately frozen in liquid nitrogen and stored at -
80°C until ribonucleic acid (RNA) analysis. Frozen fat tissue samples (50-150 mg) were 
homogenized in 2 ml RNA STAT-60 (Tel-Test, Friendswood, TX) and total RNA isolated 
according to the manufacturer’s instructions. After DNase treatment (RNase-free DNase set, 
Qiagen, Hilden, Germany), RNA was purified (RNeasy minikit, Qiagen) and the RNA 
concentration was measured using the RiboGreen fluorescent nucleic acid stain (RNA 
quantification kit, Molecular Probes, Eugene, OR) and Light Cycler (Roche Diagnostics 
GmbH, Mannheim, Germany). The quality of RNA was checked by agarose gel 
electrophoresis (Studies I-III) or by Agilent Bioanalyzer 2100 (Agilent Technologies, Santa 
Clara, CA) (Study IV). Isolated RNA was stored at -80˚C until qualification of the target 
messenger RNA (mRNA). A total of 0.1 μg RNA was reverse transcribed into 
complementary deoxyribonucleic acid (cDNA) using Moloney murine leukemia virus reverse 
transcriptase (Life Technologies, Paisley, UK) and oligo (dT)12-18 primers. 
3.2. Quantification of gene expression (studies I-IV) 
The concentration of mRNA of specific genes in adipose tissue was quantified by RT-PCR 
using the ABI 7000 Sequence Detection System instrument and software (Applied 
Biosystems, Foster City, CA). cDNA synthesized from 15 ng of total RNA was mixed with 
TaqMan Universal PCR Master Mix (Applied Biosystems) and a gene-specific primer and 
probe mixture (pre-developed TaqMan Gene Expression Assays, Applied Biosystems) in a 
final volume of 15μl (studies I and II) or 25 μl (studies III and IV). All samples were run in 
duplicate. Relative expression levels were determined using a 5- to 6-point serially diluted 
standard curve generated from human adipose tissue cDNA and was expressed in arbitrary 
units. To compensate for differences in cDNA loading, gene expression was normalized 
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relative to the average expression of two separate housekeeping genes, ribosomal protein 
large P0 (RPLP0) and TATA-box binding protein (TBP). In study I, part of the gene 
expression quantification (β-actin (ACTB), PPARγ and adiponectin) was performed by RT-
PCR using LightCycler technology (Roche Diagnostics, Mannheim, Germany) with 
LightCycler-FastStart DNA SYBR Green I Mix (Roche) and 0.5 μmol/l primers. An aliquot 
of 2 μl 1:10 diluted cDNA was brought to final volume of 20 μl and standard curves were 
created using purified cloned plasmid cDNA (QIAquick PCR Purification Kit, Qiagen) or 
specific PCR product. In study I, expression of PPARγ and adiponectin were expressed 
relative to housekeeping gene ACTB. 
 
The assays used in studies I-IV were: Hs00154355_m1 for CD68, Hs00173562_m1 for 
EMR1, Hs00355885_m1 for ITGAM, Hs00174246_m1 for ADAM8, Hs00234140_m1 for 
MCP-1, Hs00234142_m1 for MIP-1α, Hs00605917_m1 for adiponectin, Hs00234592_m1 for 
PPARγ, Hs00194153_m1 for 11β-HSD-1, Hs00174131_m1 for IL-6, Hs00174128_m1 for 
TNFα, Hs00167155_m1 for PAI-1, Hs00609415_m1 for SMPD1, Hs00906924_g1 for 
SMPD2, Hs00218713_m1 for SMPD3, Hs00220767_m1 for resistin, Hs99999910_m1 for 
TBP and Hs99999902_m1 for RPLP0. Primer and probe sets for GLUT-1, GLUT-4 and 
ACTB have been published previously (Kannisto et al. 2004, Sutinen et al. 2004). The 
expression of a housekeeping gene is not affected by any studied variables or traits, and it is 
used as an endogenous reference to all other genes whose expression is measured. In studies 
I-IV, the expression of housekeeping genes ACTB, RPLP0 and TBP were essentially 
comparable between the studied groups. 
3.3. Protein expression (studies II and IV) 
A frozen sample of human subcutaneous adipose tissue (100-430 mg) was homogenized in 
lysis buffer (Ryden et al. 2002). The homogenate was centrifuged for 30 min (+4°C, 14000 
rpm) and the supernatant was stored at -80°C until measurement of MCP-1 protein 
concentration using Human CCL2/MCP-1 ELISA Immunoassay kit (Quantikine, R&D 
Systems, Minneapolis, MN) and the Bio Assay Reader HTS 7000 Plus (Perkin Elmer, 
Norwalk, CT). Total protein was measured using the BC Assay-protein quantitation kit 
(Uptima Interchim, Montlucan, France). 
3.4. Immunohistochemistry (study IV) 
Part of the adipose tissue biopsies in study IV were used for immunohistochemical staining 
for the assesment of macrophages and necrotic adipocytes in adipose tissue. Positive CD68 
staining was used as a marker for macrophages and negative perilipin staining as a marker for 
necrotic adipocytes, as previously described (Cinti et al. 2005). Staining was performed using 
a standard protocol on sections from formalin-fixed paraffin-embedded tissue blocks. Serial 
sections were microwave-treated in 10 mmol/l citrate buffer (pH 6.0) and incubated for 1 hour 
at room temperature with primary antibodies; mouse monoclonal anti-CD68 (Novocastra 
Laboratories, Newcastle upon Tyne, U.K.), guinea pig polyclonal anti-perilipin (Acris, 
Hiddenhausen, Germany) or mouse monoclonal isotypic control (Abcam, Cambridge, U.K.) 
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for CD68. After rinsing in PBS buffer containing 0.25 % Triton X-100 (pH 7.2), sections 
were incubated with secondary biotinylated goat anti-mouse (Dako cytomation, Dako, 
Glostrup, Denmark) or biotinylated goat anti-guinea pig (Abcam) antibodies. Avidin-biotin 
peroxidase complexes (Vector Laboratories, Burlingame, CA) were added followed by 
visualization with 3.3´-diaminobenzidine tetrachloride (Vector). All sections were 
counterstained with Harris hematoxylin (Histolab, Gothenburg, Sweden). For each subject, 
the number of macrophages (identified as CD68-positive cells) and CLS (perilipin-free 
adipocyte surrounded by at least three macrophages) (Cinti et al. 2005) within the entire 
section were counted by two independent observers using a light microscope and normalized 
for the total section area. Measurement of total section area and average adipocyte area (in 
arbitrary units) was performed using the GNU Image Manipulation Program 2.2 (GIMP 2.2). 
4. Monocyte isolation, differentiation and stimulation (study III) 
In study III, 50 ml of blood was drawn from 14 subjects after an overnight fast for the in vitro 
studies assessing basal and LPS-stimulated gene expression in monocyte-derived human 
macrophages. Monocytes were isolated from buffy coats by centrifugation in Ficoll-Paque 
(Amersham Bioscience AB, Uppsala, Sweden) gradient as described (Saren et al. 1996). 
Washed cells were suspended in Macrophage-SFM Medium (Gibco, Invitrogen Corporation, 
Grand Island, NY) containing streptomysin-penicillin (Sigma, St.Louis, MO). The monocytes 
were counted and seeded on 6-well plates. After 1 hour, non-adherent cells were removed and 
GM-CSF (5 ng/ml, Sigma) was added. Monocytes were cultured for 7 days for differentiation 
into macrophages. 10 μl of LPS (10 μg/ml, LPS of Salmonella typhimurium, Sigma) or saline 
(0.9 %) per 1 ml of SFM Medium/GM-CSF was added to stimulate cultured macrophages for 
3 and 6 hours at +37°C in an atmosphere containing 5 % CO2. Gene expression of TNFα, 
resistin and 11β-HSD-1 in macrophages was measured from cell lysates, as described for 
adipose tissue (see section 3.2. in METHODS). Saline, as a control, had no effect on 
macrophage gene expression at baseline or after 3 and 6 hours. 
5. Lipidomics analysis (study IV) 
Adipose tissue sample preparation. In study IV, lipidomics analysis of subcutaneous adipose 
tissue was performed. Approximately 20 mg of adipose tissue was weighed, and 20 μl of an 
internal standard mixture and 40 μl of saline (0.9 %) were added to the sample. Lipids were 
extracted from the samples with 200 μl of chloroform:methanol (2:1) solvent, and the tissue 
was homogenized with a glass rod. After vortexing for 2 min and incubating for 1 hour at 
room temperature, the lower layer (~100 μl) was separated by centrifugation at 10000 rpm for 
3 min at room temperature. Labeled standard mixture (20 μl) was added to the lipid extract. 
Internal and external standards are listed online (http://dx.doi.org/10.2337/db07-0111). 
 
Lipidomics analysis. Lipid extracts were analyzed on a Q-ToF Premier mass spectrometer 
(Waters, Milford, MA) combined with an Acquity Ultra Performance Liquid Chromatography 
(Waters). The column was an Acquity UPLC BEH C18 (10x50 mm) with 1.7 μm particles 
(Waters) and was kept at 50°C temperature. The binary solvent system A included water (1 % 
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1M NH4Ac, 0.1 % HCOOH), and solvent system B included liquid chromatography/mass 
spectometer grade acetonitrile/isopropanal (5:2, 1 % 1M NH4Ac, 0.1 % HCOOH) (Rathburn, 
Walkerburn, Scotland). The gradient started from 65 % A/35 % B, reached 100 % B in 6 min 
and remained there for the next 7 min. The total run time including a 5 min re-equilibration 
step was 18 min. The flow rate was 0.2 ml/min and injection volume 1 μl. The temperature of 
the sample organizer was set at 10°C. Lipid profiling was carried out using positive ion mode. 
The data were collected at mass range of charge to mass ratio 300-2000, with scan duration of 
0.2 sec. The source temperature was set at 120°C, and nitrogen was used as desolvation gas 
(800 l/h) at 250°C. The voltages of the sampling cone and capillary were 39 V and 3.2 kV, 
respectively. Reserpine (50 μg/l) was used as the lock spray reference compound (5 μl/min), 
with a 10 sec scan frequency. The obtained data were converted into netCDF file format using 
Dbridge software from MassLynx (Waters). The converted data were processed using 
MZmine software version 0.60 (Katajamaa et al. 2006). Lipids were identified based on their 
retention time and charge to mass ratio using in-house built lipid database as previously 
described (Yetukuri et al. 2007). All the identified lipids were quantified by normalizing with 
corresponding internal standards. Sphingomyelins were normalized with GPCho(17:0/17:0) 
internal standard. 
6. Body composition 
6.1. Intra-abdominal and abdominal subcutaneous fat volumes (study IV) 
Subcutaneous and intra-abdominal fat areas were determined using MRI. A series of 16 T1-
weighted trans-axial scans were obtained from a region extending from 8 cm above to 8 cm 
below the 4th and 5th lumbar interspace (16 slice, field of view 375x500 mm2, slice thickness 
10 mm, breath hold repetition time 138.9 msec, echo time 4.1 msec). Fat areas were measured 
using an image analysis program (Alice 3.0, Parexel, Waltham, MA). A histogram of pixel 
intensity in the intra-abdominal region was displayed, and the intensity corresponding to the 
nadir between the lean and fat peaks was used as a cut-off point. Intra-abdominal adipose 
tissue was defined as the area of pixels in the intra-abdominal region above this cut-off point. 
Subcutaneous adipose tissue area was defined after manually drawing the demarcation of 
subcutaneous and intra-abdominal adipose tissue. 
6.2. Whole body fat content (studies I-V) 
In studies I-IV, percent whole body fat was measured using bioelectrical impedance 
plethysmography (BioElectrical Impedance Analyzer System model number BIA-101A, RJL 
Systems, Detroit, MI) (Lukaski et al. 1985). In study V, percent body fat was measured using 
DEXA (Lunar Prodigy, software version 2.15, Madison, WI) (Mazess et al. 1990). 
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6.3. Anthropometric indices (studies I-V) 
Body weight and height were measured barefoot in light clothing to calculate BMI (weight 
(kg)/height (m)2). Waist circumference was measured midway between the spina iliaca 
superior and the lower rib margin. Hip circumference was measured at the level of the greater 
trochanters. 
7. Analytical procedures (studies I-V) 
Plasma glucose concentration was measured in duplicate with Glucose analyzer II (Beckman 
Instruments, Fullerton, CA) using the glucose oxidase method (Kadish et al. 1968) (Studies I-
V). Serum insulin concentration was measured using the Auto-DELFIA kit (Wallac, Turku, 
Finland) (Studies I-IV) or radioimmunoassay (Phadeseph Insulin RIA, Pharmacia & Upjohn 
Diagnostics, Uppsala, Sweden) (Study V). Serum C-peptide concentration was measured 
using radioimmunoassay method (Kuzuya et al. 1977). HbA1c was measured using high-
pressure liquid chromatography (Stenman et al. 1984) with fully automated Glycosylated 
Hemoglobin Analyzer System (BioRad, Richmond, CA) (Studies I-IV). Serum concentrations 
of total cholesterol, HDL and TAG were measured with enzymatic kits and an autoanalyzer 
(Roche Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan), and LDL using the formula of 
Friedewald (Friedewald et al. 1972) (Studies I-V). Serum FFA concentration was also 
measured using an enzymatic kit (Wako Diagnostics, Richmond, VA) and an autoanalyzer 
(Roche Diagnostics) (Study IV). Serum ALT, AST and γGT activities were measured as 
recommended by the European Committee for Clinical Laboratory Standards (Studies I-V). 
Specific ELISA kits were used to measure serum concentrations of adiponectin (B-Bridge 
International, San Jose, CA) (Study I), MCP-1 and MIP-1α (Quantikine, R&D Systems, 
Minneapolis, MN) (Study II). 
8. Statistical analysis 
8.1. Basic statistics (studies I-V) 
In all studies, a p-value of less than 0.05 was considered statistically significant. The 
calculations were performed using GraphPad Prism (versions 3.0 and 4.0, GraphPad, San 
Diego, CA), SPSS 11.0 for Windows (SPSS, Chicago, IL) or Statview (SAS Institute, Cary, 
NC) (Studies I-IV). Statistical analyses on twin data (Study V) were performed using Stata 
statistical software (version 9.0, Stata Corporation, College Station, TX) and heritability 
analyses (Study V) using Mx statistical package (6th edition 2003, Virginia Commonwealth 
University, Richmond, VA). Logarithmic transformation of variables with non-normal 
distribution was performed. In studies I-IV, physical and biochemical characteristics of the 
study subjects were analyzed using nonparametric methods. Data are shown as mean±SEM or 
mean with 95 % confidence intervals (95 % CI). 
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Studies I and II. Insulin-sensitive and insulin-resistant groups were compared using the 
nonparametric Mann-Whitney test. Effects of insulin were analyzed using Friedman’s test 
followed by Dunn’s post hoc test to compare single measurements. Correlations were 
calculated using Spearman rank correlation coefficient. 
 
Study III. Obese and non-obese groups were compared using the Mann-Whitney test. Effects 
of LPS were analyzed using Friedman’s test followed by Dunn’s post hoc test to compare 
single measurements. Correlations were calculated using Spearman rank correlation 
coefficient. Multiple linear regression analysis was performed after logarithmic 
transformation of non-normally distributed data. 
 
Study IV. The groups with normal or high liver fat content were compared using the Mann-
Whitney test. Correlations were calculated using Spearman rank correlation coefficient. 
 
Study V. For individual twins, the statistical analyses, significance tests and 95 % CI were 
corrected for clustered sampling of co-twins within pairs by using survey methods. 
Correlations were calculated using Pearson correlation coefficient. Analysis of covariance 
was used to compare slopes and intercepts of regression lines between liver fat and serum 
ALT and liver fat and insulin for men and women. If neither slopes nor intercepts differed 
between women and men, a common regression equation was calculated for all data. Wald 
test (a t-test adapted for clustered twin data) was used to compare independent variables 
between men and women, and MZ and DZ twins. Twin similarity within each zygosity group 
was assessed using intrapair correlations to provide initial evidence for familial aggregation 
and the presence of genetic effects. 
8.2. Heritability analyses (study V) 
The intrapair correlations and heritability estimates were calculated for all subjects together 
using gender-adjusted variables. Because of high correlation between BMI and serum ALT 
(r=0.44) and BMI and insulin (r=0.56), ALT and insulin values were also adjusted for BMI. 
Thus, the heritability estimates for serum ALT and insulin are independent of gender and 
BMI. The genetic variation can be divided into additive (A) genetic effects of individual 
alleles (correlation 1.0 for MZ and 0.5 for same-sex DZ co-twins) and to dominant (D) 
genetic effects by allelic interactions within a loci (correlation 1.0 for MZ and 0.25 for same-
sex DZ co-twins). The environmental variation can be attributed to common (C) 
environmental effects shared by the co-twins (by definition, correlation 1.0 for both MZ and 
DZ co-twins) and to unique, individual-specific (non-shared), environmental (E) effects 
(uncorrelated between the co-twins). Models based on different combinations of these 
parameters can be generated; ADE, ACE, AE, DE, CE and E. 
 
Our data include only twins reared together and do not therefore allow modeling of genetic 
dominance and common environmental effects simultaneously. In classical twin data, possible 
gene-environment interactions are estimated as part of the additive genetic component that 
may therefore also reflect genetic differences in susceptibility to environmental factors. 
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Further, one has to make the assumption of random mating which, if not present, would 
increase DZ correlations and thus inflate estimates of common environmental variance and 
reduce genetic variance (Silventoinen et al. 2003). The primary objective in heritability model 
fitting is to explain the observed data with a model that best balances parsimony and goodness 
of fit with as few parameters as possible (Neale and Cardon 1992). The model fitting starts 
with full ADE or ACE models, to which the fit of the submodels AE, DE, CE and E may be 
compared by using chi-square difference test statistics and degrees of freedom (d.f.) between 
nested models. The Akaike Information Criterion (AIC) is a global test of model fit 
combining the chi-square value and d.f.. Negative values of the AIC are considered as 
evidence for a better fit. From the best fitting model, it is possible to estimate the proportion 
of total variance attributable to A, D, C and E. Bivariate Cholesky decomposition 
parameterization (Neale and Cardon 1992) was calculated to determine whether the ALT, 
insulin and BMI shared genetic or environmental effects. This was estimated by correlations 





1. Acute effects of hyperinsulinemia on gene expression in adipose 
tissue (studies I and II) 
Characteristics of the insulin-resistant and sensitive subjects in studies I and II are shown in 
Table 2 (see section 1. in SUBJECTS AND STUDY DESIGNS). Insulin-resistant subjects were 
more obese and had more body fat than lean insulin-sensitive subjects. Markers of insulin 
resistance, such as serum insulin, C-peptide and TAG concentrations were higher and HDL-
cholesterol and adiponectin (12±1 mg/l in insulin-resistant vs. 18±2 in insulin-sensitive, 
p<0.01) concentrations lower in the insulin-resistant compared to sensitive group. Whole 
body insulin sensitivity was, by definition, over 2-fold higher in insulin-sensitive compared to 
resistant subjects (8.7 mg/kg FFM⋅min vs. 4.2, respectively, p<0.001). During the euglycemic 
hyperinsulinemia, serum insulin concentration was comparable between the groups (69±4 
mU/l vs. 76±4, insulin-sensitive vs. insulin-resistant, non-significant, NS). Serum adiponectin 
concentration remained higher in the insulin-sensitive compared to resistant group during the 
insulin infusion (16±2 mg/l vs. 11±1, respectively at 3 hours; 16±2 vs. 11±1 at 6 hours, 
p<0.01 for both time points). 
Gene expression in adipose tissue 
GLUT-1, GLUT-4, PPARγ, PGC-1α and adiponectin. At baseline the adipose tissue 
expression of GLUT-1 (1033±543 vs. 722±251 arbitrary units, insulin-sensitive vs. insulin-
resistant, NS), PPARγ and PGC-1α (Figure 4) were comparable between the groups. GLUT-4 
and adiponectin expression were lower in the insulin-resistant compared to sensitive group 
(Figure 4). During hyperinsulinemia, GLUT-4 expression increased significantly in the 
insulin-sensitive group, whereas in the insulin-resistant group the increase was smaller and 
non-significant (Figure 4). GLUT-4 expression was significantly higher in the insulin-
sensitive compared to resistant group at all time points. Expression of GLUT-4 and PGC-1 
were also significantly correlated (data not shown). Adiponectin gene expression increased 
significantly during the insulin infusion only in the insulin-sensitive group and was 
significantly higher when compared to insulin-resistant group at all time points (Figure 4). 
The expression of PPARγ and PGC-1α increased significantly, but similarly, in both groups 
during the insulin infusion (Figure 4). The expression of GLUT-1 and the house-keeping 


































































Figure 4. Gene expression of GLUT-4, adiponectin, PPARγ and PGC-1α in adipose 
tissue in insulin-sensitive (white bars) and insulin-resistant (black bars) subjects at 
baseline and after 3 and 6 hours of euglycemic hyperinsulinemia. *p<0.05, **p<0.01, 
***p<0.001 for change between time points. #, p<0.05; ##, p<0.01 for difference between 
the groups. 
11β-HSD-1, TNFα, IL-6, MCP-1 and MIP-1α. Before insulin infusion, 11β-HSD-1 gene 
expression was 2.4-fold higher in the insulin-resistant compared to sensitive group. Insulin 
further increased 11β-HSD-1 expression in the insulin-resistant group with no changes in the 
insulin-sensitive group (Figure 5). TNFα expression tended to be higher in the insulin-
resistant compared to sensitive group at all time points with a significant difference at 6 hours. 
















































Figure 5. Gene expression of 11β-HSD-1 (upper panel) and TNFα (lower panel) in 
adipose tissue in insulin-sensitive (white bars) and insulin-resistant (black bars) subjects 
at baseline and after 3 and 6 hours of euglycemic hyperinsulinemia. *p<0.05 for change 
between time points. #, p<0.05; ##, p<0.01; ###, p<0.001 for difference between the 
groups. 
IL-6 expression was comparable between the groups at baseline and increased significantly 
during insulin infusion in both insulin-sensitive and resistant groups. The expression of IL-6 
was significantly higher in the insulin-resistant compared to sensitive group at 6 hours (Figure 
6). Basally, gene expression of MCP-1 and MIP-1α were comparable between the groups. 
During insulin infusion MCP-1 expression increased more in the insulin-resistant (169±59 %) 
compared to insulin-sensitive (60±22 %) group (Figure 6). In the 8 control subjects who 
received saline infusion for 6 hours, expression of MCP-1 and MIP-1α remained unchanged 






























































Figure 6. Gene expression of IL-6 (top panel), MCP-1 (middle panel) and MIP-1α 
(bottom panel) in adipose tissue in insulin-sensitive (white bars) and insulin-resistant 
(black bars) subjects at baseline and after 6 hours of euglycemic hyperinsulinemia. 
*p<0.05 for change between time points. ##, p<0.01; ###, p<0.001 for difference between 
the groups. 
CD68, EMR1, ITGAM and ADAM8. At baseline, gene expression of ITGAM and ADAM8 
were comparable between the groups, while the expression of CD68 and EMR1 were 
significantly higher in the insulin-resistant compared to insulin-sensitive group (Figure 7). At 
baseline, expression of both MCP-1 and MIP-1α correlated closely with that of CD68 (r=0.71, 
r=0.81, respectively, p<0.001 for both) and ITGAM (r=0.64, p<0.01; r=0.78, p<0.001), and 
the expression of MIP-1α also with that of EMR1 (r=0.55, p<0.01). Adipocyte cell size 
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Figure 7. Gene expression of macrophage markers CD68 (upper left panel), ITGAM 
(upper right), EMR1 (lower left) and ADAM8 (lower right) in adipose tissue in insulin-
sensitive (white bars) and insulin-resistant (black bars) subjects at baseline. *p<0.05 for 
difference between the groups. 
Protein concentration of MCP-1 in adipose tissue and of MCP-1 and MIP-1α in serum 
At baseline, adipose tissue and serum MCP-1 protein concentrations were comparable 
between the groups. Insulin increased significantly MCP-1 protein concentration in adipose 
tissue in insulin-resistant group with no change in the insulin-sensitive group (Figure 8). 
Insulin decreased serum MCP-1 concentration in the insulin-sensitive but not in the insulin-
resistant group. At 6 hours, serum MCP-1 concentration was significantly lower in the 
insulin-sensitive compared to resistant group (Figure 8). As in study IV, protein concentration 
and gene expression of MCP-1 in adipose tissue correlated significantly (r=0.53, <0.001). 
Serum MIP-1α protein concentration was under the detection limit of the assay used (46.9 
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Figure 8. Concentration of MCP-1 protein in adipose tissue (left panel) and in serum 
(right panel) in insulin-sensitive (white bars) and insulin-resistant (black bars) subjects at 
baseline and after 6 hours of euglycemic hyperinsulinemia. *p<0.05 for change between 
time points. ##, p<0.01 for difference between the groups. 
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Relationships between adipose tissue gene expression and insulin sensitivity 
Relationships between gene expression in adipose tissue and whole body insulin sensitivity 
(all subjects analyzed as one group) at baseline and after insulin infusion are shown in Table 
3. Expression of adiponectin correlated with insulin sensitivity at baseline, and that of GLUT-
4 at 3 and 6 hours. The expression of TNFα, 11β-HSD-1, IL-6 and MIP-1α correlated 
inversely with insulin sensitivity both basally and after 6 hours of insulin infusion. MCP-1 
was negatively associated with insulin sensitivity only after insulin infusion. Adipose tissue 
expression of all monocyte/macrophage markers, except for ADAM8 at baseline, correlated 
inversely with insulin sensitivity both basally and after 6 hours of hyperinsulinemia (Table 3). 
Table 3. Relationships between gene expression in adipose tissue 
and whole body insulin sensitivity (M-value) in all subjects (n=21) 
at baseline and after 3 and 6 hours of euglycemic hyperinsulinemia. 
Gene 0 hours 3 hours 6 hours 
Adiponectin 0.48* -0.16 -0.24 
GLUT-1 -0.08 -0.29 0.04 
GLUT-4 0.44 0.66** 0.73*** 
PGC-1α 0.19 0.55* 0.34 
PPARγ 0.14 -0.37 -0.14 
IL-6 -0.48* ND -0.71*** 
MCP-1 -0.33 ND -0.60** 
MIP-1α -0.62** ND -0.73*** 
TNFα -0.44* -0.53* -0.46* 
11β-HSD-1 -0.55* -0.74*** -0.82*** 
ADAM8 -0.42 ND -0.67** 
CD68 -0.66** ND -0.68*** 
EMR1 -0.62** ND -0.56** 
ITGAM -0.50* ND -0.60** 




2. Relationships between adipose tissue inflammation and liver fat 
content (study III) 
Characteristics of the non-obese and obese subjects in study III are shown in Table 2 (see 
section 1. in SUBJECTS AND STUDY DESIGNS). Obese subjects had increased serum insulin 
and TAG, and decreased HDL-cholesterol concentration compared to non-obese subjects. 
Liver fat content was significantly lower (Table 2), whereas insulin sensitivity was higher 
(8.0±0.5 vs. 5.2±0.7 mg/kg FFM⋅min, respectively, p<0.01) in non-obese compared to obese 
subjects. 
Gene expression in adipose tissue 
Adipose tissue expression of CD68 (1.2±0.1 vs. 0.7±0.1 arbitrary units, obese vs. non-obese, 
p<0.01), ITGAM (2.3±0.4 vs. 1.3±0.2, p<0.05) and 11β-HSD-1 (0.6±0.1 vs. 0.3±0.1, p<0.05) 
were increased in obese compared to non-obese subjects. TNFα expression tended to be 
increased in the obese compared to the non-obese group, but did not reach statistical 
significance (1.4±0.3 vs. 1.0±0.2, obese vs. non-obese, NS). Expression of the housekeeping 
gene RPLP0 was comparable between the groups (data not shown). 


















































































Figure 9. Relationships between adipose tissue expression (relative mRNA expression, 
arbitrary units) of CD68 and 11β-HSD-1 with BMI (top panels), with whole body insulin 
sensitivity (M-value) (middle panels) and with liver fat content (bottom panels). 
Spearman rank correlation coefficients (r) and p-values are shown. 
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Relationships between adipose tissue inflammation, liver fat content and insulin sensitivity 
Expression of both CD68 and 11β-HSD-1 in adipose tissue were inversely correlated with 
whole body insulin sensitivity and positively correlated with liver fat content and BMI 
(Figure 9). Also adipose tissue expression of ITGAM correlated positively with liver fat 
content (r=0.67, p<0.01). Expression of CD68 correlated positively with that of TNFα and 
11β-HSD-1 (Figure 10). The expression of two macrophage markers in adipose tissue, CD68 
and ITGAM, were closely correlated (r=0.81, p<0.001). In multiple linear regression analysis, 
liver fat content significantly correlated with the adipose tissue expression of CD68, ITGAM 
and 11β-HSD-1, independent of BMI (Table 4). 




























Figure 10. Relationships between adipose tissue expression (relative mRNA expression, 
arbitrary units) of CD68 and TNFα (left panel) and between CD68 and 11β-HSD-1 (right 
panel). Spearman rank correlation coefficients (r) and p-values are shown. 
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Gene expression in monocyte-derived macrophages 
Expression of CD68 in human monocyte-derived macrophages was comparable between the 
obese and non-obese groups (1.2±0.1 vs. 1.2±0.1 arbitrary units, respectively, NS). After 
stimulation with LPS, expression of TNFα was significantly increased at 3- and 6-hour time 
points compared to basal in both groups, although expression decreased from 3- to 6-hour 
time point in the obese group (Figure 11). LPS had no effects on resistin expression in neither 
groups. 11β-HSD-1 expression increased after LPS stimulation significantly, but similarly, in 
both non-obese and obese groups (Figure 11). In control studies, no changes in macrophage 



























































Figure 11. Gene expression of TNFα (top panel), resistin (middle panel) and 11β-HSD-1 
(bottom panel) in human monocyte-derived macrophages at baseline and after 3 and 6 
hours of LPS stimulation in non-obese (white bars) and obese subjects (black bars). 
*p<0.05, **p<0.01 for difference between time points. 
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3. Adipose tissue inflammation in equally obese groups of subjects 
with normal or high liver fat content (study IV) 
Characteristics of the subjects with normal (mean 2.3±0.3 %, range 1-3.5 %) or high liver fat 
content (mean 14.4±2.9 %, range 6-34 %,) are shown in Table 2 (see section 1. in SUBJECTS 
AND STUDY DESIGNS). The groups were similar with respect to age, gender, BMI, and 
subcutaneous (7400±330 cm3 in the normal and 6640±530 in the high liver fat group, NS) and 
intra-abdominal (1630±170 cm3, 1980±260, respectively, NS) fat masses. The concentration 
of serum insulin was increased and that of HDL-cholesterol decreased in the high compared 
to the normal liver fat group (Table 2). 
Gene expression in adipose tissue 
Adipose tissue expression of CD68, MCP-1, MIP-1α and PAI-1 were significantly increased 
and that of adiponectin and PPARγ decreased in the high compared to the normal liver fat 
group (Table 5). Expression of 11β-HSD-1, IL-6 and TNFα did not differ significantly 
between the groups, although TNFα tended to be increased in the high liver fat group. 
Adipose tissue expression of sphingomyelinases SMPD1 (acid sphingomyelinase) and 
SMPD3 (neutral sphingomyelinase 2) were significantly increased in the high compared to 
normal liver fat group, while SMPD2 (neutral sphingomyelinase) showed only borderline 
significance (Table 5). 
Table 5. The relative mRNA expression (arbitrary units) of different 
genes in adipose tissue in the normal and high liver fat groups. 
Gene Normal liver fat High liver fat 
PPARγ 1.1±0.1 0.9±0.1* 
Adiponectin 1.0±0.1 0.9±0.1* 
TNFα 1.5±0.3 2.4±0.8 (p=0.12) 
11β-HSD-1 5.7±1.0 5.6±0.9 
IL-6 0.1±0.03 0.1±0.02 
PAI-1 2.8±0.5 4.0±0.6* 
MCP-1 0.4±0.03 0.5±0.1* 
MIP-1α 0.4±0.1 1.0±0.2** 
CD68 1.9±0.1 3.2±0.4** 
SMPD1 1.5±0.1 1.9±0.1** 
SMPD2 1.1±0.1 1.3±0.1 (p=0.08) 
SMPD3 1.3±0.1 1.8±0.2* 




Expression of the macrophage marker CD68 correlated significantly with liver fat content but 
not with BMI (Figure 12, middle and right panels). As in study II, the protein concentration 
and gene expression of MCP-1 in adipose tissue correlated closely (r=0.53, p<0.05). 
Expression of the housekeeping genes RPLP0 and TBP did not differ between the groups 
(data not shown). 
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Figure 12. Relationships between adipose tissue expression (relative mRNA expression, 
arbitrary units) of CD68 and the number of macrophages (left panel), liver fat content 
(middle panel) and BMI (right panel). Spearman rank correlation coefficients (r) and p-
values are shown. 
Immunohistochemistry of adipose tissue 
Positive staining for the macrophage marker CD68 was observed in 19 of the 20 adipose 
tissue samples. The total number of macrophages per section area did not differ between the 
groups, despite a tendency toward higher cell number in the high liver fat group (22±6 vs. 
37±10, respectively, NS). The number of macrophages, however, was significantly correlated 
with the adipose tissue gene expression of CD68 in all subjects (Figure 12, left panel). Some 
macrophages were arranged in CLS around necrotic, perilipin-free, adipocytes (Figures 13 
and 14). Adipose tissue expression of CD68 showed a borderline significant correlation with 






Figure 13. Light microscopy showing CLS in subcutaneous adipose tissue from an obese 
woman. Immunohistochemical staining for macrophage specific CD68 (panels A and B) 
is colored brown. Panels C and D show serial sections of A and B, respectively, that were 
stained for perilipin (brown). All sections were counterstained with hematoxylin (colored 
blue). Scale bar: 20 μm. 
 
Figure 14. Light microscopy of subcutaneous adipose tissue from an obese woman 
stained for perilipin (colored brown). Dead (perilipin-negative) adipocytes are surrounded 
by macrophages forming a CLS. The blue-colored nuclei (C arrows) showed positive 
staining for the macrophage marker CD68 on a separate serial section (not shown). A 
arrows: Perilipin-positive staining (brown), B arrows: Perilipin-negative staining (light 
blue), C arrows: Macrophage (dark blue). Scale bar: 20 μm. 
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Adipocyte cell size 
The average adipocyte cross-sectional area in the sectioned tissue and fat cell size measured 
by collagenase digestion did not differ between the normal and high liver fat groups 
(2067±109 vs. 2118±207 arbitrary units, respectively, NS for cross sectional area; 25.2±0.8 
vs. 24.9±1.0 μm, respectively, NS for fat cell size). 
Lipidomics of adipose tissue 
A total of 154 lipid species were identified in adipose tissue and the differences in the high 
compared to normal liver fat group were dominated by increased ceramide, sphingomyelin 
and TAG concentration. No specific trend was observed for DAG. All 3 identified ceramide 
molecular species were increased in the high compared to normal liver fat group. The most 
abundant ceramide species, Cer(d18:1/24:1), showed significant 1.5-fold increase in the high 
liver fat group (Figure 15). The sphingomyelins were proportionally increased in the high 
liver fat group, although the most abundant sphingomyelin species SM(d18:1/16:0) did not 
differ between the groups (Figure 15). Most of the 95 identified TAG species were increased 
in the high liver fat group and the fold change between the groups correlated positively with 
the total length of FA carbon chains in TAG (Figure 16). The degree of chain saturation of FA 


































































































































Figure 15. Lipidomics analysis of subcutaneous adipose tissue. Concentrations of 
detected ceramide (Cer), DAG and selected sphingomyelin (SM) species in the normal 
(white bars) and high liver fat (black bars) groups. *p<0.05, **p<0.01 for difference 




Figure 16. The correlation between total FA chain-length in TAG and the fold change 
between the high and normal liver fat groups. Spearman rank correlation coefficient (r) 
and p-value are shown. 
4. Contribution of genetic factors to serum alanine 
aminotransferase activity, a surrogate marker of liver fat (study V) 
Characteristics of the all 313 subjects and the subgroup of 66 subjects with liver fat measures 
are shown in Table 2 (see section 1. in SUBJECTS AND STUDY DESIGNS). Study group 
comprised 178 women and 135 men that were similar with respect to BMI (24.3±0.5 kg/m2 
vs. 25.3±0.4,respectively, NS), liver fat (4.7±1.7 % vs. 6.8±2.4, NS) and serum insulin 
concentration (6±0.3 mU/l vs. 7±0.5, NS). ALT (20±2 U/l vs. 37±2, p<0.001), AST (25±1 U/l 
vs. 29±1, p<0.001) and γGT (18±1 U/l vs. 28±2, p<0.001) activities were lower in women 
compared to men. The study group comprised 120 MZ twins (57 full pairs) and 193 DZ twins 
(88 full pairs). No differences in mean variances of the physical and biochemical 
characteristics between MZ and DZ twins were found (Table 6), and therefore the assumption 
of trait similarity between MZ and DZ twins for twin modeling was met. As expected, within-
pair differences in BMI were greater in the DZ (4.6±0.4 kg/m2, range 0.0-15.2) compared to 




Table 6. Characteristics of the MZ and DZ twins in study V. 
Variable MZ  DZ p-value 
Number 120 (57 full pairs) 193 (88 full pairs)  
Age (y) 27.1±0.3 27.4±0.2 0.38 
BMI (kg/m2) 25.3±0.6 24.4±0.3 0.20 
Body fat (%) 30±1 29±1 0.43 
ALT (U/l) 27±3 27±2 0.95 
AST (U/l) 27±1 27±1 0.71 
γGT (U/l)  21±2 23±2 0.48 
Glucose (mmol/l) 5.0±0.1 4.9±0.04 0.18 
Insulin (mU/l)A 6±0.4 6±0.4 0.98 
A n=114 MZ, 187 DZ. Data are shown as mean±SEM 
Relationships of serum ALT activity and insulin concentration with liver fat content 
Serum ALT was strongly positively correlated with liver fat content in both women (r=0.70, 
95 % CI 0.62-0.77, p<0.01) and men (r=0.50, 0.36-0.62, p<0.01) (Figure 17). A strong 
positive correlation was also found between liver fat content and serum insulin concentration 
with no difference between the genders (r=0.59, 0.40-0.73, p<0.001) (Figure 17). Both 
correlations remained significant also after adjusting for BMI (r=0.42, 0.32-0.51, p<0.001 for 
ALT; r=0.37, 0.27-0.46, p<0.01 for insulin). The correlation between liver fat content and 
BMI was r=0.47 (95 % CI 0.26-0.64, p=0.057). 



































Figure 17. Relationships between liver fat content and serum ALT activity (left panel) 
and between liver fat content and serum insulin concentration (right panel) in all subjects 
(n=66). White circles denote women (n=32) and black circles denote men (n=34). 
Pearson correlation coefficients (r) and p-values are shown. 
RESULTS 
70 
Intra-pair correlations for serum ALT activity and insulin concentration 
Intra-pair correlations (twin A vs. twin B) were analyzed using BMI- and gender-adjusted 
variables. MZ twin pairs showed significantly higher intra-pair correlations for serum ALT 
compared to DZ twin pairs (r=0.65, 95 % CI 0.50-0.80, p<0.001 for MZ; r=0.04, 0.0-0.25, 
p=0.37, NS for DZ; p<0.001 for the difference between MZ and DZ) (Figure 18, upper 
panels) strongly demonstrating the influence of genetic factors. The intra-pair correlations for 
serum insulin tended to be higher for MZ compared to DZ twin pairs (r=0.58, 95 % CI 0.40-
0.76, p<0.001 for MZ; r=0.34, 0.15-0.53, p<0.001 for DZ; p=0.076 for the difference between 
MZ and DZ) (Figure 18, lower panels). For serum ALT, the DZ correlations were less than 
half of the MZ correlations, suggesting that not only additive genetic but also possibly 
dominant genetic factors influence the trait. For serum insulin, the DZ correlations were more 
than half of the MZ correlations, suggesting the presence of shared environmental effects (e.g. 
within the family). Thus, the ADE model (see section 8.2. in METHODS) for serum ALT and 
the ACE model for serum insulin were used as starting points in heritability analyses. 



















































Figure 18. Intra-pair correlations between Twin A and Twin B in MZ and DZ twin pairs 
for serum ALT activity (upper panels) and serum insulin concentration (lower panels). 
Pearson correlation coefficients (r) and p-values are shown. 
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Heritability analyses for serum ALT activity and insulin concentration 
The heritability estimates were analysed with combined data of both genders using gender- 
and BMI-adjusted values. For serum ALT, the ADE model fitted the data slightly better than 
the AE model (chi-square change p=0.035). For both models, AIC was low implying a good 
fit (AIC= -711.64 for the AE and -714.06 for the ADE model). In the ADE model, all genetic 
influence was placed on the D effect. Since dominant effects are rare in the absence of 
additive effects, the AE model was chosen as the final model for serum ALT. For serum 
insulin, the ACE model was used initially. The AIC was higher in the ACE (AIC=-664.87) 
model than in the AE model (AIC=-666.87). Dropping the C effect from the ACE model did 
not worsen the fit (p=0.97), and the point estimate for C effects in the ACE model was small 
and non-significant. This implies that shared family environmental effects for serum insulin 
are not significant and that the AE model fit the data the best. 
 
AE models were used in the subsequent analyses. Cholesky bivariate decomposition analyses 
were performed to analyze the contribution of genetic and environmental effects, and their 
correlations on serum ALT and insulin and BMI. In a model where ALT and insulin were 
adjusted for BMI and gender, genetic effects (i.e. heritability) explained 55 % (95 % CI 36-70 
%) of the variation serum ALT activity and 61 % (42-73 %) of that in serum insulin 
concentration. Contribution of environmental effects was 45 % (30-64 %) for serum ALT and 
39 % (27-58 %) for serum insulin. Bivariate genetic modeling revealed that the correlation 
between additive genetic effects on serum ALT and insulin was r=0.30 (0.09-0.51), implying 
that 9 % (r2=0.30×0.30) of the genetic factors influencing variation in serum ALT activity and 
insulin concentration are the same. No shared environmental effects explained the correlation 
between serum ALT and insulin when BMI was adjusted in the model. 
 
Bivariate models for ALT and BMI, and for insulin and BMI were estimated. For serum ALT 
and BMI (adjusted for gender), the genetic correlation was r=0.39 (95 % CI 0.12-0.58) and 
the environmental correlation r=0.51 (0.30-0.68). For serum insulin and BMI (adjusted for 
gender), the genetic correlation was r=0.53 (31-0.68) and the environmental correlation 
r=0.64 (0.46-0.77). This implies that both serum ALT and insulin share genetic and 
environmental factors with BMI. The heritability for BMI was 68 % and, as mentioned above, 
55 % for serum ALT activity and 61 % for serum insulin concentration. 
 
Genetic and environmental effects on liver fat content 
MZ pairs (n=23) with liver fat measures showed high intra-pair correlation for liver fat 
content (r=0.70, 95 % CI 0.49-0.92, p<0.001), but the number of DZ pairs with liver fat 
measures was too small to permit reliable heritability model fitting directly for liver fat 
content. Evidence of non-genetic effects was obtained from a correlation between intra-pair 
differences of liver fat content and those of BMI in MZ pairs (r=0.47, 0.07-0.74, p<0.01), 
implying that BMI differences explained 22 % of the differences in liver fat content. In a 
separate group of 13 obesity-discordant MZ pairs (BMI difference 5.0±0.5 kg/m2), the obese 
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co-twins had significantly higher liver fat content compared to the non-obese co-twins 
(7.3±2.1 % vs. 2.0±0.4, respectively, p<0.01). The effects of acquired obesity on liver fat 
content, however, varied considerably between the individual twin pairs, and this could not be 









































   
   











Figure 19. Effects of acquired obesity on liver fat content in 13 obesity-discordant MZ 





1. Acute effects of hyperinsulinemia on gene expression in adipose 
tissue (studies I and II) 
Studies I and II are among the first to compare the acute effects of in vivo hyperinsulinemia 
on genes considered to counteract (”insulin resistance genes”) or enhance (”insulin sensitivity 
genes”) insulin action in subcutaneous adipose tissue in non-diabetic insulin-sensitive and 
insulin-resistant subjects. These studies were the first to determine the acute insulin regulation 
of adipose tissue genes related to macrophage recruitment (MCP-1 and MIP-1α). The results 
showed that insulin-resistant subjects are not only characterized by failure of insulin to 
normally increase expression of ”insulin sensitivity genes” (such as GLUT-4 and adiponectin) 
but also by increased response of ”insulin resistance genes” (such as IL-6, 11β-HSD-1, MCP-
1 and TNFα) to insulin when compared to insulin-sensitive subjects. Insulin also acutely 
increases expression of 11β-HSD-1, MCP-1 and PGC-1α in human adipose tissue, and whole 
body insulin sensitivity correlates inversely with adipose tissue gene expression of several 
monocyte/macrophage markers. 
 
The study subjects were apparently healthy (except for obesity) women and were arbitrarily 
divided into more and less insulin-sensitive groups (10 insulin-sensitive and 11 insulin-
resistant subjects, respectively) based on their median whole body insulin sensitivity. As 
subjects were randomly chosen from a group of wide range of obesity, it was expected that 
insulin-resistant subjects were more obese and had more body fat compared to insulin-
sensitive subjects. Due to this approach in studies I and II, it is not possible to separate to 
which extent the different responses in gene expression to insulin are due to obesity per se. 
Thus, obesity may be a confounding factor when interpreting these relationships with insulin 
sensitivity. Adipocyte cell size is increased in obese insulin-resistant subjects and is suggested 
to impact adipose tissue gene expression (Coppack 2001). Abundant, but not totally 
consistent, data suggests differences in gene expression (Vidal 2001) and macrophage 
infiltraton (Cancello et al. 2006) between subcutaneous and visceral adipose tissue. In studies 
I and II, the repeated sampling of visceral fat in healthy subjects was not considered ethically 
or practically justifiable. 
 
Classically, insulin resistance has been considered as a defective response of an insulin-
sensitive gene, protein or pathway to insulin. The data from animal studies have suggested 
that this concept needs to be expanded because insulin not only regulates molecules and 
pathways that normally enhance insulin sensitivity but also molecules that normally induce 
insulin resistance or adipose tissue inflammation. TNFα (Iida et al. 2001), 11β-HSD-1 
(Masuzaki et al. 2001, Thieringer et al. 2001), PAI-1, MCP-1 and sterol regulatory element 
binding protein 1c (SREBP-1c) (Sartipy and Loskutoff 2003) are examples of molecules that 
retain their sensitivity to insulin or even hyperrespond to insulin in insulin-resistant states. 




Several previous studies have compared the expression of the same genes as in study I 
between non-obese insulin-sensitive and obese insulin-resistant subjects in the basal state. 
These include reports of decreased expression of the ”insulin sensitivity genes” GLUT-4 in 
obese insulin-resistant (Garvey et al. 1991), PGC-1α in non-obese insulin-resistant 
(Hammarstedt et al. 2003) and adiponectin in obese and insulin-resistant subjects (Hu et al. 
1996, Lihn et al. 2003). These findings were confirmed in study I. Deletion or overexpression 
of each of these genes has been shown to modulate insulin action in mouse models (Marshall 
and Mueckler 1994, Maeda et al. 2002, He et al. 2003, Koo et al. 2004). Reports of both 
decreased, unchanged and increased expression of PPARγ in obese compared to lean subjects 
have been published (Auboeuf et al. 1997, Vidal-Puig et al. 1997, Sewter et al. 2002, Giusti et 
al. 2003). In study I, basal expression of PPARγ was comparable between the insulin-resistant 
and sensitive groups as was the increase induced by in vivo insulin treatment. 
 
PGC-1α is a transcriptional co-activator that increases gene expression of GLUT-4 and insulin 
sensitivity in skeletal muscle (Puigserver et al. 1998). It is absent from white adipose tissue in 
mice but expression in human adipose tissue (Hammarstedt et al. 2003) was confirmed in 
study I. Previous findings are extended by demonstrating in the present study that PGC-1α 
expression in adipose tissue in vivo is acutely increased by insulin infusion. Consistent with 
regulation of GLUT-4 by PGC-1α, adipose tissue expression of PGC-1α and GLUT-4 showed 
significant correlation. 
 
Adiponectin expression increased significantly by the 6-hour time point in the insulin-
sensitive but not in the insulin-resistant group. In vitro studies in 3T3-L1 adipocytes have 
reported both increase (Scherer et al. 1995) and decrease (Fasshauer et al. 2002) in 
adiponectin expression by insulin, and increase in adiponectin secretion in human omental but 
not subcutaneous adipocytes (Motoshima et al. 2002). Previous in vivo studies in humans 
found no change after 2.5 (Lihn et al. 2003) or 3 hours (Koistinen et al. 2004) of insulin 
infusion, consistent with the data at 3-hour time point in study I. 
 
Concerning ”insulin resistance genes”, the reports of increased basal gene expression of 11β-
HSD-1 in insulin-resistant compared to sensitive subjects (Paulmyer-Lacroix et al. 2002) are 
confirmed in study I. 11β-HSD-1 expression remained higher at all time points in the insulin-
resistant compared to sensitive group, and increased in response to insulin in the former but 
not in the latter group. Previous data of insulin regulation of 11β-HSD-1 expression and 
activity are not unequivocal. In preadipocytes in vitro, insulin attenuates 11β-HSD-1 activity 
but synergizes with glucocorticoids to stimulate adipocyte differentiation with concomitant 
induction of 11β-HSD-1 activity (Stulnig and Waldhäusl 2004). In humans in vivo, consistent 
with the data at 3-hour time point in study I, hyperinsulinemia has been reported not to affect 
11β-HSD-1 adipose tissue expression in healthy or T2DM subjects (Koistinen et al. 2004). 
11β-HSD-1 is a gene abundantly expressed in macrophages in addition to adipocytes 
(Thieringer et al. 2001). Therefore, the increased expression of 11β-HSD-1 in the insulin-
resistant group after 6 hours of insulin infusion in study I could also be due to insulin action 
targeted to macrophages. 
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In study I, basal expression of adipose tissue IL-6 was comparable between the groups. Like 
11β-HSD-1, IL-6 was increased significantly more by insulin in the insulin-resistant 
compared to sensitive group. This change is most likely to occur in non-adipose cells, since 
isolated adipocytes account for only 10 % of total IL-6 release in human adipose tissue (Fried 
et al. 1998). IL-6 has been shown to downregulate GLUT-4, PPARγ and adiponectin 
expression in 3T3-L1 adipocytes (Bruun et al. 2003, Fasshauer et al. 2003b, Rotter et al. 
2003), and to increase 11β-HSD-1 activity in primary cultures of human adipose stromal cells 
(Tomlinson et al. 2004). IL-6 is released systemically by adipose tissue (Mohamed-Ali et al. 
1997) but the interstitial concentration of IL-6 in human adipose tissue is ~100 times higher 
than that in plasma (Sopasakis et al. 2004). These data suggest both paracrine and endocrine 
role for adipose tissue IL-6 in inducing insulin resistance (Rotter et al. 2003). 
 
TNFα, in contrast to IL-6, is not secreted systemically by adipose tissue (Mohamed-Ali et al. 
1997) and virtually all TNFα seems to originate from macrophages (Weisberg et al. 2003) or 
SVF cells (Fain et al. 2004a) in human adipose tissue. In a study examining the direct effect 
of insulin on macrophage gene expression using an array technique, insulin stimulated TNFα 
the most among all genes analyzed (Iida et al. 2001). In vitro, LPS has been found to increase 
TNFα production more robustly from human whole adipose tissue than from isolated 
adipocytes, while insulin had no effect on TNFα production (Sewter et al. 1999). In a human 
in vivo study using euglycemic hyperinsulinemic clamp, adipose tissue TNFα expression was 
transiently increased after 2 hours in a group of normal subjects (Krogh-Madsen et al. 2004). 
In study I, no differences in expression of TNFα between the groups were found in the basal 
state, whereas after 6 hours of insulin infusion the expression was increased significantly only 
in the insulin-resistant group. These data suggest that the response of TNFα expression to 
insulin is exaggerated in insulin-resistant subjects, although the increase by insulin failed to 
reach statistical significance. The mechanisms remain to be determined but may involve 
increased infiltration of macrophages in adipose tissue. 
 
Gene and protein expression of MCP-1 at baseline are increased in TNFα-treated insulin-
resistant 3T3-L1 adipocytes. Obese ob/ob and normal mice show increased adipose tissue 
expression of MCP-1 in response to in vivo insulin (Sartipy and Loskutoff 2003). In addition 
in mice, a transient increase in plasma concentration of MCP-1 after 1 hour of insulin 
injection was seen in obese mice while no changes was seen in WT insulin-sensitive mice 
(Sartipy and Loskutoff 2003). Consistent with these data, study II showed an exaggerated 
increase in MCP-1 gene and protein expression in adipose tissue in obese insulin-resistant as 
compared to lean insulin-sensitive subjects during insulin infusion. Gene and protein 
expression of MCP-1 in adipose tissue were also correlated significantly. Serum concentration 
of MCP-1 decreased significantly in the insulin-sensitive group, consistent with another 
saline-controlled study (Dandona et al. 2001), while there was no change in serum MCP-1 
concentration in the insulin-resistant group. These data suggest that adipose tissue is not the 
main determinant of serum MCP-1 concentration in humans, and consistent with this, a 
catheterization study in humans found no systemic release of MCP-1 protein from 
subcutaneous adipose tissue (Dahlman et al. 2005). 
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Study II showed that adipose tissue gene expression of another macrophage chemoattractant 
adipocytokine, MIP-1α, is increased in obese insulin-resistant subjects compared to normal-
weight subjects. Similar results were found in a subsequent study where adipose tissue MIP-
1α expression, in addition to MCP-1, was increased in morbidly obese subjects compared to 
normal weight controls (Huber et al. 2008). Concerning circulating MIP-1α, a previous study 
using the same assay as in study II, found detectable serum concentration of MIP-1α in only 
15 % of the T2DM patients studied (Meleth et al. 2005). MIP-1α serum concentration was 
under the detection limit (46.9 pg/ml) in all subjects in study II. 
 
In the study reporting macrophage accumulation in adipose tissue in both rodent and human 
obesity, immunohistochemical detection and quantitation of CD68-expressing cells in 
subcutaneous adipose tissue showed that average adipocyte cell size and BMI were strong 
predictors of CD68-expressing cells (Weisberg et al. 2003). The increased basal expression of 
the macrophage marker CD68 in human adipose tissue in insulin-resistant subjects is 
confirmed in the present study, and an increase in another marker gene, EMR1, is reported. 
Increase in macrophage marker gene expression is likely to reflect an increase in macrophage 
number based on immunohistochemical data in previous studies (Weisberg et al. 2003) and in 
study IV. Significant correlation between adipose tissue expression of CD68 and adipocyte 
cell size was found in study II, consistent with previous data (Weisberg et al. 2003). 
 
Studies I and II did not address the molecular mechanisms explaining how a gene can 
hyperrespond to insulin despite whole body insulin resistance that reflects insulin resistance 
mostly at the level of skeletal muscle (Nuutila et al. 1996). The multitude of genes involved in 
regulating insulin action and the discovery that adipose tissue of obese subjects contains 
inflammatory macrophages (Weisberg et al. 2003) also expressing insulin responsive genes, 
makes interpretation of the present data complex. Because of the repeated biopsies in studies I 
and II, it was considered unfeasible to take enough adipose tissue for separation of 
macrophages and adipose cells, and therefore it was not possible to locate the observed 
changes in gene expression to a given cell type. Theoretically, this implies that any of the 
following three scenarios might have taken place. First, genes hyperresponding to insulin 
could reside in a different cell type than those hyporesponding to insulin. For example, the 
hyperresponse of IL-6 to insulin that is expressed both in macrophages and adipocytes, could 
have occurred in macrophages, and the hyporesponse of adiponectin in adipocytes, the only 
cell type expressing adiponectin (Maeda et al. 1996). Second, both the hyper- and 
hyporesponse could have occurred in the same cell type but the increased basal or insulin-
stimulated expression of ”insulin resistance genes” in the insulin-resistant group could have 
modulated the response to insulin. Third, a combination of both mechanisms might have 
taken place. 
 
To conclude, acute insulin regulation of gene expression in adipose tissue of insulin-resistant 
subjects is characterized not only by hyporesponsiveness of ” insulin sensitivity genes”, such 
as GLUT-4, to insulin but also by hyperresponsiveness of ”insulin resistance genes” (IL-6, 
TNFα, 11β-HSD-1 and MCP-1). Although the attempts to ameliorate insulin resistance in 
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humans using anti-inflammatory approaches, such as TNFα antagonists, have been 
unsuccessful, the present studies show supporting evidence to continue efforts to develop 
such therapies. 
2. Relationships between adipose tissue inflammation and liver fat 
content (study III) 
The novel finding in study III was that adipose tissue inflammation, reflected as increased 
gene expression of macrophage marker genes and 11β-HSD-1, was associated with liver fat 
content in healthy non-diabetic non-obese and obese subjects. This relationship was also 
shown to be independent of obesity in multiple linear regression analysis. Human monocyte-
derived macrophages showed no differences in expression of TNFα, 11β-HSD-1 or resistin 
between non-obese and obese subjects. Study III also confirms the increased expression of 
macrophage markers CD68 and ITGAM, and of 11β-HSD-1 in human adipose tissue in obese 
compared to non-obese subjects. 
 
In keeping with most (Paulmyer-Lacroix et al. 2002, Lindsay et al. 2003, Wake et al. 2003, 
Kannisto et al. 2004), but not all (Tomlinson et al. 2002) previous studies, expression of 11β-
HSD-1 was found to be increased significantly in subcutaneous adipose tissue of obese 
insulin-resistant subjects. Overexpression of 11β-HSD-1 selectively in adipose tissue in 
transgenic mice results in visceral obesity, insulin-resistance, diabetes and hyperlipidemia 
(Masuzaki et al. 2001). In adipose tissue, gene expression of 11β-HSD-1 correlates closely 
with both protein concentration (Kannisto et al. 2004) and enzyme activity of 11β-HSD-1 
(Lindsay et al. 2003, Wake et al. 2003). As 11β-HSD-1 predominantly converts inactive 
cortisone (11-dehydrocorticosterone in mice) into biologically active cortisol (corticosterone 
in mice) in vivo (Seckl and Walker 2001), the increased expression of 11β-HSD-1 may 
increase local cortisol concentration in adipose tissue contributing to insulin resistance. The 
cell type responsible for 11β-HSD-1 overexpression in obesity cannot be determined from the 
data in study III. 
 
11β-HSD-1-KO mice have lower expression of resistin and TNFα in adipose tissue than WT 
mice (Morton et al. 2004). Thus, one might have expected TNFα expression to be increased in 
adipose tissue in obese subjects. Also, the increased CD68 expression would be expected to 
be accompanied by increased TNFα expression. Although TNFα expression was increased, 
this increase did not reach statistical significance in study III. This could have been a type 2 
error or, alternatively, due to phenotypic differences in macrophages. Activated M1-
macrophages produce high amounts of proinflammatory cytokines such as TNFα and IL-6 
while apoptotic cell engulfment appears to signal macrophages to transform into a reparative 
M2-population expressing anti-inflammatory properties (Gordon 2003, Bouloumie et al. 
2005). 
 
In study III, the expression of resistin in human macrophages (Patel et al. 2003) is confirmed, 
but no differences at baseline or after LPS-stimulation were found between obese and non-
obese subjects. Resistin expression in adipose tissue or muscle does not differ between 
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insulin-resistant and insulin-sensitive subjects (Furuhashi et al. 2003, Lee et al. 2003b). 
Although resistin has proinflammatory properties and stimulates TNFα and IL-6 production in 
human peripheral blood mononuclear cells (Bokarewa et al. 2005), its role in human 
inflammation and insulin resistance is controversial. Increased infiltration of macrophages in 
adipose tissue in obesity may warrant, however, a role for resistin in inflammation and insulin 
resistance also in humans (Nagaev et al. 2006). 
 
Expression of CD68 and the amount of CD68-positive cells are increased in obese adipose 
tissue (Weisberg et al. 2003, Xu et al. 2003b). In humans, expression of CD68 and ITGAM 
has not been previously related to liver fat content, or to expression of TNFα and 11β-HSD-1 
in adipose tissue. These positive relationships may reflect an essential role of adipose tissue 
inflammation, rather than peripheral fat per se, in regulating hepatic insulin sensitivity, since 
liver fat (Sutinen et al. 2002) and the number of adipose tissue macrophages (Sievers et al. 
2009) are increased even in patients with decreased subcutaneous fat mass. 
 
Only two other human studies, one published before (Cancello et al. 2006) and the other after 
(Tordjman et al. 2009) study III, have examined the relationships between adipose tissue 
inflammation and liver fat. These studies found no relationship between the number of 
macrophages in subcutaneous adipose tissue and liver fat content in morbidly obese subjects 
undergoing bariatric surgery. However, the number of macrophages in visceral adipose tissue 
correlated with hepatic fibro-inflammatory lesions (Cancello et al. 2006) and with steatosis, 
fibrosis and inflammation (Tordjman et al. 2009). Healthy non-obese controls were not 
included in these studies. A limitation in study III is that gene expression of two macrophage 
markers was measured but immunohistochemical studies were not possible because a needle, 
rather than surgical, biopsy of adipose tissue was taken. 
 
The studies showing macrophage infiltration in human and murine adipose tissue in obesity 
(Weisberg et al. 2003), and those showing that mice lacking IKK-β specifically in myeloid 
cells (i.e. monocytes, macrophages, neutrophils) are protected from insulin resistance in both 
skeletal muscle and the liver (Arkan et al. 2005), raised the interest in exploring the role of 
myeloid cells in the pathogenesis of insulin resistance in humans. Previous studies have 
suggested that insulin receptor tyrosine kinase activity is decreased in isolated monocytes 
from non-obese insulin-resistant compared to sensitive subjects (Frittitta et al. 1993), and that 
adhesion of human monocytes to endothelium in vitro is correlated with the degree of insulin 
resistance (Chen et al. 1999a). Freshly isolated circulating monocytes have been suggested to 
be in a proinflammatory state in obese subjects compared to non-obese controls (Ghanim et 
al. 2004). These data do not necessarily disagree with the findings in study III of unaltered 
basal and LPS-stimulated expression of TNFα, 11β-HSD-1 and resistin in human monocyte-
derived macrophages, since in vitro differentiated macrophages, not freshly isolated 
monocytes, were studied. Obviously, this warrants measurement of a larger number of genes, 





To conclude, study III demonstrates BMI-independent correlation between adipose tissue 
inflammation and liver fat content. Liver fat in turn is correlated with serum insulin and other 
signs of insulin resistance. These data may help to understand why some but not all obese 
subjects develop signs of insulin resistance. 
3. Adipose tissue inflammation in equally obese groups of subjects 
with normal or high liver fat content (study IV) 
Study IV was the first to determine whether increased liver fat content is associated with 
adipose tissue inflammation as determined by quantitative RT-PCR, immunohistochemistry 
and lipidomics in two equally obese groups of subjects with normal or high liver fat content. 
It was also the first study to apply lipidomics to analyze adipose tissue in humans. Several of 
the changes in expression of ”insulin resistance and sensitivity genes” that have been 
previously attributed to obesity, were also found to characterize subjects with high liver fat 
content independent of obesity. In addition, expression of CD68 correlated with the number 
of macrophages and CLS in adipose tissue. Study IV confirms that infiltrated macrophages 
surround perilipin-negative adipocytes to form CLS, as has been previously found in obese 
compared to lean subjects (Cinti et al. 2005). The lipidomics analysis of adipose tissue 
revealed increased concentration of ceramides, sphingomyelins and long-chain TAG in the 
high compared to normal liver fat group. 
 
In study IV, adipose tissue expression of CD68, MCP-1, MIP-1α and PAI-1 were 
significantly increased and that of PPARγ significantly decreased in the high compared to 
normal liver fat group. Previous studies have documented increases in gene and protein 
expression of each of these genes in obese compared to non-obese subjects (Alessi et al. 1997, 
Di Gregorio et al. 2005, Lee et al. 2005, Mertens et al. 2005, Kim et al. 2006). The increased 
expression of MCP-1 is of particular interest since overexpression of MCP-1 in adipose tissue 
in mice is sufficient to induce macrophage infiltration in adipose tissue, systemic insulin 
resistance and fatty liver (Kanda et al. 2006). On the other hand, all these changes are 
ameliorated in high-fat fed mice with genetic deficiency of either MCP-1 (Kanda et al. 2006) 
or its receptor CCR2 (Weisberg et al. 2006). The cellular origin of MCP-1 was not 
investigated in study IV, as several studies have consistently shown macrophages to be the 
main source of this chemokine in human adipose tissue (Bruun et al. 2005, Fain and Madan 
2005). MIP-1α is also involved in the recruitment and activation of macrophages and 
leukocytes (Maurer and von Stebut 2004). In study IV, expression of MIP-1α in human 
adipose tissue was increased in subjects with high compared to normal liver fat content. 
 
The expression of PPARγ was significantly decreased in the high compared to normal liver fat 
group in study IV. Ablation of adipocyte PPARγ expression in mice has been shown to lead to 
adipocyte necrosis and infiltration of inflammatory cells in adipose tissue (Imai et al. 2004). 
Therefore, the reduced adipose tissue expression of PPARγ in the high liver fat group may 




In addition to the reported increase in the infiltration of macrophages in adipose tissue of 
obese compared to non-obese subjects (Weisberg et al. 2003, Cancello et al. 2005), adipose 
tissue macrophages and perilipin-negative adipocytes arrange to form CLS in both obese mice 
and humans (Cinti et al. 2005). Perilipin is a protein located at the interface between the 
cytosol and TAG droplets in adipocytes and is involved in the regulation of lipolysis (Tansey 
et al. 2004). Using electron microscopy, negative perilipin staining was found in adipocytes 
with disrupted cell membrane, and that were partly engulfed by macrophages. It was therefore 
used as a marker of adipocyte death (Cinti et al. 2005). The immunohistochemical data in 
study IV confirmed the presence of CLS in human subcutaneous adipose tissue. The finding 
of increased macrophage infiltration and inflammation in adipose tissue independent of 
obesity in study IV is novel. 
 
Fat cell size associates with obesity (Hirsch and Batchelor 1976, Coppack 2001), with the 
degree of macrophage infiltration in adipose tissue (Weisberg et al. 2003) and with adipocyte 
cell death (Cinti et al. 2005, Strissel et al. 2007). In HSL-KO mice, adipocyte cell size is 
markedly increased while body fat mass remains comparable with WT mice (Cinti et al. 
2005). In these mice, adipose tissue is infiltrated with macrophages, suggesting that increased 
cell size rather than overall obesity is a trigger for macrophage infiltration. In study IV, the 
average adipocyte cell size and cross-sectional area were comparable between the groups. 
This suggests that cell size may not be the factor determining macrophage recruitment in 
adipose tissue of equally obese subjects with high as compared to low liver fat content. 
 
Liver fat content can be increased by a high-fat diet containing plenty of saturated FA as 
compared to low-fat diet in humans (Westerbacka et al. 2005). Liver fat content also 
positively correlates with intake of both total and saturated fat in T2DM subjects (Tiikkainen 
et al. 2003), and in normal weight to obese healthy MZ twins (Pietiläinen et al. 2005). Long-
chain saturated FA, with 16±1 carbons, are the main substrate for de novo synthesis of 
ceramides and other sphingolipids (Merrill 2002). Consistent with this, the lipidomics 
analysis in study IV showed significant increase in adipose tissue long-chain FA 
concentration in the high liver fat group. Thus, ceramides could contribute to the adverse 
metabolic effects of saturated fat. 
 
Hydrolysis of sphingomyelin by SMPD could also have contributed to the increase in 
ceramide content (Summers 2006). Although enzymatic activity was not determined, gene 
expression of SMPD-1 and SMPD-3 were significantly increased in the high compared to 
normal liver fat group. The SMPD pathway is stimulated by several cytokines including 
TNFα (Dbaibo et al. 2001). In study IV, gene expression of TNFα in adipose tissue was 1.6-
fold and marginally significantly increased in the high compared to normal liver fat group. 
Interestingly, SMPD activity is also found in atherosclerotic lesions (Marathe et al. 1999), and 
the ceramide content of LDL in arterial wall is higher than that of circulating LDL (Schissel et 
al. 1996). Thus, changes in inflamed adipose tissue containing macrophages bear some 
resemblance to those characteristic of atherosclerosis in the arterial wall. More recently, 
cross-sectional human studies have shown a correlation between serum ceramide and IL-6 
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concentrations in patients with coronary heart disease (De Mello et al. 2009). In addition, 
serum total ceramide concentration is increased in obese T2DM patients compared to lean and 
healthy subjects, and serum ceramide concentration correlates inversely with insulin 
sensitivity measured using euglycemic hyperinsulinemic clamp (Haus et al. 2009). 
 
To conclude, study IV demonstrated that subjects with high liver fat content show increased 
inflammation and macrophage infiltration in subcutaneous adipose tissue compared to equally 
obese subjects with normal liver fat content. In addition, the concentration of ceramides and 
long-chain TAG are increased in subjects with high liver fat. Ceramides could contribute to 
saturated fat-induced insulin resistance in adipose tissue, although the cross-sectional design 
of study IV cannot prove causality. 
4. Contribution of genetic factors to serum alanine 
aminotransferase activity, a surrogate marker of liver fat (study V) 
In study V, heritability was high and significant for both serum ALT (55 %) and insulin (61 
%). To validate the use of serum ALT as a surrogate marker of liver fat, it was measured by 
1H-MRS in a subgroup of 66 subjects. In keeping with previous findings in our group 
(Westerbacka et al. 2004, Kotronen and Yki-Järvinen 2008), significant and positive 
correlations between liver fat content and serum ALT and insulin were found. The high 
intrapair correlation for liver fat content in MZ pairs (r=0.70) was consistent with high 
heritability estimates for serum ALT and insulin. 
 
The 313 subjects were recruited from a large population-based twin cohort comprising 4929 
Finnish individual twins. The subjects in study V cover a wide range of BMI comparable with 
the whole cohort and represent healthy young adults who do not use excessive amounts of 
alcohol or regular medications. Medical history and daily alcohol consumption were carefully 
reviewed to exclude causes of steatosis or elevated liver enzymes other than those associated 
with obesity and insulin resistance. This enabled reliable estimation of genetic causes in 
variation of serum ALT activity and insulin concentration. Furthermore, in twin studies MZ 
and same sex DZ twins are perfectly matched for age, sex and ethnicity. 
 
Heritability for ALT activity has previously been estimated in two twin studies. A Danish 
study investigated 290 pairs of elderly (age range 73 to 102 years) same-sex twins and found 
35-61 % heritability for serum ALT, γGT, bilirubin, albumin and lactate dehydrogenase 
(Bathum et al. 2001). Heritability for serum ALT was 35 % and the best-fitting model was DE 
(35 % for dominant genetic and 65 % for unique environmental effects). The results did not 
change after adjusting for self-reported BMI and alcohol consumption. Information on 
medical history or medication status was not included in the analyses. In study V, almost 
twice as great heritability for serum ALT was found compared to the Danish study. In contrast 
to subjects in study V, the Danish twins were considerably older, their disease records or 
medications were not taken into account and BMI was self-reported. These factors can 




Another study included 965 Australian families with adolescent twins and their non-twin 
siblings to investigate the contribution of genetic and environmental factors to variation in 
serum ALT, AST and γGT activities, and in uric acid concentration (Middelberg et al. 2007). 
Genetic and environmental factors (e.g. diet, lifestyle) influencing these four parameters were 
studied longitudinally in the same twins at ages of 12, 14 and 16 years. The heritability of 
serum ALT was 40 %. The contribution of obesity, alcohol consumption, medications or 
disease records to heritability analyses were not reported in the latter study. 
 
Previous studies have shown that serum insulin is a good surrogate marker for liver fat 
content, even independent of age, gender and BMI (Kotronen and Yki-Järvinen 2008). The 
fatty liver is insulin-resistant contributing to hyperinsulinemia (Ryysy et al. 2000, Seppälä-
Lindroos et al. 2002) and impaired hepatic insulin clearance (Kotronen et al. 2007a). In line 
with these data, close correlation between liver fat content and insulin concentration was 
found in study V. The heritabilities for serum ALT activity (55 %) and insulin concentration 
(61 %) were of similar magnitude. These results suggest that genetic factors underlying 
interindividual differences in liver fat content may also regulate serum insulin concentration 
e.g. by changing insulin clearance and action or vice versa. Nonetheless, only a small fraction 
(9 %) of the genetic effects influencing serum ALT activity and serum insulin concentration 
were shared, indicating that these two surrogate markers of liver fat content are mainly 
determined by separate sets of genes. 
 
Taken together, the twin data in study V suggest that genetic factors contribute significantly to 
variation in serum ALT activity, a surrogate marker of liver fat content. 
 
Recently a single nucleotide polymorphism (SNP) (rs738409, C to G allele) in the human 
patatin-like phospholipase domain-containing 3 (PNPLA3) gene, encoding for adiponutrin, 
was found to be strongly correlated with increased liver fat content in African- and European-
Americans and in Hispanics in the Dallas Heart Study (Romeo et al. 2008). This correlation 
has been confirmed in subsequent studies in Argentinian subjects (Sookoian et al. 2009) and 
in different European populations (Kantartzis et al. 2009, Kotronen et al. 2009a). The genetic 
variation in PNPLA3 did not, however, influence hepatic insulin sensitivity or serum FFA 
concentration (Kotronen et al. 2009a), or serum insulin concentration (Romeo et al. 2008, 
Kantartzis et al. 2009, Romeo et al. 2010). In addition, the same adiponutrin SNP has also 
been associated with increased transaminase activities (Yuan et al. 2008, Kollerits et al. 2010, 
Romeo et al. 2010). Adiponutrin is expressed in both adipose tissue and in the liver in 
humans, and is suggested to possess both lipolytic and lipogenic properties (Wilson et al. 
2006), although its exact function is unknown to date. A recent study confirmed the TAG 
hydrolyzing ability of adiponutrin and showed that the rs738409 SNP results in intracellular 
TAG accumulation in vitro (He et al. 2010). These intriguing data warrant further studies to 




The present studies addressed the regulation of adipose tissue gene expression by insulin in 
insulin-sensitive and resistant subjects, and the interrelationships between adipose tissue 
inflammation and liver fat content in obese subjects with variable amount of liver fat. Results 
suggest that acute regulation of adipose tissue gene expression by insulin in insulin-resistant 
subjects is not only characterized by decreased response of genes related to insulin sensitivity 
but also by an increased response of genes related to insulin resistance and inflammation. 
Thus, impaired insulin action in adipose tissue may contribute to inflammation. Adipose 
tissue inflammation, defined by increased expression of inflammatory and macrophage 
marker genes, was found to correlate with liver fat content independent of obesity. The 
number of macrophages and expression of inflammatory genes, as well as concentration of 
ceramides and long-chain TAG, were increased in subjects with high liver fat content 
compared to equally obese subjects with normal liver fat. This suggests that increased liver fat 
content and adipose tissue inflammation are important determinants of insulin resistance even 
independent of obesity in humans. In addition, significant heritability for serum ALT activity 
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Abstract Aims/hypothesis: We determined the response
of selected genes to in vivo insulin in adipose tissue in 21
non-diabetic women. Materials and methods: The women
were divided into insulin-sensitive and -resistant groups
based on their median whole-body insulin sensitivity
(8.7±0.4 vs 4.2±0.3 mg kg−1 min−1 for insulin-sensitive vs
-resistant group). Subcutaneous adipose tissue biopsies
were obtained before and after 3 and 6 h of i.v. maintained
euglycaemic hyperinsulinaemia. Adipose tissue mRNA
concentrations of facilitated glucose transporter, member 1
(SLC2A1, previously known asGLUT1), facilitated glucose
transporter, member 4 (SLC2A4, previously known as
GLUT4), peroxisome proliferator-activated receptor γ
(PPARG), peroxisome proliferator-activated receptor γ
co-activator 1α (PPARGC1A), 11β-hydroxysteroid dehy-
drogenase-1 (HSD11B1), TNF, adiponectin (ADIPOQ), IL6
and the macrophage marker CD68 were measured using
real-time PCR. Results: Basal expression of ‘insulin-sen-
sitivity genes’ SLC2A4 and ADIPOQ was lower while that
of ‘insulin-resistance genes’, HSD11B1 and IL6 was signif-
icantly higher in the insulin-resistant than in the insulin-
sensitive group. Insulin significantly increased expression of
‘insulin-sensitivity genes’ SLC2A4, PPARG, PPARGC1A
and ADIPOQ in the insulin-sensitive group, while only
expression of PPARG and PPARGC1Awas increased in the
insulin-resistant group. The expression of ‘insulin-resistance
genes’ HSD11B1 and IL6 was increased by insulin in the
insulin-resistant group, but insulin failed to increase
HSD11B1 expression in the insulin-sensitive group. At 6 h,
expression of HSD11B1, TNF and IL6 was significantly
higher in the insulin-resistant than in the insulin-sensitive
group. IL6 expression increased significantly more in re-
sponse to insulin in the insulin-resistant than in the
insulin-sensitive group. CD68 was overexpressed in the
insulin-resistant as compared with the insulin-sensitive
group at both 0 and 6 h. Conclusions/interpretation: These
data suggest that genes adversely affecting insulin sensitiv-
ity hyperrespond to insulin, while genes enhancing insulin
sensitivity hyporespond to insulin in insulin-resistant
human adipose tissue in vivo.
Keywords Adipocytokines . Adiponectin . Cortisol .
Interleukin . Macrophages . PGC-1 . TNF
Abbreviations ACTB: gene encoding β-actin .
ADIPOQ: gene encoding adiponectin . HSD11B1: gene
encoding 11β-hydroxysteroid dehydrogenase-1 . PPARG:
peroxisome proliferator-activated receptor γ .
PPARGC1A: peroxisome proliferator-activated receptor γ
co-activator α . SLC2A1: facilitated glucose transporter,
member 1 . SLC2A4: facilitated glucose transporter,
member 4 . TBP: gene encoding TATA-box binding protein
Introduction
Low-grade systemic inflammation and insulin resistance
frequently coexist. Serum concentrations of cytokines, such
as IL6 [1–6] and in some studies TNF [6, 7] correlate with
markers of insulin resistance. Adipose tissue is one site of
inflammation in insulin-resistant conditions. The number of
macrophages is increased in both obese and lipoatrophic
insulin-resistant subjects [8–10], and the expression of genes
encoding IL6 [2, 6] and TNF [2, 6, 7] is increased in human
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adipose tissue. IL6 impairs insulin signalling in 3T3-L1
adipocytes in vitro [11], and adipose tissue IL6 content
correlates inversely with insulin action in vivo in humans
[12]. The increased TNF expression in adipose tissue was
recently suggested to originate exclusively from macro-
phages [8].
Insulin-resistant adipose tissue also overexpresses other
genes that possibly contribute to insulin resistance, e.g. the
gene encoding the enzyme that converts cortisone to cortisol,
11β-hydroxysteroid dehydrogenase-1 (HSD11B1), which is
expressed in both adipocytes and macrophages [13, 14].
Overexpression of this enzyme in mice results in insulin
resistance and visceral obesity [15]. In addition to these
‘insulin-resistance’ genes, another set of genes (‘insulin-
sensitivity genes’) are underexpressed in insulin-resistant
adipose tissue. These include the gene encoding adiponectin
(ADIPOQ), which is deficient in both serum and adipose
tissue of obese [16–18] and lipoatrophic [19] subjects, as
well as the genes encoding the insulin-sensitive facilitated
glucose transporter, member 4 (SLC2A4, previously known
as GLUT4) [20], the adipogenic transcription factor perox-
isome proliferator-activated receptor-γ (PPARG) [21, 22]
and its coactivator 1α (PPARGC1A) [23, 24].
Regarding acute regulation of ‘insulin-resistance’ genes,
insulin has been found to increase IL6 expression in vitro in
human adipocytes [25] and in 3T3-L1 cells [26], and
transiently in a study in vivo in human adipose tissue [27].
Data on TNF expression are inconsistent, with one study
reporting a transient increase in TNF mRNA by insulin in
vivo with no change in serum TNF [27], while another in
vivo study [28] and one in vitro study using human adipose
tissue [29] found no effect of insulin on TNF expression.
Insulin has been reported to decrease HSD11B1 expression
in vitro [13], and not to change expression during a 3-h
insulin infusion in human adipose tissue [28]. Insulin
acutely increases SLC2A4 [30, 31] and PPARG [32] ex-
pression, but there are no in vivo data on acute regulation of
PPARGC1A or ADIPOQ in vivo in human adipose tissue.
No studies to date have compared the acute effects of
insulin on ‘insulin-resistance’ and ‘-sensitivity’ genes in
insulin-resistant and -sensitive subjects. In the present
study, we compared expression of selected ‘insulin-resis-
tance’ genes (IL6, TNF,HSD11B1) and ‘insulin-sensitivity’
genes (SLC2A4, PPARG, PPARGC1A, ADIPOQ) in sub-
cutaneous adipose tissue biopsies of insulin-sensitive and
insulin-resistant subjects, and compared responses of these
genes to acute hyperinsulinaemia by repeating the biopsies
after 3 and 6 h of insulin infusion. We also determined
whether expression of the macrophage marker CD68 is
increased in the insulin-resistant vs -sensitive subjects, and
whether its expression is regulated by insulin.
Subjects, materials and methods
Subjects and study designs A total of 21 non-diabetic ap-
parently healthy Caucasian women were recruited on the
basis of the following inclusion criteria: (1) age 18–60 years,
and (2) no known acute or chronic disease other than obesity
based on history and physical examination and standard
laboratory tests (blood counts, serum creatinine, thyroid-
stimulating hormone, electrolyte concentrations and electro-
cardiogram). Other exclusion criteria included pregnancy
and treatment with drugs that may alter glucose tolerance. In
each subject, whole-body insulin sensitivity was measured
using the euglycaemic insulin clamp technique (insulin
infusion rate 1 mU kg−1 min−1 for 6 h) and needle biopsies
of adipose tissue were taken before and after 3 and 6 h of
hyperinsulinaemia. The women were divided into insulin-
sensitive (n=11) and insulin-resistant (n=10) groups, on the
basis of their median rate of whole-body insulin sensitivity.
The nature and potential risks of the study were
explained to all subjects prior to obtaining their written
informed consent. The study was carried out in accordance
with the principles of the Declaration of Helsinki. The
protocol was approved by the ethics committee of Helsinki
University Central Hospital.
Whole-body insulin sensitivity Whole-body insulin sensitiv-
ity was measured using the insulin clamp technique [33]. The
study was begun at 07:30 hours after an overnight fast. Two
18-gauge catheters (Venflon; Viggo-Spectramed, Helsingborg,
Sweden) were inserted, one in an antecubital vein for in-
fusion of insulin and glucose, and another retrogradely in a
heated hand vein to obtain arterialised venous blood for
measurement of glucose concentrations every 5 min and
serum free insulin concentration every 30 min. Regular
human insulin (Insulin Actrapid; Novo Nordisk, Denmark)
was infused in a primed-continuous fashion. The rate of the
continuous insulin infusion was 1 mU kg−1 min−1 for 6 h.
Normoglycaemia was maintained by adjusting the rate of a
20% glucose infusion based on plasma glucose measure-
ments from arterialised venous blood every 5 min. Whole-
body insulin sensitivity was determined from the glucose
infusion rate required to maintain normoglycaemia between
30 and 360 min [33].
Adipose tissue biopsy and total RNA cDNA preparation A
needle aspiration biopsy of abdominal subcutaneous fat was
taken under local intracutaneous anaesthesia at baseline and
after 3 and 6 h of hyperinsulinaemia [34]. Each biopsy
sample was taken from different locations in the left, middle
and right lower abdominal region. The sample was imme-
diately frozen and stored in liquid nitrogen until analysis.
Frozen tissue samples (50–150 mg) were homogenised in
2 ml RNA STAT-60 (Tel-Test, Friendswood, TX, USA) and
total RNA isolated according to the manufacturer’s in-
structions. After DNase treatment (RNase-free DNase Set;
Qiagen, Hilden, Germany) RNA was purified using the
RNeasy Minikit (Qiagen). RNA concentrations were mea-
sured using the RiboGreen fluorescent nucleic acid stain
(RNA Quantification Kit; Molecular Probes, Eugene, OR,
USA). The quality of RNA was checked by agarose gel
electrophoresis. Isolated RNA was stored at −80°C until
quantification of target mRNAs. A total of 0.1 μg RNAwas
transcribed into cDNA using Moloney murine leukaemia
virus reverse transcriptase (Life Technologies, Paisley, UK)
and oligo (dT)12–18 primers.
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Quantification of mRNA concentrations Quantification of
the gene encoding β-actin (ACTB), PPARG and ADIPOQ
mRNAwas performed in Helsinki (E.K.) by real-time PCR
using LightCycler technology (Roche Diagnostics, Mann-
heim, Germany). An aliquot of 2 μl 1:10 diluted cDNAwas
brought to a final volume of 20 μl, which contained
3 mmol/l magnesium chloride, 2 μl LightCycler-FastStart
DNA SYBR Green I Mix (Roche Diagnostics) and
0.5 μmol/l primers. After the initial activation of the DNA
polymerase at 95°C for 10 min, the amplification conditions
were as follows: 40 cycles consisting of denaturation at
95°C for 15 s, annealing for 5 s at 57°C (ACTB), 56°C
(PPARG) and 58°C (ADIPOQ) and extension at 72°C. The
extension times (s) were calculated from the amplicon size
(bp/25). Fluorescent data were acquired at the end of each
extension phase. After amplification, a melting curve
analysis from 65°C to 95°C with a heating rate of 0.1°C/s
with a continuous fluorescence acquisition was made. The
primers for PPARG, ADIPOQ and ACTB have been
described [35]. A standard curve for PPARG was created
using purified cloned plasmid cDNA (QIAquick PCR
Purification Kit; Qiagen). For human ACTB and ADIPOQ
expression, standard curves were created from a specific
PCR product. To account for differences in RNA loading,
PPARG and ADIPOQ were expressed relative to ACTB.
The mRNA expression levels of facilitated glucose
transporter, member 1 (SLC2A1, previously known as
GLUT1), SLC2A4, PPARGC1A, TNF,HSD11B1 and the
gene encoding TATA-box binding protein (TBP) were
measured in Stockholm (K.K., M.K., R.M.F.) using TaqMan
real-time PCR according to the manufacturer’s protocol
using an ABI PRISM 7000 Sequence Detection System
instrument and software (PE Applied Biosystems, Foster
City, CA, USA). cDNA synthesised from 15 ng total RNA
was mixed with TaqMan Universal PCR Master Mix
(Applied Biosystems). Primer and probe sets for SLC2A1,
SLC2A4, PPARGC1A and HSD11B1 were designed using
the manufacturer’s software and sequences available in
GeneBank, and the sequences have been published pre-
viously [35, 36]. Differences in the loading of cDNA were
adjusted for by expressing results relative to TBP. Expression
levels were quantified in arbitrary units by generating a six-
point serial standard curve. After these analyses were per-
formed, obese subjects were reported to have an excess of
macrophages in adipose tissue [8, 9], and IL6 was shown to
cause insulin resistance in adipocytes [11]. Therefore CD68
and IL6were quantified later in remaining 0- and 6-h samples
and expressed relative to TBP. TNF,CD68, IL6 and TBPwere
measured using Pre-Developed TaqMan Assay Reagents
(assay numbers Hs00174128_m1, Hs00154355_m1, Hs0
0174131_m1 and Hs99999910_m1, respectively; Applied
Biosystems). The specificity of each primer and probe set was
confirmed by visualisation of a single PCR product by agarose
gel electrophoresis.
Other measurements Blood samples were taken after an
overnight fast for measurement of plasma glucose, serum
insulin and C-peptide, serum triglyceride and total and
HDL cholesterol concentrations. The percentage (%) of
body fat was determined by using bioelectrical impedance
analysis (BioElectrical Impedance Analyzer System
Model #BIA-101A; RJL Systems, Detroit, MI, USA)
[37]. Waist circumference was measured midway between
spina iliaca superior and the lower rib margin, and hip
circumference at the level of the greater trochanters [38].
Analytical procedures Plasma glucose concentrations were
measured in duplicate with the glucose oxidase method
(Glucose Analyzer II; Beckman Instruments, Fullerton,
CA, USA) [39]. Serum free insulin concentrations were
measured using the Auto-DELFIA kit from Wallac (Turku,
Finland) and C-peptide concentrations by RIA [40]. HbA1c
was measured by HPLC using the fully automated Glyco-
sylated Hemoglobin Analyzer System (BioRad, Richmond,
CA, USA) [41]. Serum total cholesterol, HDL cholesterol
and triglyceride concentrations were measured with enzy-
matic kits from Roche Diagnostics using an autoanalyser
(Roche Diagnostics Hitachi 917; Hitachi, Tokyo, Japan).
LDL cholesterol concentration was calculated using the
formula of Friedewald [42]. Serum adiponectin concentra-
tions were measured using an ELISA kit from B-Bridge
International (San Jose, CA, USA).
Table 1 Physical and biochem-
ical characteristics of the study
subjects divided into insulin-
sensitive and -resistant groups
on the basis of their median
whole-body insulin sensitivity
Data are means±SEM
Insulin-sensitive Insulin-resistant p value
Number 11 10 –
Age (years) 32±3 40±3 NS
Body weight (kg) 69±4 90±4 <0.01
BMI (kg/m2) 24.7±1.1 32.7±1.8 <0.001
Whole-body fat (%) 28±2 36±1 <0.001
Fat mass (kg) 20±2 35±4 <0.01
Waist-to-hip-ratio 0.86±0.01 0.91±0.01 <0.01
Fasting plasma glucose (mmol/l) 5.1±0.1 5.6±0.2 <0.01
Fasting serum insulin (mU/l) 3±1 10±1 <0.001
Fasting serum C-peptide (nmol/l) 0.4±0.1 0.8±0.1 <0.001
Fasting serum LDL cholesterol (mmol/l) 2.2±0.1 3.1±0.1 <0.01
Fasting serum triglycerides (mmol/l) 0.8±0.1 1.4±0.2 <0.01
Fasting serum HDL cholesterol (mmol/l) 1.4±0.1 1.3±0.1 <0.001
Fasting serum adiponectin (mg/l) 18±2 12±1 <0.01
134
Statistical analyses All parameters were analysed using
non-parametric methods. Insulin-sensitive and -resistant
groups were compared using the Mann–Whitney test.
Effects of insulin were analysed using Friedman’s test
followed by Dunn’s post hoc test to compare single measure-
ments. Correlations were calculated using Spearman’s rank
correlation coefficient. p>0.05 was considered statistically
significant. The calculations were performed using SPSS
11.0 for Windows (SPSS, Chicago, IL, USA). All data are
shown as means±SEM.
Results
Clinical characteristics Characteristics of the groups are
given in Table 1. The insulin-resistant group was more
obese than the insulin-sensitive group. Markers of insulin
resistance, including serum fasting insulin, C-peptide and
triglyceride concentrations were higher and HDL choles-
terol and adiponectin concentrations were lower in the
insulin-resistant than in the insulin-sensitive group.
Fig. 1 The expression of ‘insulin-
sensitivity genes’ SLC2A4,
PPARG, PPARGC1A and
ADIPOQ in (a–d) insulin-sensitive
(n=11) and (e–h) insulin-resistant
(n=10) subjects at 0, 3 and 6 h
during euglycaemic hyperinsu-
linaemia (rate of continuous insu-
lin infusion 1 mU kg−1 min−1).
*p<0.05, **p<0.01, ***p<0.001
for change between time points;
#p<0.05, ##p<0.01 for difference
between groups
Table 2 The relationship (Spearman’s r) between gene expression
in adipose tissue and whole-body insulin sensitivity
Gene 0 h 3 h 6 h
SLC2A1/TBP −0.08 −0.29 0.04
Insulin-sensitivity genes
SLC2A4/TBP 0.44# 0.66** 0.73***
PPARG/ACTB 0.14 −0.37 −0.14
PPARGC1A/TBP 0.19 0.55* 0.34
ADIPOQ/ACTB 0.48* −0.16 −0.24
Insulin-resistance genes
IL6/TBP −0.48* ND −0.71***
TNF/TBP −0.44* −0.53* −0.46*
HSD11B1/TBP −0.55* −0.74*** −0.82***
Macrophage marker







During the insulin infusion, serum insulin concentrations
were similar in insulin-sensitive and -resistant groups (69±4
vs 76±4 mU/l, respectively; NS). By definition, whole-
body insulin sensitivity was 107% higher in the insulin-
sensitive than the insulin-resistant group (8.7±0.4 vs 4.2±
0.3 mg kg−1 min−1, p<0.0001).
Expression of genes encoding SLC2A1, SLC2A4, PPARG,
PPARGC1A and ADIPOQ in adipose tissue Before the
start of the insulin infusion, the mRNA concentrations of
SLC2A1 (1033±543 vs 722±251, insulin-sensitive vs -re-
sistant; NS), PPARG and PPARGC1A (Fig. 1) were com-
parable between the two groups. SLC2A4 gene expression
was lower in the insulin-resistant than the insulin-sensitive
group at baseline (p<0.05). The mRNA concentrations of
SLC2A1 and the housekeeping genes (ACTB and TBP) were
comparable between the groups and remained unchanged
during insulin infusion in both groups (data not shown).
During the insulin infusion, SLC2A4 mRNA concentrations
increased 2.2-fold in the insulin-sensitive group, whereas
expression of SLC2A4 remained unchanged in the insulin-
resistant group (Fig. 1). At 6 h, SLC2A4 expression was
significantly higher in the insulin-sensitive than the insulin-
resistant group. In univariate correlation analysis (all subjects
analysed as one group), SLC2A4 mRNA correlated with
whole-body insulin sensitivity at 3 h (Spearman’s r=0.66,
p<0.01) and 6 h (r=0.73, p<0.001) and almost significantly
at 0 h (Table 2). The expression of PPARG and PPARGC1A
increased significantly during insulin infusion in both groups
with no differences between the groups (Fig. 1). PPARGC1A
and SLC2A4 mRNA concentrations correlated with each
other at 0 h (r=0.66, p<0.01) and 6 h (r=0.38, p<0.05). The
changes in gene expression between 0 and 6 h of insulin
infusion were confirmed in independent assays for the
quantification of SLC2A4, PPARG and PPARGC1A (data not
shown).
ADIPOQ gene expression at all time points was sig-
nificantly higher in the insulin-sensitive than the insulin-
resistant group (Fig. 1). ADIPOQ mRNA concentrations
increased significantly in the former but not in the latter
group (Fig. 1). Serum adiponectin concentrations were
significantly higher in the insulin-sensitive than the insulin-
resistant group before (Table 1) and during insulin infusion
at 3 h (16±2 vs 11±1 mg/l, respectively; p<0.01) and 6 h
(16±2 vs 11±1 mg/l, p<0.01).
Fig. 2 The expression of ‘insulin-
resistance genes’ HSD11B1 and
TNF in (a, b) insulin-sensitive
(n=11) and (c, d) insulin-resistant
(n=10) subjects at 0, 3 and 6 h
during euglycaemic hyperinsuli-
naemia (rate of continuous insulin
infusion 1 mU kg−1 min−1).




Fig. 3 The expression of (a) IL6 and (b) the macrophage marker
CD68 in insulin-sensitive and insulin-resistant subjects at 0 and 6 h
during euglycaemic hyperinsulinaemia (rate of continuous insulin
infusion 1 mU kg−1 min−1). *p<0.05 for change between time points;
#p<0.05, ##p<0.01 for difference between groups
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HSD11B1, TNF and IL6 Before insulin infusion, HSD11B1
mRNA concentrations were 2.4-fold higher in the insulin-
resistant than the insulin-sensitive group (Fig. 2). Insulin
further increased HSD11B1 mRNA concentrations in the
former group, while there were no changes in the insulin-
sensitive group. TNF mRNA concentrations tended to be
higher in the insulin-resistant than the insulin-sensitive group
at all time points with a significant difference at 6 h (Fig. 2).
Insulin did not change TNF concentrations significantly. IL6
gene expression increased by insulin in both groups and
expression was significantly higher in the insulin-resistant
than in the insulin-sensitive group at 6 h (Fig. 3). Also, the
increase in IL6 gene expression by insulin was significantly
higher in the insulin-resistant than the insulin-sensitive group
(p<0.02).
Expression of macrophage marker CD68 Before and
during the insulin infusion, CD68 mRNA concentrations
were significantly higher in the insulin-resistant than the
insulin-sensitive group (Fig. 3).
Discussion
The present data are the first to compare the responses of
genes thought to counteract insulin action (‘insulin-resis-
tance genes’) and enhance insulin action (‘insulin-sensitivity
genes’) to insulin in vivo in adipose tissue. The study was
performed in apparently healthy subjects (except for obesity)
who were arbitrarily divided into less insulin-sensitive
(insulin-resistant group) and more insulin-sensitive (insulin-
sensitive group) based on their median whole-body insulin
sensitivity. The results show that insulin resistance is not
only characterised by failure of insulin to normally increase
expression of ‘insulin-sensitivity genes’ (SLC2A4, ADI
POQ) but also by hyperresponsiveness of ‘insulin-resistance
genes’ (IL6, HSD11B1, TNF) to insulin.
The multitude of genes involved in regulating insulin
action and the discovery that adipose tissue of obese
subjects contains an excess of macrophages [8], which also
express insulin-action genes, makes interpretation of the
present data complex. Because of the need for repeated
biopsies, it was unfeasible to take enough adipose tissue to
allow separation of macrophages and adipose cells, and
therefore we were unable to allocate the observed changes
in gene expression to a given cell type. Theoretically, this
implies that any of the following scenarios might have
taken place. Firstly, genes hyperresponding to insulin could
reside in a different cell type than those hyporesponding to
insulin. For example, the hyperresponse to insulin of IL6,
which is expressed both in macrophages and in adipocytes,
could have occurred in macrophages and the hyporesponse
of adiponectin in adipocytes, which is the only cell type
expressing adiponectin [43]. Secondly, both the hyper- and
hyporesponse could have occurred in the same cell type but
the increased basal or insulin-stimulated expression of
‘insulin-resistance genes’ in the insulin-resistant group
could have modulated the response to insulin. Thirdly, a
combination of both mechanisms might have been
involved. These possibilities will be further discussed
below in conjunction with the individual genes.
We divided the present study subjects on the basis of
their whole-body insulin sensitivity. As expected the
insulin-resistant subjects were more obese and had more
whole-body fat than the insulin-sensitive subjects. We
cannot therefore distinguish between effects of obesity as
compared with insulin sensitivity on gene expression in
adipose tissue. Adipocyte cell size is increased in insulin-
resistant obese subjects and may influence adipose gene
expression [44]. There are abundant, albeit controversial,
data on differences in gene expression between different
adipose tissue depots [45]. Repeated sampling of intra-
abdominal fat was not ethically justifiable in healthy
subjects.
Several previous studies have compared expression of
one or several of the genes in the basal state, i.e. after an
overnight fast, between non-obese insulin-sensitive and
obese insulin-resistant subjects. These include reports of
decreased expression of the ‘insulin-sensitivity genes’
SLC2A4 [20, 46, 47], PPARGC1A [23] and ADIPOQ [16,
48]. These findings were confirmed in the present study.
Deletion or overexpression of each of these genes has been
shown to modulate insulin action in mouse models [21, 49–
52]. Data are inconsistent regarding PPARG, with reports
of decreased [53, 54] or unchanged [55, 56] expression of
the gene encoding PPARG1, and decreased [57], un-
changed [53, 55] or increased [54, 56] expression of the
gene encoding PPARG2 in obese as compared with lean
subjects. The relative abundance of the mRNAs of PPARG1
and PPARG2 is also controversial [32, 55–57]. In the present
study, PPARG expression was comparable between the in-
sulin-resistant and the insulin-sensitive group (Fig. 1).
Regarding expression of the ‘insulin-resistance genes’, we
confirm reports of increased basal expression of HSD11B1
[58, 59]. In addition, at 6 h of insulin infusion gene ex-
pression of TNF and IL6 was greater in the insulin-resistant
than in the insulin-sensitive group (Figs. 2 and 3).
Regarding acute regulation of gene expression by in-
sulin, the present data are, to the best of our knowledge,
novel in comparing acute changes in gene expression in
insulin-sensitive and -resistant subjects and in demonstrating
that insulin increases mRNA concentrations of HSD11B1
and PPARGC1A in human adipose tissue in vivo. Previous
studies have shown that insulin increases SLC2A4 expres-
sion in skeletal muscle [30, 60], and that this effect is blunted
in skeletal muscle in insulin-resistant as compared with
insulin-sensitive subjects [30, 60]. This was confirmed in
adipose tissue in the present study. PPARGC1A is a tran-
scriptional coactivator, which induces gene expression of
SLC2A4 in skeletal muscle [61]. It is absent from white
adipose tissue in mice but is expressed in human adipose
tissue [23]. We confirm the presence of PPARGC1A in
human adipose tissue [23] and extend previous findings by
demonstrating that insulin acutely increases PPARGC1A
expression in vivo. PPARGC1A and SLC2A4 expression
was significantly correlated, which is in keeping with data
showing that overexpression of PPARGC1A in skeletal
muscle increases SLC2A4 content and insulin sensitivity
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[24]. Overexpression of PPARGC1A increases energy
expenditure by stimulating thermogenesis in brown fat in
mice [62]. This increases the need for fuels such as glucose.
Increases in gluconeogenesis in the liver and glucose
utilisation in peripheral tissues by PPARGC1A could help
to maintain energy supply, even if regulated in a tissue-
specific fashion by insulin. Insulin has been shown to
acutely (i.e. within 3 h) increase expression of PPARG, but
the response was similar in lean and obese subjects and in
type 2 diabetic patients [32]. In the present study, we also
found that PPARG gene expression responded similarly to
insulin in both groups studied (Fig. 1).
Regarding ‘insulin-resistance genes’, HSD11B1 was
higher at all time points in the insulin-resistant as compared
with the insulin-sensitive group, and increased in response to
insulin in the former but not in the latter group (Fig. 2). Data
regarding insulin regulation of HSD11B1 gene expression
and activity are not unequivocal. In preadipocytes, insulin
attenuates HSD11B1 activity but synergises with glucocor-
ticoids to stimulate adipocyte differentiation that is asso-
ciated with induction of HSD11B1 activity [63]. In vivo,
consistent with the present data at the 3 h time point, 3 h of
hyperinsulinaemia has been reported not to change HSD11
B1 expression in type 2 diabetic or healthy men [28].
HSD11B1 is a gene that is abundantly expressed in
macrophages in addition to adipocytes [14]. Therefore the
increase in HSD11B1 in the insulin-resistant group could
also be due to insulin action in macrophages, although this
possibility remains hypothetical. Like HSD11B1, IL6 was
increased significantly more by insulin in the insulin-
resistant than the insulin-sensitive subjects (Fig. 3). This
most probably occurred in non-adipose cells, since isolated
adipocytes account for only 10% of total IL6 release from
human adipose tissue [4]. IL6 may antagonise insulin action
[1] by several mechanisms. It has been shown to down-
regulate SLC2A4, PPARG and ADIPOQ expression in 3T3-
L1 adipocytes [11, 64, 65], and increase HSD11B1 activity
in primary cultures of adipose stromal cells [66]. The
interstitial IL6 concentration in human adipose tissue is
∼100 times higher than that in plasma [67] and IL6, in
contrast to TNF, is released from adipose tissue systemically
[3]. The high local concentration of IL6 and the existence of
all components important for IL6 signalling in human fat
cells suggest that IL6 originating from non-fat cells in part
induces insulin resistance in a paracrine fashion [11].
TNF expression after 6 h of insulin infusion was higher
in insulin-resistant than in insulin-sensitive subjects. Two
recent studies have found virtually all TNF to be derived
from macrophages [9] or non-fat cells [68] in human
adipose tissue. In a study examining the direct effect of
insulin on macrophage gene expression using an array
technique, insulin stimulated TNF the most among all
genes in the analysis [69]. In an earlier study, lipopolysac-
charide was found to increase TNF production more
robustly from human whole-adipose tissue than from
isolated adipocytes [29]. In the latter study, insulin had no
effect on TNFproduction. In a study that also used the
insulin clamp technique and measured TNF expression in a
group of normal subjects, insulin was found to increase
TNF expression in adipose tissue transiently after 2 h [27].
In another study, 4 h of in vivo hyperinsulinaemia had no
effect on subcutaneous adipose tissue TNF mRNA con-
centration in lean or obese subjects [28]. Our data suggest
that the response of TNF to insulin is exaggerated in
insulin-resistant subjects, although the increase by insulin
failed to reach statistical significance. Whether this is
because an increased number of macrophages (vide infra)
hyperrespond to insulin remains to be determined.
In the study reporting macrophage accumulation in adi-
pose tissue in obesity, immunohistochemical detection and
quantification of CD68-expressing cells in subcutaneous
adipose tissue showed that average adipocyte size and BMI
were strong predictors of CD68-expressing cells [9]. The
increase in the present study of CD68 expression in insulin-
resistant obese subjects therefore most probably reflects an
increase in the number of macrophages in adipose tissue.
ADIPOQ mRNA concentration increased significantly
by 6 h in the insulin-sensitive but not the insulin-resistant
group (Fig. 1). ADIPOQ expression has been studied in
two previous in vivo studies, which found no change after
2.5 h [48] and 3 h [28] of insulin infusion, consistent with
the present data after 3 h. In vitro, in 3T3-L1 adipocytes,
insulin has been reported both to increase [70] and decrease
[71] adiponectin expression. In human adipocytes, insulin
has been reported to increase adiponectin secretion from
omental but not subcutaneous adipocytes [72].
We conclude that acute insulin regulation of gene
expression in insulin-resistant adipose tissue is character-
ised not only by hyporesponsiveness of insulin-sensitivity
genes such as SLC2A4 to insulin but also by hyperrespon-
siveness of insulin-resistance genes (IL6, TNF, HSD11B1).
Although attempts made to date in humans using anti-
inflammatory approaches such as TNF antagonists to
ameliorate insulin resistance have been unsuccessful, the
present study supports continued development of such
therapies.
Acknowledgements We gratefully acknowledgeMs Katja Tuominen
and Mia Urjansson for excellent technical assistance. The study was
supported by grants from the Academy of Finland (J. Westerbacka, H.
Yki-Järvinen), the Sigrid Juselius (H. Yki-Järvinen) and EVO (J.
Westerbacka, H. Yki-Järvinen) foundations, the Karolinska Institute (A.
Hamsten) and the Swedish Heart-Lung Foundation (A. Hamsten).
References
1. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C,
Pratley RE (2001) Circulating interleukin-6 in relation to adipos-
ity, insulin action, and insulin secretion. Obes Res 9:414–417
2. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G
(2001) Adipose tissue tumor necrosis factor and interleukin-6
expression in human obesity and insulin resistance. Am J
Physiol Endocrinol Metab 280:E745–E751
3. Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997)
Subcutaneous adipose tissue releases interleukin-6, but not
tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab
82:4196–4200
138
4. Fried SK, Bunkin DA, Greenberg AS (1998) Omental and
subcutaneous adipose tissues of obese subjects release inter-
leukin-6: depot difference and regulation by glucocorticoid.
J Clin Endocrinol Metab 83:847–850
5. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA,
Schunkert H (2000) Hormone replacement therapy and
interrelation between serum interleukin-6 and body mass
index in postmenopausal women: a population-based study.
J Clin Endocrinol Metab 85:1340–1344
6. Maachi M, Pieroni L, Bruckert E et al. (2004) Systemic low-
grade inflammation is related to both circulating and adipose
tissue TNFalpha, leptin and IL-6 levels in obese women. Int J
Obes Relat Metab Disord 28:993–997
7. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM
(1995) Increased adipose tissue expression of tumor necrosis
factor-alpha in human obesity and insulin resistance. J Clin Invest
95:2409–2415
8. Xu H, Barnes GT, Yang Q et al. (2003) Chronic inflammation
in fat plays a crucial role in the development of obesity-related
insulin resistance. J Clin Invest 112:1821–1830
9. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,
Ferrante AWJ (2003) Obesity is associated with macrophage
accumulation in adipose tissue. J Clin Invest 112:1796–1808
10. Kannisto K, Sutinen J, Korsheninnikova E et al. (2003)
Expression of adipogenic transcription factors, peroxisome
proliferator-activated receptor gamma co-activator 1, IL-6 and
CD45 in subcutaneous adipose tissue in lipodystrophy
associated with highly active antiretroviral therapy. AIDS
17:1753–1762
11. Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6)
induces insulin resistance in 3T3-L1 adipocytes and is, like IL-
8 and tumor necrosis factor-alpha, overexpressed in human fat
cells from insulin-resistant subjects. J Biol Chem 278:45777–
45784
12. Bastard JP, Maachi M, Van Nhieu JT et al. (2002) Adipose
tissue IL-6 content correlates with resistance to insulin
activation of glucose uptake both in vivo and in vitro. J Clin
Endocrinol Metab 87:2084–2089
13. Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman
KE (1998) 11Beta-hydroxysteroid dehydrogenase 1 in adipo-
cytes: expression is differentiation-dependent and hormonally
regulated. J Steroid Biochem Mol Biol 64:251–260
14. Thieringer R, Le Grand CB, Carbin L et al. (2001) 11 Beta-
hydroxysteroid dehydrogenase type 1 is induced in human
monocytes upon differentiation to macrophages. J Immunol
167:30–35
15. Paterson JM, Morton NM, Fievet C et al. (2004) Metabolic
syndrome without obesity: hepatic overexpression of 11beta-
hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc
Natl Acad Sci USA 101:7088–7093
16. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel
adipose-specific gene dysregulated in obesity. J Biol Chem
271:10697–10703
17. Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadipo-
nectinemia in obesity and type 2 diabetes: close association
with insulin resistance and hyperinsulinemia. J Clin Endocrinol
Metab 86:1930–1935
18. Arita Y, Kihara S, Ouchi N et al. (1999) Paradoxical decrease of
an adipose-specific protein, adiponectin, in obesity. Biochem
Biophys Res Commun 257:79–83
19. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y,
Nyman T, Yki-Jarvinen H (2003) Circulating concentration of
adiponectin and its expression in subcutaneous adipose tissue in
patients with highly active antiretroviral therapy-associated
lipodystrophy. J Clin Endocrinol Metab 88:1907–1910
20. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina
JM, Ciaraldi TP (1991) Pretranslational suppression of a
glucose transporter protein causes insulin resistance in
adipocytes from patients with non-insulin-dependent diabetes
mellitus and obesity. J Clin Invest 87:1072–1081
21. He W, Barak Y, Hevener A et al. (2003) Adipose-specific
peroxisome proliferator-activated receptor gamma knockout
causes insulin resistance in fat and liver but not in muscle. Proc
Natl Acad Sci USA 100:15712–15717
22. Hevener AL, He W, Barak Y et al. (2003) Muscle-specific
PPARγ deletion causes insulin resistance. Nat Med 9:1491–
1497
23. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U
(2003) Reduced expression of PGC-1 and insulin-signaling
molecules in adipose tissue is associated with insulin resistance.
Biochem Biophys Res Commun 301:578–582
24. Michael LF, Wu Z, Cheatham RB et al. (2001) Restoration of
insulin-sensitive glucose transporter (GLUT4) gene expression
in muscle cells by the transcriptional coactivator PGC-1. Proc
Natl Acad Sci USA 98:3820–3825
25. Vicennati V, Vottero A, Friedman C, Papanicolaou DA (2002)
Hormonal regulation of interleukin-6 production in human
adipocytes. Int J Obes Relat Metab Disord 26:905–911
26. Fasshauer M, Klein J, Lossner U, Paschke R (2003) Interleukin
(IL)-6 mRNA expression is stimulated by insulin, isoprotere-
nol, tumour necrosis factor alpha, growth hormone, and IL-6 in
3T3-L1 adipocytes. Horm Metab Res 35:147–152
27. Krogh-Madsen R, Plomgaard P, Keller P, Keller C, Pedersen
BK (2004) Insulin stimulates interleukin-6 and tumor necrosis
factor-alpha gene expression in human subcutaneous adipose
tissue. Am J Physiol Endocrinol Metab 286:E234–E238
28. Koistinen HA, Forsgren M, Wallberg-Henriksson H, Zierath JR
(2004) Insulin action on expression of novel adipose genes in
healthy and type 2 diabetic subjects. Obes Res 12:25–31
29. Sewter CP, Digby JE, Blows F, Prins J, O’Rahilly S (1999)
Regulation of tumour necrosis factor-alpha release from human
adipose tissue in vitro. J Endocrinol 163:33–38
30. Schalin-Jäntti C, Yki-Järvinen H, Koranyi L et al. (1994) Effect
of insulin on GLUT-4 mRNA and protein concentrations in
skeletal muscle of patients with NIDDM and their first-degree
relatives. Diabetologia 37:401–407
31. Vidal H, Auboeuf D, De Vos P et al. (1996) The expression of
ob gene is not acutely regulated by insulin and fasting in human
abdominal subcutaneous adipose tissue. J Clin Invest 98:251–
255
32. Rieusset J, Andreelli F, Auboeuf D et al. (1999) Insulin acutely
regulates the expression of the peroxisome proliferator-
activated receptor-gamma in human adipocytes. Diabetes
48:699–705
33. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp
technique: a method for quantifying insulin secretion and
resistance. Am J Physiol 237:E214–E223
34. Yki-Järvinen H, Nikkilä EA, Kubo K, Foley JE (1986) Assay
of glucose transport in human fat cells obtained by needle
biopsy. Diabetologia 29:287–290
35. Sutinen J, Kannisto K, Korsheninnikova E et al. (2004) Effects
of rosiglitazone on gene expression in subcutaneous adipose
tissue in highly active antiretroviral therapy-associated lipo-
dystrophy. Am J Physiol Endocrinol Metab 286:E941–E949
36. Kannisto K, Pietilainen KH, Ehrenborg E et al. (2004)
Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in
adipose tissue is associated with acquired obesity and features
of insulin resistance: studies in young adult monozygotic twins.
J Clin Endocrinol Metab 89:4414–4421
37. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI (1985)
Assessment of fat-free mass using bioelectrical impedance
measurements of the human body. Am J Clin Nutr 41:810–817
38. Marti B, Tuomilehto J, Salomaa V, Kartovaara L, Korhonen HJ,
Pietinen P (1991) Body fat distribution in the Finnish
population: environmental determinants and predictive power
for cardiovascular risk factor levels. J Epidemiol Community
Health 45:131–137
39. Kadish AH, Little RL, Sternberg JC (1968) A new and rapid
method for the determination of glucose by measurement of
rate of oxygen consumption. Clin Chem 14:116–131
139
40. Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH
(1977) Determination of free and total insulin and C-peptide in
insulin-treated diabetics. Diabetes 26:22–29
41. Stenman U-H, Pesonen K, Ylinen K, Huhtala ML, Teramo K
(1984) Rapid chromatographic quantitation of glycosylated
haemoglobins. J Chromatogr 297:327–332
42. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of
the concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge. Clin
Chem 18:499–502
43. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y,
Matsubara K (1996) cDNA cloning and expression of a novel
adipose specific collagen-like factor, apM1 (AdiPose Most
abundant Gene transcript 1). Biochem Biophys Res Commun
221:286–289
44. Coppack SW (2001) Pro-inflammatory cytokines and adipose
tissue. Proc Nutr Soc 60:349–356
45. Vidal H (2001) Gene expression in visceral and subcutaneous
adipose tissues. Ann Med 33:547–555
46. Giacchetti G, Faloia E, Taccaliti A et al. (1994) Decreased
expression of insulin-sensitive glucose transporter mRNA
(GLUT-4) in adipose tissue of non-insulin-dependent diabetic
and obese patients: evaluation by a simplified quantitative PCR
assay. J Endocrinol Invest 17:709–715
47. Carvalho E, Jansson PA, Nagaev I, Wenthzel AM, Smith U
(2001) Insulin resistance with low cellular IRS-1 expression is
also associated with low GLUT4 expression and impaired
insulin-stimulated glucose transport. FASEB J 15:1101–1103
48. Lihn AS, Ostergard T, Nyholm B, Pedersen SB, Richelsen B,
Schmitz O (2003) Adiponectin expression in adipose tissue is
reduced in first-degree relatives of type 2 diabetic patients. Am
J Physiol Endocrinol Metab 284:E443–E448
49. Marshall BA, Mueckler MM (1994) Differential effects of
GLUT-1 or GLUT-4 overexpression on insulin responsiveness
in transgenic mice. Am J Physiol 267:E738–E744
50. Tozzo E, Shepherd PR, Gnudi L, Kahn BB (1995) Transgenic
GLUT-4 overexpression in fat enhances glucose metabolism:
preferential effect on fatty acid synthesis. Am J Physiol 268:
E956–E964
51. Maeda N, Shimomura I, Kishida K et al. (2002) Diet-induced
insulin resistance in mice lacking adiponectin/ACRP30. Nat
Med 8:731–737
52. Koo SH, Satoh H, Herzig S et al. (2004) PGC-1 promotes
insulin resistance in liver through PPAR-alpha-dependent
induction of TRB-3. Nat Med 10:530–534
53. Yang X, Enerback S, Smith U (2003) Reduced expression of
FOXC2 and brown adipogenic genes in human subjects with
insulin resistance. Obes Res 11:1182–1191
54. Sewter C, Blows F, Considine R, Vidal-Puig A, O’Rahilly S
(2002) Differential effects of adiposity on peroxisomal
proliferator-activated receptor gamma1 and gamma2 messenger
ribonucleic acid expression in human adipocytes. J Clin
Endocrinol Metab 87:4203–4207
55. Auboeuf D, Rieusset J, Fajas L et al. (1997) Tissue distribution
and quantification of the expression of mRNAs of peroxisome
proliferator-activated receptors and liver X receptor-alpha in
humans: no alteration in adipose tissue of obese and NIDDM
patients. Diabetes 46:1319–1327
56. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. (1997)
Peroxisome proliferator-activated receptor gene expression in
human tissues. Effects of obesity, weight loss, and regulation by
insulin and glucocorticoids. J Clin Invest 99:2416–2422
57. Giusti V, Verdumo C, Suter M, Gaillard RC, Burckhardt P,
Pralong F (2003) Expression of peroxisome proliferator-
activated receptor-gamma1 and peroxisome proliferator-acti-
vated receptor-gamma2 in visceral and subcutaneous adipose
tissue of obese women. Diabetes 52:1673–1676
58. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH
(1999) Cortisol metabolism in human obesity: impaired
cortisone→cortisol conversion in subjects with central adipos-
ity. J Clin Endocrinol Metab 84:1022–1027
59. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M
(2002) Expression of the mRNA coding for 11beta-hydroxy-
steroid dehydrogenase type 1 in adipose tissue from obese
patients: an in situ hybridization study. J Clin Endocrinol Metab
87:2701–2705
60. Andersen PH, Lund S, Vestergaard H, Junker S, Kahn BB,
Pedersen O (1993) Expression of the major insulin regulatable
glucose transporter (GLUT4) in skeletal muscle of noninsulin-
dependent diabetic patients and healthy subjects before and
after insulin infusion. J Clin Endocrinol Metab 77:27–32
61. Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC-1 alpha):
transcriptional coactivator and metabolic regulator. Endocr Rev
24:78–90
62. Lin J, Wu H, Tarr PT et al. (2002) Transcriptional co-activator
PGC-1 alpha drives the formation of slow-twitch muscle fibres.
Nature 418:797–801
63. Stulnig TM, Waldhausl W (2004) 11beta-Hydroxysteroid
dehydrogenase type 1 in obesity and type 2 diabetes.
Diabetologia 47:1–11
64. Bruun JM, Lihn AS, Verdich C et al. (2003) Regulation of
adiponectin by adipose tissue-derived cytokines: in vivo and in
vitro investigations in humans. Am J Physiol Endocrinol Metab
285:E527–E533
65. Fasshauer M, Kralisch S, Klier M et al. (2003) Adiponectin
gene expression and secretion is inhibited by interleukin-6 in
3T3-L1 adipocytes. Biochem Biophys Res Commun 301:
1045–1050
66. Tomlinson JW, Moore J, Cooper MS et al. (2001) Regulation of
expression of 11beta-hydroxysteroid dehydrogenase type 1 in
adipose tissue: tissue-specific induction by cytokines. Endocri-
nology 142:1982–1989
67. Sopasakis VR, Sandqvist M, Gustafson B et al. (2004) High
local concentrations and effects on differentiation implicate
interleukin-6 as a paracrine regulator. Obes Res 12:454–460
68. Fain JN, Bahouth SW, Madan AK (2004) TNFalpha release by
the nonfat cells of human adipose tissue. Int J Obes Relat
Metab Disord 28:616–622
69. Iida KT, Shimano H, Kawakami Y et al. (2001) Insulin up-
regulates tumor necrosis factor-alpha production in macro-
phages through an extracellular-regulated kinase-dependent
pathway. J Biol Chem 276:32531–32537
70. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF
(1995) A novel serum protein similar to C1q, produced
exclusively in adipocytes. J Biol Chem 270:26746–26749
71. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R
(2002) Hormonal regulation of adiponectin gene expression in
3T3-L1 adipocytes. Biochem Biophys Res Commun
290:1084–1089
72. Motoshima H, Wu X, Sinha MK et al. (2002) Differential
regulation of adiponectin secretion from cultured human
omental and subcutaneous adipocytes: effects of insulin and
rosiglitazone. J Clin Endocrinol Metab 87:5662–5667
140
II
Insulin regulation of MCP-1 in human adipose tissue of obese
and lean women
Jukka Westerbacka,1,2 Anja Cornér,1 Maria Kolak,3 Janne Makkonen,1,2 Ursula Turpeinen,4
Anders Hamsten,3 Rachel M. Fisher,3 and Hannele Yki-Järvinen1,2
1University of Helsinki, Department of Medicine, Division of Diabetes, and 2Minerva Medical Research Institute, Helsinki,
Finland; 3Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Institutet, Stockholm, Sweden;
4HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
Submitted 30 November 2006; accepted in final form 27 December 2007
Westerbacka J, Cornér A, Kolak M, Makkonen J, Turpeinen U,
Hamsten A, Fisher RM, Yki-Järvinen H. Insulin regulation of
MCP-1 in human adipose tissue of obese and lean women. Am J
Physiol Endocrinol Metab 294: E841–E845, 2008. First published 12
February 2008; doi:10.1152/ajpendo.00653.2006.—CCL2 (MCP-1,
monocyte chemoattractant protein 1) and CCL3 (MIP-1!, macro-
phage inflammatory protein 1!) are required for macrophage infiltra-
tion in adipose tissue. Insulin increases CCL2 expression in adipose
tissue and in serum more in insulin-resistant obese than in insulin-
sensitive lean mice, but whether this is true in humans is unknown.
We compared basal expression and insulin regulation of CCL2 and
CCL3 in adipose tissue and MCP-1 and MIP-1! in serum between
insulin-resistant and insulin-sensitive human subjects. Subcutaneous
adipose tissue biopsies and blood samples were obtained before and at
the end of 6 h of in vivo euglycemic hyperinsulinemia (maintained by
the insulin clamp technique) in 11 lean insulin-sensitive and 10 obese
insulin-resistant women, and before and after a 6-h saline infusion in
8 women. Adipose tissue mRNA concentrations of monocyte/macro-
phage markers CD68, EMR1, ITGAM, ADAM8, chemokines CCL2
and CCL3, and housekeeping gene ribosomal protein large P0
(RPLP0) were measured by means of real-time PCR at baseline. In
addition, mRNA concentrations of CCL2, CCL3, and RPLP0 were
measured after insulin infusion. Levels of MCP-1 and MIP-1! were
determined in serum, and protein concentration of MCP-1 was deter-
mined in adipose tissue at baseline and after insulin infusion. Basally,
expression of the macrophage markers CD68 and EMR1 were in-
creased in adipose tissue of insulin-resistant subjects. Insulin in-
creased MCP-1 gene and protein expression significantly more in the
insulin-resistant than in the insulin-sensitive subjects. Basally expres-
sion of CCL2 and CCL3 and expression of macrophage markers
CD68 and ITGAM were significantly correlated. In serum, MCP-1
decreased significantly in insulin-sensitive but not insulin-resistant
subjects. MIP-1! was undetectable in serum. Insulin regulation of
CCL2 differs between insulin-sensitive and -resistant subjects in a
direction that could exacerbate adipose tissue inflammation.
adipocytes; adipokines; insulin sensitivity; monocyte chemoattractant
protein
MCP-1 PLAYS A KEY ROLE in recruitment of monocytes but not
neutrophils or eosinophils to sites of injury (6, 26). It also
induces insulin resistance in adipocytes via downregulation of
genes such as SLC2A4 (the gene encoding GLUT-4), lipopro-
tein lipase, and peroxisome proliferator-activated receptor-"
(16). Recently, it was demonstrated that deletion of the CCR2
receptor for monocyte chemoattractant protein (MCP)-1 in
obese mice strains matched for adiposity reduced macrophage
content and the inflammatory profile of adipose tissue, in-
creased adiponectin expression, ameliorated hepatic steatosis,
and improved systemic glucose homeostasis and insulin sen-
sitivity (21). In mice with established obesity, short-term treat-
ment with a pharmacological antagonist of MCP-1 lowered
macrophage content of adipose tissue and improved insulin
sensitivity without significantly altering body mass or improv-
ing hepatic steatosis (21).
In murine adipocytes in vitro and ob/ob mice in vivo, insulin
increases expression and secretion of MCP-1 (16). In the latter
in vivo experiment, the response to insulin was exaggerated in
obese insulin-resistant compared with lean mice (16). Thus, as
previously described for plasminogen activator inhibitor
(PAI)-1 (15) and sterol regulatory element binding protein
(SREBP)-1c (17) in mice, MCP-1 may retain its sensitivity to
insulin or even hyperrespond to insulin in insulin-resistant
states. Hyperinsulinemia might under such conditions acceler-
ate monocyte recruitment and worsen insulin resistance (16).
These data may or may not be relevant to humans, since insulin
has been reported to decrease serum MCP-1 levels in humans
(5), and since catheterization studies of human subcutaneous
tissues have suggested that MCP-1 is not released systemati-
cally (4). There are no studies comparing the response of CCL2
expression or of its levels in serum to insulin between insulin-
sensitive and insulin-resistant human subjects.
In the present study, we examined how acute in vivo hyper-
insulinemia in human insulin-resistant compared with insulin-
sensitive subjects regulates expression of the chemokines
CCL2 and CCL3 and MCP-1 protein concentration in adipose
tissue. We also determined whether expression of multiple mac-
rophage markers basally is correlated with chemokine expression.
The latter genes included CD68 and EMR1 (epidermal growth
factor module-containing mucin-like hormone receptor 1), and
ADAM8 (a disintegrin and metallopeptidase domain 8), which are
macrophage-specific markers, and ITGAM (integrin, alpha M),
which is an integrin found in monocytes, macrophages, neutro-
phils, and NK cells.
MATERIALS AND METHODS
Subjects and study designs. A total of 21 nondiabetic Caucasian
women were recruited based on the following inclusion criteria:
1) age 18–60 years; 2) no known acute or chronic disease other than
obesity based on history and physical examination and standard
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laboratory tests (blood counts, serum creatinine, thyroid stimulating
hormone, electrolyte concentrations, and electrocardiogram); and
3) body mass index (BMI) ! 40 kg/m2. Other exclusion criteria
included treatment with drugs that may alter glucose tolerance or
pregnancy. In each subject, whole-body insulin sensitivity was mea-
sured according to the euglycemic insulin clamp technique (insulin
infusion rate 1 mU !kg"1 !min"1 for 6 h), and needle biopsies of
adipose tissue were taken before and after 6 h of hyperinsulinemia.
The women were divided into lean insulin-sensitive (n # 11, age 32 $
3 yrs, body wt 69 $ 4 kg, BMI 24.7 $ 1.1 kg/m2) and obese
insulin-resistant (n # 10, age 40 $ 3 yrs, body wt 90 $ 4 kg, BMI
32.7 $ 1.8 kg/m2) based on their median rate of whole-body insulin
sensitivity measured by the euglycemic insulin clamp technique (23).
There were two postmenopausal women in both groups. In 8 women
(age 36 $ 4 yrs, BMI 28.2 $ 2.9 kg/m2), CCL2 and CCL3 expres-
sions were measured in adipose tissue before and at the end of a 6-h
saline infusion.
The nature and potential risks of the study were explained to all
subjects prior to obtaining their written informed consent. The study
was carried out in accordance with the principles of the Declaration of
Helsinki. The protocol was approved by the ethics committee of the
Helsinki University Central Hospital.
Adipose tissue biopsy and total RNA cDNA preparation. Needle
aspiration biopsies of abdominal subcutaneous fat were taken under
local intracutaneous anesthesia at baseline and after 6 h of hyperin-
sulinemia from the left and right lower abdominal region (25). The
samples were immediately frozen and stored in liquid nitrogen until
analysis. Frozen tissue samples (50–150 mg) were homogenized in 2
ml RNA STAT-60 (Tel-Test, Friendswood, TX), and total RNA was
isolated as previously described (19). RNA was stored at "80°C until
quantification of target mRNAs. A total of 0.1 %g RNA was tran-
scribed into cDNA via Moloney murine leukemia virus reverse
transcriptase (Life Technologies, Paisley, UK) and oligo (dT)12–18
primers (19). Part of the fresh sample was used to isolate adipocytes
through incubation with collagenase to measure adipocyte size with
microscope (7).
Gene expression analyses. mRNA expression of CD68, EMR1,
ITGAM, ADAM8, CCL2, CCL3, and ribosomal protein large P0
(RPLP0) was quantified by real-time PCR by means of the ABI 7000
Sequence Detection System instrument and software (Applied Bio-
systems). cDNA synthesized from 15 ng of total RNA was mixed
with TaqMan Universal PCR Master Mix (Applied Biosystems)
and a gene-specific primer and probe mixture (predeveloped
TaqMan Gene Expression Assays, Applied Biosystems) in a final
volume of 15 %l. The assays used were: CD68, Hs00154355_m1;
EMR1, Hs00173562_m1; ITGAM, Hs00355885_m1; ADAM8,
Hs00174246_m1; CCL2, Hs00234140_m1; CCL3, Hs00234142_m1;
and RPLP0, Hs99999902_m1. All samples were run in duplicate.
Relative expression levels were determined by means of a 5-point
serially diluted standard curve, generated from cDNA from human
adipose tissue. Expression levels were expressed in arbitrary units and
normalized relative to the housekeeping gene RPLP0 to compensate
for differences in cDNA loading.
Measurement of MCP-1 protein expression in adipose tissue. A
frozen sample (5 from the insulin-sensitive and 7 from the insulin-
resistant group) of human subcutaneous adipose tissue (100–250 mg)
was homogenized in lysis buffer. The homogenate was centrifuged for
30 min (&4°C, 14,000 rpm), and the supernatant was stored at "80°C
until measurement of the MCP-1 concentration with the Human
CCL2/MCP-1 Immunoassay kit (Quantikine; R&D Systems, Minne-
apolis, MN) and the Bio Assay Reader HTS 7000 Plus (Perkin Elmer,
Norwalk, CT). Total protein was measured with the BC Assay-protein
quantitation kit (Uptima Interchim, Montlucan, France).
Other measurements. Blood samples were taken after an overnight
fast for measurement of plasma glucose, serum insulin, C-peptide,
serum triglycerides, and total and HDL cholesterol concentrations, as
described (23). Serum MCP-1 and macrophage inflammatory protein
(MIP)-1' concentrations were measured with ELISA kits (Quan-
tikine, R&D Systems, Minneapolis, MN, USA).
Statistical analyses. All parameters were analyzed via nonparametric
methods. Insulin-sensitive and insulin-resistant groups were compared
via the Mann-Whitney test. Effects of insulin were analyzed via
Friedman’s test followed by Dunn’s post hoc test to compare single
measurements. Correlations were calculated via Spearman’s rank
correlation coefficient. A P value of less than 0.05 was considered
statistically significant. The calculations were performed with SPSS
11.0 for Windows (SPSS, Chicago, IL). All data are shown as mean $
standard error of mean.
Fig. 1. Gene expressions of monocyte/macrophage markers
CD68, ITGAM, EMR1 and ADAM8 relative to housekeep-
ing gene (RPLP0) expression in adipose tissue in insulin-
sensitive (IS, open bars) and insulin-resistant (IR, filled
bars) subjects at baseline. *P ! 0.05 for IS vs. IR.
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RESULTS
The insulin-resistant group was more obese than the insulin-
sensitive group (BMI 32.7 ! 1.8 vs. 24.7 ! 1.1, P " 0.001),
and had higher insulin concentrations (10 ! 1 vs. 3 ! 1 mU/l,
P " 0.001). During the insulin infusion, serum insulin con-
centrations were similar in insulin-sensitive and insulin-resis-
tant groups (69 ! 4 vs. 76 ! 4 mU/l, insulin-sensitive vs.
insulin-resistant, NS). Whole-body insulin sensitivity was 95%
higher in the insulin-sensitive than in the insulin-resistant
group (8.7 ! 0.4 vs. 4.2 ! 0.3 mg !kg#1 !min#1, P "
0.0001). Other characteristics have been described in (23).
Gene expressions of CD68, EMR1, ITGAM, ADAM8, CCL2
(MCP-1), and CCL3 (MIP-1!), and MCP-1 protein concen-
tration in adipose tissue. Before start of the insulin infusion,
the mRNA concentrations of ITGAM, ADAM8, CCL2, and
CCL3 were comparable between the insulin-sensitive and in-
sulin-resistant groups, but the mRNA concentrations of CD68
and EMR1 were significantly higher in the insulin-resistant
than in the insulin-sensitive group (Fig. 1). At baseline, CCL2
and CCL3 expressions correlated closely with those of CD68
(r $ 0.71, P " 0.001 and r $ 0.81, P " 0.001 for CCL2 and
CCL3, respectively) and ITGAM (r $ 0.64, P " 0.01 and r $
0.78, P " 0.001, respectively), and CCL3 correlated with
EMR1 (r $ 0.55, P " 0.01). CCL2 expression increased
significantly more by insulin in the insulin-resistant than in the
insulin-sensitive group (Fig. 2). The % increase in CCL2 gene
expression was 60 ! 22% in insulin-sensitive and 169 ! 59%
in insulin-resistant subjects (P $ 0.08). Similarly, the protein
concentration of MCP-1 in adipose tissue increased signifi-
cantly by insulin in the insulin-resistant group but remained
unchanged in the insulin-sensitive group (Fig. 3). CCL2 ex-
pression and MCP-1 protein concentration in adipose tissue
were significantly correlated (r $ 0.53, P $ 0.008). In the 8
subjects who received a 6-h saline infusion, expressions of
CCL2 and CCL3 remained unchanged (data not shown). Adi-
pocyte size correlated significantly with the mRNA concentra-
tion of CD68 (r $ 0.63, P $ 0.024).
Whole-body insulin sensitivity was inversely correlated with
basal expression of macrophage markers as follows: CD68
(Spearman’s r $ #0.58, P " 0.01), EMR1 (r $ #0.62, P "
0.01), ITGAM (r $ #0.50, P " 0.05), ADAM8 (r $ #0.42,
P $ 0.058, NS). After adjustment for BMI and age, these
correlations were as follows: CD68 (r $ #0.44, P " 0.05),
EMR1 (r $ #0.28, NS), ITGAM (r $ #0.67, P " 0.001),
ADAM8 (r $ #0.21, NS). Whole-body insulin sensitivity
correlated with CCL2 (r $ #0.60, P " 0.01) and CCL3 (r $
#0.73, P " 0.001) expression in adipose tissue at 6 h.
Serum MCP-1 and MIP-1! concentration. At baseline, se-
rum MCP-1 concentrations were comparable in the insulin-
sensitive and insulin-resistant groups (291 ! 19 vs. 343 ! 34
pg/ml, insulin-sensitive vs. insulin-resistant, NS). Insulin de-
creased serum MCP-1 concentration significantly in the insulin-
sensitive group but not in the insulin-resistant group (Fig. 3).
Fig. 2. The gene expressions of chemokines CCL2 (MCP-1, monocyte che-
moattractant protein 1) and CCL3 (MIP-1%, macrophage inflammatory protein
1%) relative to housekeeping gene ribosomal protein large P0 (RPLP0) expres-
sion in adipose tissue in IS (open bars) and IR (filled bars) subjects at 0 and 6 h
during euglycemic hyperinsulinemia (rate of continuous insulin infusion 1
mU !kg#1 !min#1). *P " 0.05, **P " 0.01 for change between time points.
##P " 0.01, ###P " 0.001 for IS vs. IR.
Fig. 3. Serum concentration of MCP-1 (top) and MCP-1 protein concentration
in adipose tissue in IS (open bars) and IR (filled bars) subjects at 0 and 6 h
during euglycemic hyperinsulinemia (rate of continuous insulin infusion 1
mU !kg#1 !min#1). **P " 0.01 for change between time points, ##P " 0.01
for IS vs. IR.
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At 6 h, serum MCP-1 concentration was significantly lower in
the insulin-sensitive than in the insulin-resistant group (216 !
14 vs. 313 ! 26 pg/ml, P " 0.01 insulin-sensitive vs. insulin-
resistant). Serum MIP-1# was under the detection limit of the
assay (46.9 pg/ml) in all subjects.
DISCUSSION
The present data are the first to compare responses of the
chemokines MCP-1 and MIP-1# to insulin in vivo in adipose
tissue between insulin-resistant obese and insulin-sensitive
lean women. In vivo euglycemic hyperinsulinemia increased
gene and protein expression of MCP-1 (CCL2) more in adipose
tissue and decreased MCP-1 less in serum in insulin-resistant
than in insulin-sensitive subjects. We also found that whole-
body insulin resistance was closely correlated with increased
expression of the monocyte/macrophage markers. An increase
in basal MCP-1 gene and protein expression has previously
been documented in human adipocyte cultures from obese
compared with lean subjects (1, 4), and in adipose tissue of
ob/ob mice (16). Regarding expression of CCL2 in adipose
tissue, we have previously shown that CCL2 correlates signif-
icantly with the concentration of MCP-1 protein in adipose
tissue (9).
Classically, insulin resistance has been defined as a defective
response of an insulin-sensitive gene, protein, or pathway to
insulin. In recent years, data from animal studies have sug-
gested that this concept needs to be expanded. Insulin not only
regulates molecules and pathways that normally enhance insu-
lin sensitivity, but also molecules that normally confer insulin
resistance. Examples of such molecules include TNF-# (8, 23),
11$-HSD-1 (10, 20), and PAI-1 (15) and SREBP-1c (17),
which continue to respond to insulin in insulin-resistant states.
In the present study, we found CCL2 gene expression in
adipose tissue to hyperrespond to insulin in the insulin-resistant
subjects (Fig. 2). This finding resembles the transient hyperre-
sponse to insulin (peaking at 1 h in db/db and at 3 h in
wild-type mice) described in 3T3-L1 adipocytes made insulin
resistant by TNF-# treatment in vitro (16). The insulin-resis-
tant 3T3-L1 adipocytes also overproduced MCP-1 protein.
In vivo, insulin increased MCP-1 mRNA concentrations in
adipose tissue of ob/ob mice more than in wild-type mice.
There was also a transient increase after 1 h of insulin injection
in MCP-1 protein in plasma in the ob/ob mice, which was
lacking from the wild-type insulin sensitive mice, in which
serum MCP-1 levels remained unchanged for 6 h (16). The
present data showing an exaggerated increase in CCL2 gene
and protein expression in adipose tissue in insulin-resistant
obese compared with insulin-sensitive lean subjects are con-
sistent with data in mice. However, in serum, MCP-1 de-
creased significantly in the control group, consistent with
another study also showing a decrease in serum MCP-1 by
insulin but not by saline in vivo (5). We did not detect any
change in serum MCP-1 in the insulin-resistant group when the
level was measured at 0 and 6 h. The data suggest that adipose
tissue is not the main determinant of circulating MCP-1 levels
in humans. Consistent with this, a catheterization study in
humans found no release of MCP-1 from subcutaneous adipose
tissue to the circulation (4). Serum MIP-1# levels were unde-
tectable in all subjects. In a study using the same assay, only
15% of the type 2 diabetic patients had detectable concentra-
tion of MIP-1# in serum (12).
We also confirm increased basal expression of the macro-
phage markers CD68 in human adipose tissue in insulin-
resistant subjects (1, 22) and report an increase in EMR1.
CD68 (3), ADAM-8 (24), and EMR1 (11) are macrophage-
specific markers, and ITGAM is a member of an integrin
family mediating leukocyte adhesion and migration processes
(18). This increase in macrophage gene expression is likely to
reflect an increase in macrophage number based on previous
data (22), including our own (9). Obesity per se may be a
confounding factor when interpreting the data regarding asso-
ciations to insulin sensitivity. However, in the present study
there were also two overweight (BMI 27–30 kg/m2) subjects
and one obese subject in the insulin-sensitive group. None of
the insulin-resistant subjects had a BMI " 27 kg/m2.
The present study did not address the molecular mechanisms
explaining how a gene can hyperrespond to insulin despite
whole-body insulin resistance, which reflect mostly insulin
resistance at the level of skeletal muscle (13). It is of interest in
this respect that insulin inhibition of hormone-sensitive lipase
in macrophages, unlike in adipocytes, does not involve activa-
tion of the PI 3-kinase pathway (14). In ob/ob mice, macro-
phages are characterized by reduced insulin receptor expres-
sion and signaling, which leads to upregulation of, e.g., the
proatherogenic CD36, a scavenger receptor-accumulating
lipid. It has recently been demonstrated that macrophages
are localized to dead adipocytes (2) and that the rate of
adipocyte death is dramatically increased in obesity. Con-
sistent with these data, macrophage marker CD68 expres-
sion was significantly correlated with adipocyte size in the
present study. Free lipid droplets of dead adipocytes are
engulfed by macrophages, which become multinucleated
giant cells (2). Against this background, the ability of
hyperinsulinemia to promote inflammation in adipose tissue
might be viewed as a protective mechanism which help to
facilitate removal of dead adipocytes.
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ORIGINAL ARTICLE
Increased expression of the macrophage markers and
of 11b-HSD-1 in subcutaneous adipose tissue, but
not in cultured monocyte-derived macrophages,
is associated with liver fat in human obesity
J Makkonen1, J Westerbacka1, M Kolak2, J Sutinen1, A Cornér1, A Hamsten2, RM Fisher2 and
H Yki-Järvinen1,2
1Division of Diabetes, Department of Medicine, University of Helsinki and Minerva Medical Research Institute, Helsinki,
Finland and 2Atherosclerosis Research Unit, King Gustaf V Research Institute, Department of Medicine Solna, Karolinska
Institutet, Stockholm, Sweden
Objective: To determine whether increased expression of macrophage markers and of inflammatory markers in subcutaneous
adipose tissue is associated with liver fat in human obesity. We also determined whether expression of TNF (gene encoding TNF-a),
HSD11B1 (gene encoding 11b-HSD-1) and RETN (gene encoding resistin) in cultured monocyte-derived macrophages differs
between obese/overweight and non-obese subjects.
Design: Cross-sectional comparison of obese/overweight and non-obese subjects with respect to adipose tissue gene
expression, gene expression in monocyte-derived macrophages, liver fat content and in vivo insulin sensitivity.
Subjects: Adipose tissue gene expression, gene expression in monocyte-derived macrophages, liver fat content and in vivo
insulin sensitivity: 10 healthy non-obese (24.271.0 kg/m2) and 10 healthy obese/overweight (33.171.7 kg/m2) women. Gene
expression in monocyte-derived macrophages: seven healthy non-obese (22.170.7 kg/m2) and seven healthy obese/
overweight (36.972.2 kg/m2) women.
Measurements: Adipose tissue biopsies and blood samples for isolation of peripheral mononuclear cells were taken after an
overnight fast. Liver fat content was measured using magnetic resonance proton spectroscopy. Whole body insulin sensitivity
was measured using the hyperinsulinemic euglycemic clamp technique. Expression levels of TNF, HSD11B1, RETN and the
macrophage markers CD68 and ITGAM were determined by real-time PCR.
Results: In adipose tissue, expression of HSD11B1, ITGAM and CD68 was significantly increased in the obese/overweight as
compared to the non-obese group. Expression of all these genes was closely positively correlated with liver fat content and inversely
correlated with whole body insulin sensitivity. The associations between expression of CD68, ITGAM and HSD11B1 and liver fat
were independent of obesity. There were no differences in TNF, HSD11B1, RETN or CD68 gene expression basally
or after stimulation with lipopolysaccharide in monocyte-derived macrophages between obese/overweight and non-obese subjects.
Conclusion: Accumulation of fat in the liver is associated with increased adipose tissue inflammation independent of obesity.
International Journal of Obesity (2007) 31, 1617–1625; doi:10.1038/sj.ijo.0803635; published online 24 April 2007
Keywords: adipokines; cytokines; inflammation; insulin resistance; ITGAM; liver fat
Introduction
Several studies in genetically engineered animal models have
documented that lack of subcutaneous and visceral fat is
associated with severe insulin resistance and fat accumula-
tion in insulin-sensitive tissues.1 For example, A-ZIP/F-1
mice, which have no white adipose tissue subcutaneously
or elsewhere, have dramatically reduced brown fat,
severe hepatosteatosis, diabetes, and elevated glucose,
insulin, triglyceride and free fatty acid concentrations.
Transplantation of wild-type adipose tissue into these
mice reverses hyperglycemia, decreases insulin concentra-
tions, corrects insulin signaling defects and normalizes
fat content in the liver and muscle.2 This implies that
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fat accumulation in insulin-sensitive tissues indeed can
cause insulin resistance, although the stored triglyceride
itself is likely to be inert. These data in mice appear relevant
for humans since highly active antiretroviral therapy-
associated lipodystrophy as well as more rare forms of
human lipoatrophies have uniformly been associated with
a fatty liver.3
Although fat accumulation in the liver seems important
for the development of insulin resistance, other studies
suggest that myeloid cells are a prerequisite for development
of insulin resistance in insulin-sensitive tissues. Mice lacking
IkB kinaseb, a central coordinator of inflammatory responses
through activation of NF-kB in myeloid cells (macrophages
and neutrophils), are protected from insulin resistance in
skeletal muscle and the liver.4 In humans, the number of
macrophages and expression of macrophage markers such
as CD68 are increased in obese and lipoatrophic insulin-
resistant subjects.5–7 Macrophages are the major source of
both IL-6 and tumor necrosis factor a (TNF-a) in adipose
tissue.6,8–11 These cytokines can induce insulin resistance
locally in adipose cells via downregulation of adipokines
such as adiponectin12,13 which is abundantly secreted
systematically and has insulin-sensitising properties espe-
cially in the liver.14,15 Expression of the enzyme converting
cortisone to cortisol, 11b-HSD-1, is also increased in insulin-
resistant obese subjects.16,17 This enzyme is expressed in
both adipocytes and macrophages.18,19 Its overexpression in
mice results in insulin resistance and visceral obesity.20
Human fat cells, unlike those of mice, do not produce
resistin21 but resistin has been suggested to be produced by
human peripheral blood mononuclear cells.22 Unlike in
mice, resistin may not, however, be related to insulin
sensitivity in humans.23,24
Until now, only one study has explored the possibility that
adipose tissue inflammation is related to hepatic lesions
in obesity in humans.25 This study included a group of
morbidly obese nondiabetic and diabetic subjects. The
number of macrophages in omental but not subcutaneous
fat was found to be correlated with histological liver
pathology other than hepatic steatosis. Insulin sensitivity
was not directly quantitated. There are no studies examining
the relationship between adipose tissue inflammation and
liver fat content in non-obese and nonmorbidly obese
subjects.
In the present study, we determined whether expression
of the macrophage markers and of TNF and HSD11B1
in subcutaneous adipose tissue is related to liver fat
content measured by proton spectroscopy and to whole
body insulin sensitivity measured by the euglycemic
insulin clamp technique. We also determined whether
such relationships are independent of obesity. Since it
has been suggested that susceptibility genes for insulin
action may even reside in myeloid cells,4 we also
compared expression of TNF, HSD11B1 and gene encoding
resistin (RETN) in cultured blood monocyte-derived
macrophages.
Methods
Subjects and study designs
Subjects. To determine the relationship between adipose
tissue inflammation, liver fat content and insulin sensitivity,
20 nondiabetic apparently healthy Caucasian women were
recruited based on the following inclusion criteria: (1) age
18–60 years, (2) no known acute or chronic disease other
than obesity based on history, physical examination and
standard laboratory tests (blood counts, serum creatinine,
thyroid-stimulating hormone, electrolyte concentrations
and electrocardiogram). Other exclusion criteria included
pregnancy or treatment with drugs that may alter glucose
tolerance. In each subject, a needle biopsy of adipose tissue
was taken for measurement of gene expression and liver fat
content was measured with proton spectroscopy and whole
body insulin sensitivity using the euglycemic insulin clamp
technique (insulin infusion rate 1 mU/kg/min for 2 h). In
addition, a separate blood sample was taken for isolation of
peripheral blood monocytes. The subjects were divided based
on their median body mass index (BMI) into obese/over-
weight (BMI428 kg/m2, n¼10) and non-obese (BMIo28
kg/m2, n¼10) groups. Gene expression of TNF, HSD11B1,
CD68 and ITGAM was measured in adipose tissue and in un-
stimulated monocyte-derived macrophages. These subjects
also participated in a study26 examining effects of a 6 h
insulin infusion on adipose tissue gene expression measured
at 0, 3 and 6 h. Data on liver fat and monocyte-derived
macrophages are novel. In addition to these measurements,
gene expression of TNF, HSD11B1 and RETN was measured
basally and after 3 and 6 h of lipopolysaccharide (LPS)
stimulation in 14 women, which were recruited using the
same inclusion and exclusion as mentioned above and
divided into obese/overweight (BMI428 kg/m2, n¼7) and
non-obese (BMIo28 kg/m2, n¼7) groups. An age-matched
pair (one obese/overweight and one non-obese subject) was
studied on the same day. A blood sample was taken for
differentiation of peripheral blood monocytes into macro-
phages (see below). Macrophages were stimulated with either
LPS or saline.
The nature and potential risks of the study were explained
to all subjects before obtaining their written informed
consent. The ethics committees of the Helsinki University
Central Hospital and Karolinska Institutet approved the
protocol.
Adipose tissue biopsy and total RNA and cDNA preparation
A needle aspiration biopsy of abdominal subcutaneous fat
was taken before insulin infusion under local anesthesia.27
The fat sample was immediately frozen and stored in liquid
nitrogen until analysis. Frozen fat tissue samples (50–
150 mg) were homogenized in 2 ml RNA STAT-60 (Tel-Test,
Friendswood, TX, USA) and total RNA isolated according to
the manufacturer’s instructions. After DNase treatment
(RNase-free DNase set, Qiagen, Hilden, Germany), RNA
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was purified using the RNeasy minikit (Qiagen, Hilden,
Germany). RNA concentrations were measured using the
RiboGreen fluorescent nucleic acid stain (RNA quantification
kit, Molecular Probes, Eugene, OR, USA) and Light Cycler
(Roche Diagnostics GmbH, Mannheim, Germany). The
quality of RNA was checked by agarose gel electrophoresis.
Isolated RNA was stored at 801C until qualification of the
target mRNAs. A total of 0.1 mg RNA was reverse transcribed
into cDNA using Moloney murine leukemia virus reverse
transcriptase (Life Technologies, Paisley, UK) and oligo
(dT)12–18 primers.
Quantification of mRNA concentrations
mRNA expression levels of TNF, HSD11B1, CD68, RETN and
ribosomal protein large P0 (RPLP0) were quantified by real-
time PCR using the ABI 7000 Sequence Detection System
instrument and software (Applied Biosystems, Foster City,
CA, USA). cDNA synthesized from 15 ng of total RNA was
mixed with TaqMan Universal PCR Master Mix (Applied
Biosystems) and a gene-specific primer and probe mixture
(predeveloped TaqMan Gene Expression Assays, Applied
Biosystems). The assays used were TNF, Hs00174128_m1;
HSD11B1, Hs00194153_m1; CD68, Hs00154355_m1; IT-
GAM, Hs00355885_m1; RETN, Hs00220767_m1 and RPLP0,
Hs99999902_m1. All samples were run in duplicate. Relative
expression levels were determined using a five-point serially
diluted standard curve, generated from cDNA from either
human adipose tissue or monocyte-derived macrophages
(depending on the samples being analyzed). Expression
levels were expressed in arbitrary units and normalized
relative to the housekeeping gene RPLP0 to compensate
for differences in cDNA loading. The levels of RPLP0 were
comparable between non-obese and obese subjects in both
studies.
Liver fat content
Liver fat content was measured using magnetic resonance
proton spectroscopy as previously described.28
Whole body insulin sensitivity
Whole body insulin sensitivity was measured using the
insulin clamp technique.29 The study started at 0730 after
an overnight fast. Two 18-gauge catheters (Venflon; Viggo-
Spectramed, Helsingborg, Sweden) were inserted, one in an
antecubital vein for infusion of insulin and glucose, and
another retrogradely in a heated hand vein to obtain
arterialized venous blood for measurement of glucose
concentrations every 5 min and serum-free insulin concen-
tration every 30 min. Regular human insulin (Insulin
Actrapid, Novo Nordisk, Denmark) was infused in a
primed-continuous fashion. The rate of the continuous
insulin infusion was 1 mU/kg/min for 2 h. Normoglycemia
was maintained by adjusting the rate of a 20% glucose
infusion based on plasma glucose measurements from
arterialized venous blood every 5 min. Whole body insulin
sensitivity was determined from the glucose infusion rate,
corrected for changes in glucose pool size (M-value), required
to maintain normoglycemia between 30 and 120 min.29 The
M-value was expressed as mg/kg fat free mass per per minute.
Isolation and culture of macrophages
Preparation of macrophage monolayers. For the in vitro studies
assessing basal and LPS-stimulated gene expression, blood
was drawn after an overnight fast. Human monocytes were
isolated from buffy coats by centrifugation in Ficoll-Paque
(Amersham Bioscience AB, Uppsala, Sweden) gradient as
described.30 Washed cells were suspended in Macrophage-
SFM Medium (Gibco, Invitrogen Corporation, Grand Island,
NY, USA) containing streptomycin and penicillin (Sigma, St
Louis, MO, USA). The monocytes were counted, and seeded
on plates. After 1 h, nonadherent cells were removed and
granulocyte monocyte colony stimulating factor (GM-CSF)
(5 ng/ml, Sigma) was added. Monocytes were then cultured
for up to 7 days for differentiation into macrophages.
Stimulation of macrophages
In study II, 10 ml of LPS (10 mg/ml, LPS of Salmonella
typhimurium, Sigma) or saline per 1 ml of SFM Medium/
GM-CSF was added to stimulate cultured macrophages for 3
and 6 h at þ371C in an atmosphere containing 5% CO2.
Macrophage mRNA analysis
Macrophage mRNA analysis was performed from cell lysates
similarly as described for adipose tissue.
Other measurements
Blood samples were taken after an overnight fast for
measurement of plasma glucose, serum insulin, HbA1C,
serum alanine aminotransferase concentrations, serum tri-
glyceride, total cholesterol, high-density lipoprotein (HDL)
and LDL low-density lipoprotein cholesterol concentrations.
The percent of body fat was determined by bioelectrical
impedance analysis (BioElectrical Impedance Analyzer
System model #BIA-101A; RJL Systems, Detroit, MI, USA).31
Waist circumference was measured midway between spina
iliaca superior and the lower-rib margin, and hip circumfer-
ence at the level of the greater trochanters.32
Analytical procedures
Plasma glucose concentrations were measured in duplicate
with the glucose oxidase method using Beckman Glucose
analyzer II (Beckman Instruments, Fullerton, CA, USA).33
Serum-free insulin concentrations were measured using the
Auto-DELFIA kit from Wallac (Turku, Finland). HbA1C was
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measured by high-pressure liquid chromatography using the
fully automated Glycosylated Hemoglobin Analyzer System
(BioRad, Richmond, CA, USA).34 Serum total cholesterol,
HDL cholesterol and triglyceride concentrations were mea-
sured with enzymatic kits from Roche Diagnostics (Roche
Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan) using an
autoanalyzer. LDL cholesterol concentration was calculated
using the formula of Friedewald et al.35
Statistical analyses
Obese/overweight and non-obese groups were compared
using the Mann–Whitney test. Effects of LPS were analyzed
using Friedman’s test followed by Dunn’s post hoc test to
compare single measurements. Spearman’s rank correlations
were calculated. A P-value of less than 0.05 was considered
statistically significant. Multiple linear regression analysis
was performed after logarithmic transformation of data if
necessary. The calculations were performed using GraphPad
Prism version 3.0 (GraphPad Inc., San Diego, CA, USA) and
SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA). All data
are shown as mean7standard error of mean (s.e.m.).
Results
Subject characteristics
Characteristics of the 10 non-obese and 10 obese/overweight
subjects, whose adipose tissue gene expression, gene expres-
sion in monocyte-derived macrophages, liver fat content and
in vivo insulin sensitivity were measured, are given in Table 1.
Liver fat content and markers of insulin resistance, including
serum fasting insulin and triglyceride concentrations were
higher and the HDL cholesterol concentration was lower
in the obese/overweight compared to the non-obese group
(Figure 1). Liver fat content averaged 6.872.5% in obese/
overweight and 0.870.1% in non-obese subjects (Po0.05).
Whole body insulin sensitivity (M-value) was 35% lower in
the obese/overweight than the non-obese group (5.270.7 vs
8.070.5 mg/kg fat free mass per minute, obese/overweight vs
non-obese, Po0.01). Characteristics of the non-obese and
obese/overweight subjects whose macrophage gene expres-
sion was measured after LPS stimulation are also given in
Table 1.
Adipose tissue gene expression
In adipose tissue, the expression of CD68 (1.270.1 vs
0.770.1, obese/overweight vs non-obese, Po0.01), ITGAM
(2.370.4 vs 1.370.2, obese/overweight vs non-obese,
Po0.05) and HSD11B1 (0.670.1 vs 0.370.1, obese/over-
weight vs non-obese, Po0.05) was significantly higher (1.7-
fold, 1.8-fold and 2.0-fold, respectively) in the obese/over-
weight than the non-obese group. Adipose tissue TNF
expression was slightly, but not significantly, increased in
the obese/overweight as compared to the non-obese group
(1.470.3 vs 1.070.2, obese/overweight vs non-obese, NS).
Relationship between markers of adipose tissue inflammation,
liver fat and insulin sensitivity
The relationships between adipose tissue gene expression
and measures of whole body insulin sensitivity, liver fat
content and BMI are shown in Figure 2. Both CD68 and
HSD11B1 expression in adipose tissue were inversely corre-
lated with whole body insulin sensitivity and positively
correlated with percent liver fat and MBI (Figure 2). ITGAM
expression in adipose tissue correlated positively with
percent liver fat (r¼0.67, Po0.01). Adipose tissue CD68
expression also correlated positively with those of TNF and
HSD11B1 (Figure 3). The expression of two macrophage
markers in adipose tissue, CD68 and ITGAM, was closely
correlated (r¼0.81, Po0.0001). In multiple linear regression
analysis, liver fat was independent of BMI and significantly
associated with expression of CD68, ITGAM and HSD11B1 in
adipose tissue (Table 2).
Table 1 Clinical and biochemical characteristics of the non-obese and obese/overweight groups
Variable Non-obesea (n¼ 10) Obese/overweighta (n¼10) Non-obeseb (n¼7) Obese/overweightb (n¼ 7)
Age (years) 3473 3974 4173 4173
BMI (kg/m2) 24.271.0 33.171.7*** 22.170.7 36.972.2***
Waist (cm) 8573 10273** 7472 11274***
Hip (cm) 9773 11473** 9571 12274***
HbA1C (%) 5.170.1 5.470.2 5.370.1 5.670.3
fS-insulin (mU/l) 471 971** 371 1172*
fP-glucose (mmol/l) 5.270.1 5.570.2 4.670.2 5.170.3
Liver fat (%) 0.870.1 6.872.5* ND ND
S-ALAT (U/l) 2374 3476 1672 2774*
fS-triglycerides (mmol/l) 0.8870.10 1.3970.17* 0.6870.07 1.5370.25*
fS-HDL cholesterol (mmol/l) 1.7970.08 1.3870.08** 1.7670.10 1.2270.13**
fS-LDL cholesterol (mmol/l) 2.3970.14 2.9670.24 2.0470.21 2.6070.29
Abbreviations: BMI, body mass index; fP, fasting plasma; fS, fasting serum; HDL, high-density lipoprotein; LDL, low-density lipoprotein; S-ALAT, serum alanine
aminotransferase. Data are shown as mean7s.e.m. *Po0.05, **Po0.01 and ***Po0.001 for non-obese vs obese/overweight subjects. aThese subjects underwent
measurements of liver fat content, whole body insulin sensitivity and adipose tissue gene expression. bIn these subjects, a blood sample was taken to study gene
expression basally and after stimulation with LPS in monocyte-derived macrophages.
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Gene expression in monocyte-derived macrophages
In monocyte-derived macrophages, there were no differ-
ences between the obese/overweight and non-obese groups
regarding TNF (37.4712.6 vs 37.875.6, obese/overweight
vs non-obese, NS), CD68 (1.270.1 vs 1.270.1, obese/over-
weight vs non-obese, NS) or HSD11B1 (0.770.1 vs 0.570.1,
obese/overweight vs non-obese, NS) expression. In the
obese/overweight and non-obese subjects, whose macro-
phages were stimulated with LPS, TNF expression increased
significantly from basal to 3 h and from basal to 6 h in
both non-obese and obese/overweight groups (Figure 4). The
increase was similar in both groups. RETN expression
remained unchanged with no differences between the
groups (Figure 4). LPS also increased HSD11B1 expression
Figure 1 Liver fat content, fasting serum insulin, triglycerides and HDL cholesterol in 10 non-obese (white bars) and 10 obese/overweight (black bars) subjects.
*Po0.05, **Po0.001 for non-obese vs obese/overweight.
Figure 2 The relationships (r denotes Spearman’s rank correlation coeffi-
cient) between adipose tissue expression of CD68 and HSD11B1 with BMI
(upper panels), with whole body insulin sensitivity (M-value) (middle panels)
and with % liver fat (lower panels). Expression levels are given relative to the
housekeeping gene RPLP0.
Figure 3 The relationships (r denotes Spearman’s rank correlation coeffi-
cient) between adipose tissue TNF and CD68 expression (upper panel) and
between adipose tissue HSD11B1 and CD68 expression (lower panel).
Expression levels are given relative to the housekeeping gene RPLP0.
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significantly and similarly in the obese/overweight and
non-obese groups (Figure 4). There were no changes in gene
expression after saline stimulation.
Discussion
In the present study, we confirmed increased expression of
the macrophage markers CD68 and ITGAM, and of HSD11B1
in human adipose tissue in obese/overweight as compared
to non-obese subjects. The novel finding was that these
changes were associated with liver fat content and whole
body insulin sensitivity. These relationships were shown to
be independent of obesity. We found no alterations in
expression of TNF, HSD11B1 or RETN in monocyte-derived
macrophages between obese/overweight and non-obese
subjects.
In keeping with most,16,17,36–41 but not all42 previous
studies, we found expression of HSD11B1 to be significantly
increased in obese/overweight subcutaneous adipose tissue.
Adipose tissue HSD11B1 mRNA levels correlate closely with
11b-HSD-1 enzyme activity37,43 and with 11b-HSD-1 protein
expression in adipose tissue.36 11b-HSD-1 acts predomi-
nantly as a reductase in vivo, converting inactive cortisone
(11-dehydrocorticosterone in mice) into biologically active
cortisol (corticosterone in mice).44 Hence increased
HSD11B1 gene expression may increase local corticosteroid
concentrations in subcutaneous adipose tissue. Overexpres-
sion of HSD11B1 selectively in adipose tissue in transgenic
mice results in visceral obesity, insulin resistance, diabetes
and hyperlipidemia.45 The cell type responsible for HSD11B1
overexpression in obesity cannot be determined from the
present data.
HSD11B1 knockout mice have lower RETN and TNF mRNA
levels in adipose tissue than wild-type mice.46 If mouse data
were applicable to humans, one might have expected TNF
expression to be increased in adipose tissue from obese/
overweight subjects in the current study. Also, the increased
CD68 expression would be expected to be accompanied by
a significant increase in TNF expression. Although TNF was
increased, the increase was not statistically significant. This
could have been a type 2 error or, alternatively, due to
phenotypic differences in macrophages. As reviewed else-
where,47,48 activated macrophages produce high amounts of
proinflammatory cytokines such as TNF-a while apoptotic
cell engulfment appears to signal macrophages to transform
into a reparative population which expresses less proinflam-
matory cytokines.49 Regarding resistin, we confirm resistin
expression in human macrophages50 but found no difference
in resistin expression in macrophages between obese/over-
weight and non-obese subjects. Although resistin has
proinflammatory properties and stimulates TNF-a and IL-6
production in human peripheral blood mononuclear cells,22
RETN expression in adipose tissue or muscle does not differ
between insulin-resistant and insulin-sensitive subjects.51–53
Expression of the macrophage marker CD68 and the
percentage of CD68-positive cells has been shown to be
increased in obese adipose tissue,5,6 but CD68 expression has
previously neither been shown to be related to whole body
insulin resistance or liver fat content, nor to expression of
TNF and HSD11B1 in adipose tissue. These relationships may
reflect a role of adipose tissue inflammation, rather than
Table 2 Multiple linear regression analysis of associates of liver fat
Dependent variable Independent variables Regression coefficient7s.e. P-value (two-tail) Squared multiple R100 (%)
Liver fat (log) BMI 0.03870.01 0.016 58.3
CD68 0.5870.19 0.008
Liver fat (log) BMI 0.03370.01 0.025 63.8
ITGAM (log) 1.1070.31 0.002
Liver fat (log) BMI 0.02670.02 0.16 53.6
HSD11B 1.2570.51 0.022
Abbreviation: BMI, body mass index.
Figure 4 The expressions of TNF, RETN and HSD11B1 in monocyte-derived
macrophages at 0, 3 and 6 h after LPS stimulation in non-obese (white bars)
and obese/overweight subjects (black bars). *Po0.05, **Po0.01 for compa-
rison between time points. Expression levels are given relative to house-
keeping gene RPLP0.
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peripheral fat, in regulating hepatic insulin sensitivity, since
liver fat and the number of adipose tissue macrophages
are also increased in patients with subcutaneous lipo-
atrophy.28,54,55 In obese mice, deletion of either the mono-
cytes chemoattractant protein-1 (MCP-1 or CCL2) gene 56 or
its receptor (CCR2)57 are associated with reduction in the
number of macrophages in adipose tissue and liver fat
content. Only one previous human study has examined
the relationship between adipose tissue inflammation and
liver abnormalities. Cancello et al.25 found no relationship
between the number of macrophages in subcutaneous
adipose tissue and liver fat content in morbidly obese
subjects. The number of macrophages in omental adipose
tissue correlated with liver histologic lesions but not with
liver fat.25 No healthy lean controls were included in this
study. A limitation of our study is that we measured gene
expression of two macrophage markers but could not
perform immunohistochemical studies because a needle
rather than surgical biopsy of adipose tissue was taken.
The studies showing macrophage infiltration in human
and murine adipose tissue5,6 and that mice lacking IkB
kinaseb are protected from insulin resistance in skeletal
muscles and the liver4 raised the interest in exploring the
role of myeloid cells in the pathogenesis of insulin resistance
in humans. Early studies suggested that insulin receptor
tyrosine kinase activity is low in freshly isolated monocytes
from non-obese insulin-resistant as compared to sensitive
subjects.58 Mononuclear cell adhesion to the endothelium
has also been found to correlate with the degree of insulin
resistance.59 Recently, freshly isolated circulating monocytes
were suggested to be in a proinflammatory state in obese
subjects compared to normal-weight controls.60 These data
do not necessarily disagree with the present findings of
unaltered basal and stimulated expression of insulin resis-
tance genes in monocyte-derived macrophages, since we did
not study freshly isolated monocytes in which gene expres-
sion reflects both acquired and genetic factors. Obviously
this warrants isolation of macrophages from adipose tissue
and measurement of a larger number of genes as well as a
direct assessment of the macrophage fraction.
In conclusion, in keeping with previous data the expres-
sion of macrophage markers is increased in obese human
adipose tissue. This sign of inflammation is correlated with
liver fat content independent of obesity. Liver fat content in
turn is correlated with serum insulin and other signs of
insulin resistance. These data may help to understand why
only some but not all obese subjects develop signs of insulin
resistance.
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OBJECTIVE—We sought to determine whether adipose tissue
is inflamed in individuals with increased liver fat (LFAT) inde-
pendently of obesity.
RESEARCH DESIGN AND METHODS—A total of 20 nondia-
betic, healthy, obese women were divided into normal and high
LFAT groups based on their median LFAT level (2.3  0.3 vs.
14.4  2.9%). Surgical subcutaneous adipose tissue biopsies were
studied using quantitative PCR, immunohistochemistry, and a
lipidomics approach to search for putative mediators of insulin
resistance and inflammation. The groups were matched for age
and BMI. The high LFAT group had increased insulin (P 
0.0025) and lower HDL cholesterol (P  0.02) concentrations.
RESULTS—Expression levels of the macrophage marker CD68,
the chemokines monocyte chemoattractant protein-1 and mac-
rophage inflammatory protein-1, and plasminogen activator
inhibitor-1 were significantly increased, and those of peroxisome
proliferator–activated receptor- and adiponectin decreased in the
high LFAT group. CD68 expression correlated with the number of
macrophages and crown-like structures (multiple macrophages
fused around dead adipocytes). Concentrations of 154 lipid species
in adipose tissue revealed several differences between the groups,
with the most striking being increased concentrations of triacyl-
glycerols, particularly long chain, and ceramides, specifically
Cer(d18:1/24:1) (P  0.01), in the high LFAT group. Expression of
sphingomyelinases SMPD1 and SMPD3 were also significantly in-
creased in the high compared with normal LFAT group.
CONCLUSIONS—Adipose tissue is infiltrated with macro-
phages, and its content of long-chain triacylglycerols and cer-
amides is increased in subjects with increased LFAT compared
with equally obese subjects with normal LFAT content. Cer-
amides or their metabolites could contribute to adverse effects of
long-chain fatty acids on insulin resistance and inflammation.
Diabetes 56:1960–1968, 2007
R
ecent studies have shown that the fatty liver is
insulin resistant and overproduces many, if not
most, of the cardiovascular risk factors associ-
ated with the metabolic syndrome (1). Insulin
resistance in the liver results in VLDL overproduction,
which leads to hypertriglyceridemia and low HDL choles-
terol levels (2). The liver, once fatty, also overproduces
fibrinogen, von Willebrand factor, C-reactive protein (3),
and plasminogen activator inhibitor (PAI)-1 (3,4). Resis-
tance to insulin inhibition of hepatic glucose production
basally and postprandially results in hyperglycemia and
hyperinsulinemia (1). Abdominal obesity is more common
in individuals with a fatty liver than in those without, and
intra-abdominal fat correlates with liver fat (LFAT) (5,6).
However, the amount of fat in the liver is poorly correlated
with subcutaneous obesity (1,5) and predicts the meta-
bolic syndrome (7), type 2 diabetes (8,9), and cardiovas-
cular disease (10) independent of obesity.
Factors regulating LFAT content independent of obesity
are poorly understood. Previous studies have shown that
adipose tissue in obese subjects is inflamed compared
with nonobese subjects (11,12). This inflammation is char-
acterized by an increase in macrophage numbers and
expression of macrophage markers such as CD68 (11,12).
Expression of insulin-resistant genes and the local produc-
tion of their protein products by macrophages in adipose
tissue are also increased in obese compared with non-
obese subjects (13–16). These and other changes may
contribute to increased lipolysis and adiponectin defi-
ciency, which characterize adipose tissue of insulin-resis-
tant subjects and may increase LFAT content (17). The
stimulus for macrophage accumulation in adipose tissue,
on the other hand, is unclear. The first studies comparing
obese and nonobese subjects showed macrophage accu-
mulation to be directly related to cell size (11). Recently,
Cinti et al. (18) showed that in obese compared with
nonobese subjects, macrophages surround dead adipo-
cytes, and they suggested that adipocyte cell death could
serve as one stimulus for macrophage infiltration.
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Regarding the causes of adipose tissue inflammation, we
have previously shown in two independent studies that the
percentage of total fat in diet is positively correlated with
LFAT content (19,20). This could alter fatty acid compo-
sition of adipose tissue (21). Recent advances in ultra-
performance liquid chromatography combined with mass
spectrometry methodology and data processing have en-
abled structural characterization and quantitation of hun-
dreds of lipid species in minute biological samples (22,23).
Such methodology has hitherto not been used to study
human adipose tissue.
In the present study, we reasoned that fat accumulation
in the liver distinguishes between those obese subjects
who develop insulin resistance and those who do not. We
hypothesized if adipose tissue inflammation is important
for fat accumulation in the liver, then adipose tissue
should be inflamed in obese subjects who have excess fat
in the liver compared with equally obese subjects with
normal LFAT content. To examine this, we recruited a
group of obese women with a narrow range of BMIs and
measured their LFAT content using proton magnetic res-
onance spectroscopy and body composition using mag-
netic resonance imaging (MRI) and other techniques. The
women were divided into groups with high and normal
LFAT content, based on their median LFAT content. The
groups were matched with respect to age and body weight.
A surgical biopsy of subcutaneous adipose tissue was
taken for immunohistochemistry and gene expression
studies. Lipidomic analyses were performed using the
ultra-performance liquid chromatography combined with
mass spectrometry platform.
RESEARCH DESIGN AND METHODS
A total of 20 obese (BMI 30–40 kg/m2) but otherwise healthy women not using
any medications were recruited on the basis of the following inclusion criteria:
1) aged 18–60 years; 2) no known major organ system disease determined by
history, physical examination, and standard laboratory tests (hemoglobin,
sedimentation rate, and electrolytes plasma glucose); 3) alcohol consumption
20 g/day assessed by a questionnaire (24); 4) no history of liver diseases; and
5) stable weight for the last 6 months. All patients had been obese for several
years, were physically inactive, and reported consuming a normal Finnish
diet.
Patients were studied after an overnight fast. A blood sample was taken for
measurement of plasma glucose, serum insulin and C-peptide, serum triglyc-
eride, and total and HDL cholesterol concentrations. A surgical subcutaneous
adipose tissue biopsy, yielding 5 g tissue, was performed under local
anesthesia. Part of the biopsy, which was used for gene expression analyses,
was immediately frozen in liquid nitrogen and kept at 80°C. Another part of
the biopsy was fixed in formalin and embedded in paraffin. Fat cell size was
measured by collagenase digestion, as previously described (25). Intrahepatic
fat content (percentage LFAT) was determined by magnetic resonance proton
spectroscopy, and subcutaneous and abdominal fat areas were measured by
MRI. Whole body composition was measured by bioelectrical impedance
plethysmography (BioElectrical Impedance Analyzer System, model no. BIA-
101A; RJL Systems, Detroit, MI). Waist circumference was measured midway
between the spina iliaca superior and the lower rib margin, and hip circum-
ference was measured at the level of the greater trochanters. The nature and
potential risks of the study were explained to all subjects before obtaining
their written informed consent. The study was approved by the ethics
committees of the Helsinki University Central Hospital and the Karolinska
Institutet.
Total RNA and cDNA preparation. Frozen adipose tissue (50–150 mg) was
homogenized in 2 ml RNA STAT-60 (Tel-Test, Friendswood, TX), and total
RNA was isolated according to the manufacturer’s instructions, as described.
After DNase treatment, RNA was purified using the RNeasy mini kit (Qiagen,
Hilden, Germany). RNA concentrations were measured using the RiboGreen
fluorescent nucleic acid stain (RNA quantification kit; Molecular Probes,
Eugene, OR). The quality of RNA was analyzed by Agilent Bioanalyzer 2100
(Agilent Technologies). Average yields of total RNA were 3  1 g per 100 mg
adipose tissue wet wt and did not differ between the groups. Isolated RNA was
stored at 80°C until the quantification of the target mRNAs. A total of 0.1 g
RNA was transcribed into cDNA using Moloney murine leukemia virus reverse
transcriptase (Life Technologies, Paisley, U.K.) and oligo (dT)12-18 primer.
Quantification of gene expression. mRNA expression of specific genes was
quantified by real-time PCR using the ABI 7000 Sequence Detection System
instrument and software (Applied Biosystems). cDNA synthesized from 15 ng
total RNA was mixed with TaqMan Universal PCR Master Mix (Applied
Biosystems) and a gene-specific primer and probe mixture (predeveloped
TaqMan Gene Expression Assays; Applied Biosystems) in a final volume of
25 l. The assays used included: Hs00154355_m1 for CD68, Hs00234140_m1
for CCL2, Hs00234142_m1 for CCL3, Hs00605917_m1 for adiponectin,
Hs00234592_m1 for peroxisome proliferator–activated receptor (PPAR)-,
Hs00194153_m1 for 11	HSD1, Hs00174131_m1 for interleukin 6,
Hs00174128_m1 for tumor necrosis factor (TNF)-, Hs00167155_m1 for PAI-1,
Hs00609415_m1 for SMPD1, Hs00906924_g1 for SMPD2, Hs00218713_m1 for
SMPD3, Hs99999910_m1 for TBP (TATA-box binding protein), and
Hs99999902_m1 for RPLP0 (ribosomal protein large P0). All samples were run
in duplicate. Relative expression levels were determined using a five-point
serially diluted standard curve, generated from cDNA of human adipose
tissue. Gene expression was expressed in arbitrary units and normalized
relative to the housekeeping genes RPLP0 and TBP to compensate for
differences in cDNA loading. The average of these two values was used for
normalization.
Immunohistochemistry. Subcutaneous biopsies from all subjects were used
for immunohistochemical staining for the study of macrophages and necrotic
adipocytes. CD68 was used as a marker for macrophages, and perilipin was
used as a negative marker for necrotic adipocytes, as previously described by
Cinti et al. (18). Staining was performed using a standard protocol on sections
from formalin-fixed paraffin-embedded tissue blocks. Serial sections were
microwave-treated in 10 mmol/l citrate buffer (pH 6.0) and then incubated for
1 h at room temperature with primary antibodies, mouse monoclonal anti-
CD68 (Novocastra Laboratories, Newcastle upon Tyne, U.K.), polyclonal
guinea pig anti-perilipin (Acris, Hiddenhausen, Germany), or with a mouse
monoclonal isotypic control (Abcam, Cambridge, U.K.) for CD68. After rinsing
in PBS buffer containing 0.25% Triton X-100 (pH 7.2), sections were incubated
with secondary biotinylated goat anti-mouse (Dako cytomation; Dako,
Glostrup, Denmark) or biotinylated goat anti–guinea pig (Abcam) antibodies.
Avidin-biotin peroxidase complexes (Vector Laboratories, Burlingame, CA)
were added followed by visualization with 3.3
-diaminobenzidine tetrachlo-
ride (Vector). All sections were counterstained with Harris hematoxylin
(Histolab, Göteborg, Sweden). For each subject, the numbers of macrophages
(identified as CD68 cells) and crown-like structures within the entire section
were counted by two independent observers using a light microscope and
normalized for the total section area. A crown-like structure was defined as a
perilipin-free adipocyte surrounded by at least three macrophages (18).
Measurement of total section area and average adipocyte area (in arbitrary
units) was performed using the GNU Image Manipulation Program 2.2 (GIMP
2.2).
Measurement of monocyte chemoattractant protein (MCP)-1 expres-
sion in adipose tissue. A frozen sample of human subcutaneous adipose
tissue (100–430 mg) was homogenized in lysis buffer (26). The homogenate
was centrifuged for 30 min (4°C, 14,000 rpm) and the supernatant stored at
80°C until measurement of the MCP-1 concentration using the Human
CCL2/MCP-1 Immunoassay kit (Quantikine; R&D Systems, Minneapolis, MN)
and the Bio Assay Reader HTS 7000 Plus (Perkin Elmer, Norwalk, CT). Total
protein was measured using the BC Assay-protein quantitation kit (Uptima
Interchim, Montlucan, France).
Lipidomics/adipose tissue sample preparation. Approximately 20 mg
adipose tissue was weighed, and 20 l of an internal standard mixture and 40
l NaCl (0.9%) were added to the sample. Lipids were extracted from the
samples with 200 l chloroform:methanol (2:1) solvent, and the tissue was
homogenized with a glass rod. After vortexing for 2 min and incubating for 1 h
at room temperature, the lower layer (100 l) was separated by centrifuga-
tion at 10,000 rpm for 3 min at room temperature. Labeled standard mixture
(20 l) was added to the lipid extract. Internal and external standards are
listed in the supplemental materials (found in the online appendix [available
at http://dx.doi.org/10.2337/db07-0111]).
Lipidomic analysis. Lipid extracts were analyzed on a Q-ToF Premier mass
spectrometer (Waters, Milford, MA) combined with an Acquity ultra-
performance liquid chromatography. The column was an Acquity ultra-
performance liquid chromatography bridged ethyl hybrid C18 10  50 mm
with 1.7-m particles and was kept at 50°C. The binary solvent system A
included water (1% 1M NH4Ac, 0.1% HCOOH), and solvent system B
included LC/MS grade (Rathburn) acetonitrile/isopropanal (5:2, 1% 1M
NH4Ac, 0.1% HCOOH). The gradient started from 65% A/35% B, reached
100% B in 6 min, and remained there for the next 7 min. The total run time,
including a 5-min reequilibration step, was 18 min. The flow rate was 0.2
ml/min, and injection volume was 1 l. The temperature of the sample
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organizer was set at 10°C. Lipid profiling was carried out using positive ion
mode. The data were collected at mass range of charge/mass ratio
300 –2,000, with a scan duration of 0.2 s. The source temperature was set
at 120°C, and nitrogen was used as desolvation gas (800 l/h) at 250°C. The
voltages of the sampling cone and capillary were 39 V and 3.2 kV,
respectively. Reserpine (50 g/l) was used as the lock spray reference
compound (5 l/min), with a 10-s scan frequency.
The obtained data were converted into netCDF file format using Dbridge
software from MassLynx (Waters). The converted data were processed using
MZmine software version 0.60 (22). Lipids were identified based on their
retention time and mass/charge ratio using our in-house built lipid database as
previously described (27). All the identified lipids were quantified by normal-
izing with corresponding internal standards. Sphingomyelins were normalized
with GPCho(17:0/17:0) internal standard.
Analytical procedures. Plasma glucose concentrations were measured in
duplicate with the glucose oxidase method (Glucose Analyzer II; Beckman
Instruments, Fullerton, CA). Serum-free insulin concentrations were mea-
sured using the Auto-DELFIA kit from Wallac (Turku, Finland) and C-peptide
concentrations by radioimmunoassay. Serum total cholesterol, HDL choles-
terol, and triglyceride concentrations were measured with enzymatic kits
from Roche Diagnostics, and serum free fatty acids were measured with an
enzymatic kit from Wako using an autoanalyzer (Roche Diagnostics Hitachi
917; Hitachi, Tokyo, Japan). The concentration of LDL cholesterol was
calculated using the Friedewald formula.
Statistical analysis. Statview (SAS Institute, Cary, NC) software was used to
perform the statistical analysis. Physical and biochemical characteristics of
the study subjects were analyzed using nonparametrical methods. Groups
were compared using the Mann-Whitney test. All correlations were performed
using Spearman’s rank correlation. Differences in gene expression and lipido-
mics data were compared by unpaired t test after logarithmical transformation
of variables (gene expression data only) with non–normal distribution.
Statistical significance was assigned to a value of P  0.05. Data are presented
as mean  SEM.
FIG. 1. LFAT percentage and fasting serum (fS) insulin, fS-HDL cholesterol, and fS-triglyceride concentrations in women with normal () and
high (f) LFAT. *P < 0.05, **P < 0.01, ***P < 0.001.
TABLE 1
Physical and biochemical characteristics of the study subjects divided into normal and high LFAT groups
Normal LFAT High LFAT Significance*
n 10 10 —
Age (years) 44  3 37  2 NS
Body weight (kg) 98  2 98  3 NS
BMI (kg/m2) 35.4  1.1 36.7  0.8 NS
Waist-to-hip ratio 0.98  0.06 0.97  0.03 NS
Whole body fat (%) 39.7  1.0 37.1  1.2 NS (0.08)
Intra-abdominal fat (cm3) 1,631  167 1,979  261 NS
Subcutaneous fat (cm3) 7,407  333 6,644  526 NS
Fat mass (kg) 38.7  1.3 36.7  1.9 NS
LFAT (%) 2.3  0.3 14.4  2.9 0.0002
Fasting plasma glucose (mmol/l) 5.1  0.2 5.5  0.2 NS
A1C (%) 5.4  0.1 5.7  0.2 NS
Fasting serum insulin (mU/l) 8.4  1.0 13.9  1.2 0.0025
Fasting serum C-peptide (nmol/l) 0.88  0.07 1.12  0.10 NS (0.08)
Fasting serum LDL cholesterol (mmol/l) 2.6  0.2 3.0  0.2 NS
Fasing serum HDL cholesterol (mmol/l) 1.5  0.1 1.2  0.1 0.02
Fasting serum triglycerides (mmol/l) 1.2  0.1 1.5  0.2 NS
Fasting serum free fatty acids (mol/l) 669  101 606  76 NS
Data are means  SEM. *Exact P values are shown in parentheses for significances in the 0.05–0.10 range.
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RESULTS
The 20 women were divided into two groups according to
their LFAT content: normal LFAT (n  10, range 1–3.5%,
mean 2.3  0.3%) and high LFAT (n  10, range 6–34%,
mean 14.4  2.9%). Characteristics of the normal and high
LFAT groups are listed in Table 1. The groups were
similar, with respect to age, sex, BMI, and subcutaneous
and intra-abdominal fat masses. Fasting serum insulin
concentrations were significantly higher and HDL choles-
terol concentrations lower in the high LFAT group com-
pared with the normal LFAT group (Table 1 and Fig. 1).
Expression in subcutaneous adipose tissue of the mac-
rophage markers CD68, CCL2 (MCP-1) and CCL3 (macro-
phage inflammatory protein [MIP]-1), and PAI-1 was
significantly higher in the high LFAT group compared with
the normal LFAT group (Table 2 and Fig. 2). MCP-1 protein
expression in adipose tissue correlated with gene expres-
sion (r  0.53, P  0.023). Expression of adiponectin and
PPAR- was significantly lower in the high LFAT group
than in the normal LFAT group (Table 2). Expression of
11	HSD1, interleukin 6, and TNF- did not differ signifi-
cantly between the groups, although TNF- tended to be
increased in the high LFAT group (Table 2). Expression of
the housekeeping genes RPLP0 and TBP did not differ
between the groups (RPLP0: 1.9  0.3 vs. 2.1  0.2, NS,
and TBP: 4.0  0.5 vs. 4.0  0.4, NS, for normal vs. high
LFAT groups, respectively). Expression of the macro-
phage marker CD68 correlated significantly with LFAT
(r  0.67, P  0.0035) but not with BMI (r  0.10, NS) (Fig.
3B and C).
Adipocyte cell size. The average adipocyte cross-sec-
tional area in the sectioned tissue and fat cell size mea-
sured by collagenase digestion did not differ between the
normal and high LFAT groups (2,067  109 vs. 2,118  207
arbitrary units, NS, for cross-sectional area and 25.2  0.8
vs. 24.9  1.0 m for fat cell size, NS).
Immunohistochemistry. Positive staining for the macro-
phage marker CD68 was seen in 19 of 20 adipose tissue
biopsies. The total number of macrophages per section
area did not differ between the normal and high LFAT
groups (22  6 vs. 37  10, NS, for normal vs. high LFAT
groups, respectively) but did correlate significantly with
the mRNA expression of CD68 in adipose tissue in all
subjects (r  0.53, P  0.02) (Fig. 3A). Some macrophages
were arranged in crown-like structures (Fig. 4) around
necrotic perilipin-free adipocytes (Fig. 5). The number of
crown-like structures per section area correlated with
borderline significance with the mRNA expression of
CD68 (r  0.44, P  0.057).
Lipidomics of adipose tissue. Lipids were analyzed from
subcutaneous adipose tissue of normal and high LFAT
subjects. A total of 154 lipid molecular species were
identified. The differences were dominated by increased
ceramides, sphingomyelins, ether phospholipids, and tria-
cylglycerols. No specific trend was observed for ester-
linked phospholipids or diacylglycerols. Specifically, all
FIG. 2. mRNA expression of CD68, CCL2, CCL3, and PAI-1 in subcutaneous adipose tissue in women with normal () and high (f) LFAT.
Expression is in arbitrary units normalized for housekeeping genes RPLP0 and TBP. *P < 0.05, **P < 0.01.
TABLE 2
Relative gene expression levels in subcutaneous adipose tissue in
normal and high LFAT groups
Gene Normal LFAT High LFAT P
CD68 1.9  0.1 3.2  0.4 0.003
CCL2 0.35  0.03 0.52  0.08 0.05
CCL3 0.36  0.07 1.0  0.2 0.002
Adiponectin 1.0  0.1 0.9  0.1 0.04
11	HSD1 5.7  1.0 5.6  0.9 NS
IL6 0.12  0.03 0.12  0.02 NS
TNF- 1.5  0.3 2.4  0.8 NS (0.12)
PAI-1 2.8  0.5 4.0  0.6 0.03
PPAR- 1.1  0.09 0.9  0.05 0.04
SMPD1 1.5  0.1 1.9  0.1 0.01
SMPD2 1.1  0.1 1.3  0.1 NS (0.08)
SMPD3 1.3  0.1 1.8  0.2 0.05
Data are means  SEM. Expression of each gene is normalized to the
expression of housekeeping genes TBP and RPLP0.
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three identified ceramide molecular species were in-
creased in the high LFAT group, with the most abundant
species Cer(d18:1/24:1) being increased 1.5-fold (P  0.01)
(Fig. 6A). The sphingomyelin molecular species were
proportionally increased, although the levels of the most
abundant sphingomyelin molecular species SM(d18:1/16:0)
did not differ between the normal and high LFAT groups.
Expression levels in adipose tissue of the sphingomyeli-
nases SMPD1 and SMPD3 were significantly greater in the
high LFAT group compared with the normal LFAT group
(Table 2). Most of the 95 identified triacylglycerol species
were increased in the high LFAT group. The degree of
difference was positively correlated with the triacylglyc-
erol carbon chain length (Fig. 6B). No such trend was
observed for the degree of fatty acid saturation. Several of
the most elevated triacylglycerol species contained an odd
number of total fatty acid chain carbons (Fig. 6B).
DISCUSSION
This is the first study that has sought to determine whether
increased LFAT, independent of obesity, is associated with
adipose tissue inflammation as determined by quantitative
PCR, immunohistochemistry, and lipidomics approaches.
It is also the first study to use a lipidomics approach to
analyze adipose tissue in human subjects. We found that
several of the changes previously attributed to obesity
characterize equally obese subjects who differ with re-
spect to LFAT content. High LFAT was associated with
increased expression of CD68, CCL2 (MCP-1), CCL3 (MIP-
1), and PAI-1 and decreased expression of PPAR- in
adipose tissue. Average fat cell sizes were similar between
the groups when measured using both collagenase diges-
tion and morphometry. CD68 expression in adipose tissue
correlated with the number of macrophages and crown-
like structures when adipose tissue was analyzed by
immunohistochemistry. We also found, as has previously
been found in obese subjects compared with lean subjects
by Cinti et al. (18), that the crown-like structures sur-
rounded perilipin-negative adipocytes. The lipidomics
analysis revealed in the high LFAT group an increase in the
sphingolipid ceramide and in long-chain triacylglycerols.
Although this human study cannot prove cause and effect,
ceramide synthesis is stimulated by long-chain fatty acids,
and ceramides can induce both inflammation and insulin
resistance (28).
We divided the study subjects according to their median
LFAT into two groups. These groups were matched with
respect to age, sex, BMI, waist circumference, and amounts
of intra-abdominal and subcutaneous fat measured with MRI.
The highest LFAT content in the normal LFAT group was
3.5% and the lowest content in the high LFAT group 6%. In the
Dallas Heart Study (29), in which LFAT was measured in
2,349 subjects using proton magnetic resonance spectros-
copy, the upper limit of normal for LFAT was defined as
5.56%. This upper limit for LFAT, when measured with
spectroscopy, is similar to that which we have found to
correspond to the upper limit of S-alanine aminotransferase
in women and men (5). Based on these data, the normal
LFAT group in the present study indeed had normal LFAT
content, and the high LFAT group had increased LFAT. In
keeping with previous data in weight-matched groups (1,30),
the subjects with increased LFAT had signs of insulin resis-
tance (higher insulin and lower HDL cholesterol concentra-
tions) compared with those with normal LFAT (Table 1).
Expression of CD68, CCL2 (MCP-1) and CCL3 (MIP-1),
and PAI-1 were significantly increased and PPAR- signif-
icantly decreased in the high compared with the normal
LFAT group (Table 2). Previous studies have documented
increases in gene and protein expression of each of these
genes in obese subjects compared with nonobese subjects
(31–35). The increased expression of MCP-1 is of particu-
lar interest because overexpression of CCL2 (MCP-1) in
adipose tissue in mice is sufficient to induce insulin
resistance and macrophage infiltration and increase tri-
glyceride content (36). CCR2 (CCL2 receptor) deficiency
has opposite effects (37). We did not attempt to determine
FIG. 3. The relationship between CD68 expression in adipose tissue
and the number of macrophages (A) (r  0.53, P  0.02), LFAT (B) (r 
0.67, P  0.0035), and BMI (C) (r  0.10, NS).
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the cellular origin of MCP-1, as several studies have
consistently shown macrophages to be the main source of
this chemokine in human adipose tissue (11,12,38). CCL3
(MIP-1) is a monokine involved in the recruitment and
activation of polymorphonuclear leukocytes (39). In the
present study, PPAR- expression was significantly lower
in the high than in the normal LFAT group. Ablation of
adipocyte PPAR- expression in mice has been shown to
lead to adipocyte necrosis and infiltration of inflammatory
cells in adipose tissue (40). Therefore, the current obser-
vation of reduced adipose tissue PPAR- expression in the
high LFAT group may have contributed to the greater
levels of inflammation in the adipose tissue of these
subjects.
Previous studies by Cancello et al. (13) and Cinti et al.
(18) have demonstrated that the number of macrophages
is increased in obese subjects compared with nonobese
subjects. Furthermore, several studies have shown that
macrophages form crown-like structures (11,12,38), which
surround perilipin-negative adipocytes (18). The number
of crown-like structures was increased in both obese mice
and humans. The present data confirm the presence of
these structures in human subcutaneous adipose tissue.
The finding of increased macrophage infiltration indepen-
dent of obesity is novel. The crown-like structures were
found to surround perilipin-negative adipocytes. Perilipin,
a protein involved in the regulation of lipolysis, is located
at the interface between the cytosol and the triacylglycerol
droplets of adipocytes (41). Cinti et al. (18) found negative
perilipin staining in adipocytes, the membranes of which
were disrupted and engulfed by macrophages when stud-
ied by electron microscopy. Negative perilipin staining
was used as a marker of adipocyte death in the current
study.
Fat cell size has been shown to correlate with obesity in
multiple studies (42) and was also closely correlated with
the degree of obesity in studies showing macrophage
infiltration in adipose tissue (11). In a study by Cinti et al.
(18), cell death correlated with mean adipocyte size. In
HSL/ mice, adipocyte cell size was markedly increased
but body fat mass similar to that of wild-type mice. In
these HSL/ mice, adipose tissue was infiltrated with
macrophages, implying that increased cell size rather than
overall obesity is a trigger for macrophage infiltration (18).
In the present study in equally obese groups, we found no
difference in average fat cell size.
Regarding the mechanisms underlying the increase of
ceramides, several factors could be involved. First, dietary
FIG. 4. Representative pictures showing crown-like structures in subcutaneous adipose tissue from an obese woman. Immunohistochemical
staining for macrophage specific CD68 (A and B) is colored brown. C and D: Serial sections of A and B, respectively, were stained for perilipin
(brown). All sections were counterstained with hematoxylin (colored blue). Scale bar: 20 m.
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supplementation has been shown to increase plasma
sphingomyelin concentrations (28). Sphingolipids are par-
ticularly abundant in dairy products, suggesting that their
intake was greater in the high rather than the normal LFAT
group. This theory is supported by the observation in the
lipidomics analysis that the most upregulated triacylglyc-
erol species contained odd numbers of total fatty acid
carbons (Fig. 6B), implying that the concentration of
odd-chain fatty acids was increased. Such fatty acids are
likely to include fatty acids of exogenous origin specific
for ruminant fat, namely 15:0 and 17:0, which are biologi-
cal markers of dairy fat intake (43). These data are in
agreement with previous data demonstrating that a rela-
tive high-fat intake correlates with increased LFAT both in
type 2 diabetic patients (19) and in monozygotic twins
discordant for obesity (20) and that LFAT content can be
increased by a high-fat compared with low-fat diet in
humans (44). Thus, ceramides could be mediators of the
adverse metabolic effects of high-fat diets.
Increased de novo biosynthesis or hydrolysis of sphin-
gomyelin via activation of sphingomyelinase(s) could also
have contributed to the increase in ceramide content in
the high LFAT group (28). The initial rate-limiting step of
de novo biosynthesis of ceramides is strongly dependent
on long-chain fatty acid availability (28), which was, based
on the lipidomics analysis of adipose tissue, significantly
increased in the high LFAT compared with the normal
LFAT group. Finally, although enzymatic activities were
not determined, expression levels of SMPD1 (acid sphin-
gomyelinase) and SMPD3 (neutral sphingomyelinase 2)
were significantly increased in the high compared with the
normal LFAT group. Both SMPD1 and SMPD3 are in-
creased by several cytokines including TNF- (45). In the
present study, TNF- expression in adipose tissue was
1.6-fold greater in the high LFAT group, but this was not
statistically significant (P  0.12), possibly due to a type II
error. Interestingly, sphingomyelinase expression is
heavily increased in the arterial intima (46), and the
ceramide content of LDL in the arterial wall is higher than
that of native LDL in the plasma (47). Thus, the changes in
inflamed adipose tissue containing macrophages bear
some resemblance to changes characteristic of atheroscle-
rosis in the arterial wall.
In conclusion, we demonstrated that adipose tissue is
infiltrated with macrophages and that its content of long-
chain triacylglycerols and ceramides is increased in sub-
FIG. 5. Light microscopy of subcutaneous adipose tissue from an obese woman stained for perilipin (brown) showing dead (perilipin-free)
adipocytes surrounded by macrophages (blue) forming a crown-like structure. The blue-colored nuclei (labeled C) stained positive for the
macrophage-specific marker CD68 on a serial section (not shown). A arrows, perilipin-positive staining; B arrows, perilipin-negative staining; and
C arrows, macrophages. Scale bar: 20 m.
INFLAMMATION IN FAT AND FATTY LIVER
1966 DIABETES, VOL. 56, AUGUST 2007
jects with increased LFAT compared with equally obese
subjects with normal LFAT content. Ceramides could
mediate adverse effects of long-chain fatty acids and
induce both insulin resistance and inflammation, although
the present study does not prove cause and effect.
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Genetic factors contribute to variation in serum
alanine aminotransferase activity independent of obesity and alcohol:
A study in monozygotic and dizygotic twinsq
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Background/Aims: This study aimed to determine the heritability of serum alanine aminotransferase (S-ALT) and fast-
ing serum insulin (fS-insulin) concentration as well as determine the association of these measures with liver fat content in
young adult monozygotic (MZ) and dizygotic (DZ) twins.
Methods: Three hundred and thirteen individual twins were recruited from a population-based cohort (n = 4929). The
study subjects represented a wide range of body mass indexes (BMI), were free of any diseases or regular medications
and had an intake of less than two drinks of alcohol/day. To verify that S-ALT is a marker of liver fat, it was measured
by proton magnetic resonance spectroscopy (1H MRS) in 66 subjects. Heritability estimations were performed using BMI-
and gender-adjusted values.
Results: Intra-pair correlations were significantly higher in the MZ twins than the DZ twins for both S-ALT (0.65 for
MZ and 0.04 for DZ) and fS-insulin (0.58 and 0.34, respectively). Heritability of S-ALT was 55% and that of fS-insulin
61%. In the 66 subjects S-ALT (r = 0.70 for women and r = 0.50 for men, p 6 0.01 for both) and fS-insulin (r = 0.58 and
r = 0.59, respectively, p 6 0.01 for both) concentrations correlated significantly with liver fat content.
Conclusions: These twin data suggest that approximately 60% of the variation in S-ALT, a marker of liver fat content,
is genetically determined.
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the
most common cause of steatosis and elevated liver
enzymes in the US [1]. NAFLD is defined as fat accumu-
lation in the liver exceeding 5–10% by weight in subjects
who do not consume significant amounts of alcohol and
who do not have clinical or laboratory evidence of auto-
immune, viral or toxin-induced liver disease, or of
inborn errors of metabolism [2]. An increase in liver
fat due to NAFLD is an integral feature of the meta-
bolic syndrome and closely correlated with all its com-
ponents; central obesity, insulin resistance,
dyslipidemia and hypertension [3].
Liver fat and serum alanine aminotransferase (S-
ALT) correlate with body mass index (BMI), but the
relationship is weak [4]. Thus, at any given BMI, liver
fat content and S-ALT vary considerably. In lipody-
strophic patients, liver fat is increased despite an almost
complete lack of subcutaneous fat [5]. The causes of
interindividual variation in liver fat content independent
of BMI and obesity are unclear. There are almost no
data regarding the possible contribution of genetic fac-
tors to variation in liver fat content. Family clustering
[6,7], interethnic variation [8,9] and single nucleotide
polymorphism (SNP) studies (e.g. genes involved in lipid
metabolism, inflammation, oxidative stress and iron
metabolism) suggest that genetic factors may be impor-
tant in determining steatosis [10–16] and non-alcoholic
steatohepatitis (NASH) [17–26].
In this study, we estimated the relative roles of genetic
and environmental influences on inter-individual varia-
tion in S-ALT and fasting serum insulin (fS-insulin) con-
centrations in young adult monozygotic (MZ) and
dizygotic (DZ) twins. The relationship between S-ALT
and fS-insulin and directly measured (proton magnetic
resonance spectroscopy,1H MRS) liver fat content was
determined in a subset of 66 subjects.
2. Patients and methods
2.1. Subjects and study design
The participants were recruited from a population-based longitudi-
nal study (FinnTwin16) of five consecutive birth cohorts (1975–1979)
of twins (n = 4929 individuals), their siblings and parents, identified
through the national population registry of Finland [27]. The twins
had been studied by questionnaires at 16, 17, 18.5 and 23–27 years
of age. The present study subjects were same-sex pairs enrolled based
on their responses to questions on weight and height at the last follow-
up, with the aim to cover the full BMI range of both normal-weight
and obese subjects. The present sample comprised of MZ (n = 120
twins, 57 full pairs, 36 female and 21 male pairs) and same-sex DZ
(n = 193 twins, 88 pairs, 50 female and 38 male pairs) twins. The
mean ± SE BMI of the study sample, based on self-reported data
was 24.1 ± 0.2 kg/m2, range 17.6–42.9 kg/m2, which is comparable
with the whole cohort (22.9 ± 0.1 kg/m2, range 14.0–44.2 kg/m2).
Exclusion criteria included (1) any known acute or chronic disease
other than obesity based on medical history and physical examination,
electrocardiogram and standard laboratory tests (blood counts, serum
creatinine, serum thyroid stimulating hormone (S-TSH) and electrolyte
concentrations), (2) pregnancy and lactation (in women), (3) clinical
signs or symptoms of hepatitis or inborn errors of metabolism, (4) a
history of use of toxins or drugs associated with liver steatosis, (5) reg-
ular medications other than oral contraceptives, (6) self-reported alco-
hol consumption more than 2 drinks (24 g of alcohol) per day [28]
(daily average of a four-week period by questionnaire, 39 individuals
were excluded because of excess drinking) and (7) unstable weight
(±5 kg) for the past three months. Among female subjects, 12 women
had given birth to one child, five to two children and two to three chil-
dren. Zygosity was confirmed by genotyping of ten informative genetic
markers [29]. All pairs were Caucasian, and their mean age was
27.3 ± 0.2 years (range 23.2–32.2).
Each subject was studied after an overnight fast of 10–12 h. Blood
samples were taken for screening purposes as detailed above and for
measurements of S-ALT, serum aspartate aminotransferase activity
(S-AST), serum gamma glutamyl transferase activity (S-GGT) and
fS-insulin and fasting plasma glucose (fP-glucose) concentrations.
Medical history was reviewed and physical examination was per-
formed, and weight and height were measured barefoot in light cloth-
ing to calculate BMI (kg/m2). Percent body fat was measured by using
dual-energy X-ray absorptiometry (DEXA) (Lunar Prodigy, software
version 2.15, Madison, WI) [30]. To validate the use of S-ALT as a
marker of liver fat content in the present study, liver fat was measured
by 1H MRS in a subgroup of 66 subjects (46 MZ and 20 DZ subjects)
with BMIs ranging from 19.4 kg/m2 to 45.8 kg/m2. We also analysed
how liver fat content differs between MZ twins discordant for obesity
(n = 13 twin pairs, 6 female and 7 male pairs) using a previously char-
acterized subgroup [29,31–35], whose intra-pair BMI differences were
on the average 5.0 ± 0.5 kg/m2. Informed consent was obtained from
each patient included in the study. The protocol was designed and per-
formed according to the principles of the Helsinki Declaration and was
approved by the Ethical Committee of the Helsinki University Central
Hospital.
2.2. Liver fat content (1H MRS)
The liver fat content was determined using proton magnetic reso-
nance spectroscopy as previously described [4].
2.3. Analytical procedures
fP-Glucose concentrations were measured in duplicate with the glu-
cose oxidase method using Glucose Analyzer II (Beckman Instru-
ments, Fullerton, CA) [36], fS-insulin with radioimmunoassay
(Phadeseph Insulin RIA, Pharmacia & Upjohn Diagnostics, Uppsala,
Sweden), and S-ALT, S-AST and S-GGT activities as recommended
by the European Committee for Clinical Laboratory Standards.
2.4. Statistical analyses
Non-normally distributed data were used after logarithmic trans-
formation. For individual twins, the statistical analyses, significance
tests and 95% confidence intervals (95% CI) were corrected for clus-
tered sampling of co-twins within pairs by using survey methods
[37]. Pearson’s correlation coefficients were calculated to determine
associations between liver fat, liver enzymes, fS-insulin and BMI.
Analysis of covariance was used to compare slopes and intercepts of
regression lines between liver fat vs. S-ALT and liver fat vs. fS-insulin
for men and women. If neither slopes nor intercepts differed between
women and men, a common regression equation was calculated for
all data. Wald test (T-test adapted for clustered twin data) for indepen-
dent samples was used to compare males and females, and MZ and DZ
twins. Twin similarity within each zygosity group was assessed using
intra-pair correlations to provide initial evidence for familial aggrega-
tion and the presence of genetic effects. These statistical analyses were
performed using the Stata statistical software (release 9.0; Stata Corpo-
ration, College Station, TX) and GraphPad Prism (version 4.00 for
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Windows; GraphPad Software, San Diego, CA). A p-value less than
0.05 was considered statistically significant. Data are means ± SE
unless otherwise indicated.
2.5. Heritability analyses
The intra-pair correlations and heritability estimates were calcu-
lated for both genders together using gender-adjusted variables.
Because of high correlation between BMI and S-ALT (r = 0.44) and
BMI and fS-insulin (r = 0.56), BMI-adjusted values of S-ALT and
fS-insulin were used. Thus, the heritability estimates for S-ALT and
fS-insulin were independent of gender and BMI. Quantification of
the genetic and environmental effects on S-ALT and fS-insulin concen-
trations was performed using the Mx statistical package (6th ed., Rich-
mond, VA) [38,39].
The genetic variation can be divided into additive (A) genetic effects
of individual alleles (correlation 1.0 for MZ and 0.5 for same-sex DZ
co-twins) and to dominant (D) genetic effects by allelic interactions
within a loci (correlation 1.0 for MZ and 0.25 for same-sex DZ co-
twins). The environmental variation can be attributed to common
(C) environmental effects shared by the co-twins (by definition, corre-
lation 1.0 for both MZ and DZ co-twins) and unique, individual-spe-
cific (non-shared), environmental (E) effects (uncorrelated between the
co-twins). One can fit models based on different combinations of these
parameters: ADE, ACE, AE, DE, CE and E. Our data include only
twins reared together and do therefore not allow modeling of genetic
dominance and common environmental effects simultaneously. In clas-
sical twin data, possible gene–environment interaction effects are esti-
mated as part of additive genetic component, which thus may also
reflect genetic differences in susceptibility to environmental factors.
Further, we need to make the assumptions of random mating which,
if not present, would increase DZ correlations and thus inflate esti-
mates of common environmental variance and reduce genetic variance
[40].
The primary objective in heritability model fitting is to explain
the observed data by finding a model that best balances parsimony
and goodness of fit with as few parameters as possible [39]. The
model fitting starts with full ADE or ACE models, to which the
fit of the submodels AE, DE, CE and E may be compared by using
chi-square difference test statistics and degrees of freedom (d.f.)
between nested models. The Akaike Information Criterion (AIC)
is a global test of model fit combining the chi-square value and
d.f.; negative values of the AIC are considered to provide evidence
for a better fit. From the best fitting model, it is possible to estimate
the proportion of total variance attributable to A, D, C and E.
Bivariate Cholesky decomposition parameterization [39] was calcu-
lated to determine whether the S-ALT, fS-insulin and BMI shared
genetic or environmental effects. This was estimated by correlations




3.1.1. Women and men
The study sample of 313 subjects comprised 178
women and 135 men. Women and men were similar
with respect to BMI (24.3 ± 0.5 vs. 25.3 ± 0.4 kg/m2,
women vs. men, p = 0.09) and liver fat (4.7 ± 1.7 vs.
6.8 ± 2.4%, respectively, p = 0.46). fS-insulin concen-
trations were also comparable (6.1 ± 0.3 vs.
6.7 ± 0.5 mU/l, p = 0.30), while S-ALT (20 ± 2 vs.
37 ± 2 U/l, p < 0.001), S-AST (25 ± 1 vs. 29 ± 1 U/l,
p < 0.001) and S-GGT (18 ± 1 vs. 28 ± 2 U/l,
p < 0.001) concentrations were significantly lower in
women than in men.
3.1.2. MZ and DZ twins (Table 1)
A total of 120 MZ twins (57 full pairs) and 193 DZ
twins (88 full pairs) were studied. There were no differ-
ences in mean variances of the physical and biochemical
characteristics between MZ and DZ twins (Table 1), and
thus the assumption of trait similarity between MZ and
DZ twins for twin modeling was met. As expected,
within-pair differences in BMI were greater in the DZ
(4.6 ± 0.4 kg/m2, range 0.0–15.2 kg/m2) than in the
MZ twins (2.7 ± 0.4 kg/m2, range 0.1–10.1 kg/m2,
p < 0.001).
3.2. Relationships between S-ALT and fS-insulin
concentrations, and liver fat content
S-ALT was strongly positively correlated with liver
fat content in both women (r = 0.70, 95% CI 0.62–
0.77, p = 0.002) and men (r = 0.50, 95% CI 0.36–0.62,
p = 0.01) (Fig. 1). A strong positive correlation was also
found between liver fat content and fS-insulin concen-
tration. This was similar in both genders (r = 0.59,
95% CI 0.40–0.73, p < 0.001) (Fig. 1). BMI-adjusted cor-
relation between S-ALT and liver fat was 0.42 (95% CI
0.32–0.51, p < 0.001) and between fS-insulin and liver
fat 0.37 (95% CI 0.27–0.46, p = 0.006). The correlation
between liver fat content and BMI was 0.47 (95% CI
0.26–0.64, p = 0.057).
3.3. Intra-pair correlations for S-ALT and fS-insulin
concentrations
Assessments of within-pair similarity were per-
formed by using BMI- and gender-adjusted measures.
Results were similar if the percent body fat was used
instead of BMI for the adjustments (data not shown).
The intra-pair correlations (twin A vs. twin B) for S-
ALT were significantly higher (p < 0.001 for the differ-
ence between MZ and DZ correlation coefficients) for
MZ (r = 0.65, 95% CI 0.50–0.80, p < 0.001) than for
DZ twin pairs (r = 0.04, 95% CI 0.0–0.25, p = 0.37)
(Fig. 2), demonstrating the influence of genetic factors.
For fS-insulin, the intra-pair correlations tended to be
higher (p = 0.076) for MZ (r = 0.58, 95% CI 0.40–
0.76, p < 0.001) than for DZ (r = 0.34, 95% CI 0.15–
0.53, p < 0.001) pairs (Fig. 2). For S-ALT, the DZ
correlations were less than half of the MZ correla-
tions, suggesting that not only additive genetic but
also possibly dominant genetic factors influence the
trait. For fS-insulin, the DZ correlations were more
than half of the MZ correlations, suggesting the pres-
ence of shared environmental effects (e.g. within the
family). Thus, we used the ADE model for S-ALT
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and the ACE model for fS-insulin as starting point in
heritability analyses.
3.4. Heritability analyses for S-ALT and fS-insulin
concentrations
The heritability estimates were analysed using the
combined data of both genders with gender- and BMI-
adjusted values. For S-ALT, the ADE model fitted the
data slightly better than the AE model (chi-square
change p = 0.035). For both models, AIC was low,
implying good fit (AIC = 711.64 for the AE and
714.06 for the ADE model). In the ADE model, all
of the genetic influence was placed on the D effect. Since
dominant effects are rare in the absence of additive
effects, the AE model was chosen as the final model
for S-ALT.
For fS-insulin, the ACE model was used initially. The
AIC was higher in the ACE (AIC = 664.87) model
than in the AE model (AIC = 666.87). Dropping the
C effect from the ACE model did not worsen the fit
(p = 0.97), and the point estimate for C effects in the
ACE model was small and non-significant. This implies
that shared family environmental effects for fS-insulin
are not significant and that the AE model fit the data
the best.
AE models were used in the subsequent analyses.
Next, three Cholesky bivariate decomposition analyses
were performed to analyze the contributions of genetic
and environmental effects and their correlations on
S-ALT, fS-insulin and BMI. First, in a model where
S-ALT and fS-insulin were adjusted for BMI and gen-
der, genetic effects explained 55% (95% CI 36–70%) of
the variation of S-ALT and 61% (95% CI 42–73%) of
that of fS-insulin. The contribution of environmental
effects was 45% (95% CI 30–64%) for S-ALT and 39%
Table 1
Physical and biochemical characteristics of the MZ and DZ twins.
Variable MZ DZ p-Value
Number of twins 120 (57 full pairs) 193 (88 full pairs)
Age (years) 27.1 ± 0.3 27.4 ± 0.2 0.38
Body mass index (kg/m2) 25.3 ± 0.6 24.4 ± 0.3 0.20
Body fat (%) 30.0 ± 1.3 28.8 ± 0.9 0.43
fS-ALT (U/l) 27.2 ± 2.5 27.4 ± 1.8 0.95
fS-AST (U/l) 27.1 ± 1.2 26.5 ± 0.9 0.71
fS-GGT (U/l) 21.0 ± 1.9 22.8 ± 1.7 0.48
fP-Glucose (mmol/l) 5.0 ± 0.1 4.9 ± 0.04 0.18
fS-Insulin (mU/l)a 6.3 ± 0.4 6.3 ± 0.4 0.98
Data are means ± SE, p-value is calculated using Wald test for equality of means in MZ and DZ twins.
MZ, monozygotic; DZ, dizygotic; fS-, fasting serum; fP-, fasting plasma; ALT, alanine aminotransferase activity; AST, aspartate aminotransferase
activity; GGT, gamma glutamyl transferase activity.
a n = 114 MZ, 187 DZ.
Fig. 1. The relationship between liver fat content (measured using 1H
MRS) and S-ALT (log scales) (r = 0.70, p = 0.002 for women; r = 0.50,
p = 0.01, for men) and the relationship between liver fat content and fS-
insulin concentration (log scales) (r = 0.59, p < 0.001 for both genders).
Open circles denote women (n = 32) and filled circles denote men
(n = 34). 1H MRS, proton magnetic resonance spectroscopy; S-ALT,
serum alanine aminotransferase activity; fS-, fasting serum.
Fig. 2. Intra-pair correlations between twin A and twin B in MZ and DZ
twins for BMI- and gender-adjusted S-ALT (log scale) (r = 0.65,
p < 0.001 for MZ; r = 0.04, p = 0.37 for DZ) and for BMI- and
gender-adjusted fS-insulin concentrations (log scale) (r = 0.58, p < 0.001
for MZ; r = 0.34, p = 0.001 for DZ). MZ, monozygotic; DZ, dizygotic;
S-ALT, serum alanine aminotransferase activity; fS-, fasting serum.
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(95% CI 27–58%) for fS-insulin. Bivariate genetic mod-
eling revealed that the correlation between additive
genetic effects on S-ALT and fS-insulin was 0.30 (95%
CI 0.09–0.51), implying that 9% (0.30  0.30) of the
genetic factors influencing variation in S-ALT and fS-
insulin concentrations are the same. No shared environ-
mental effects explained the correlation between S-ALT
and fS-insulin when BMI was adjusted in the model.
Second, two bivariate models for S-ALT and BMI,
and for fS-insulin and BMI, were estimated. In the
bivariate model for S-ALT and BMI (adjusted for gen-
der), the genetic correlation between these two measures
was 0.39 (95% CI 0.12–0.58) and the environmental cor-
relation 0.51 (95% CI 0.30–0.68). In the bivariate model
for fS-insulin and BMI, the genetic correlation
(adjusted for gender) was 0.53 (95% CI 0.31–0.68) and
the environmental correlation 0.64 (95% CI 0.46–
0.77). This implies that both S-ALT and fS-insulin
share both genetic and environmental factors with
BMI. The heritability for BMI was 68% in these models
and, as mentioned above, 55% for S-ALT and 61% for
fS-insulin.
3.5. Genetic and lifestyle effects on liver fat content
In the 23 MZ pairs with liver fat measures, the intra-
pair correlation for liver fat content was high (r = 0.70,
95% CI 0.49–0.92, p < 0.001), but the number of DZ
pairs with liver fat measures was too small to permit reli-
able heritability model fitting directly for liver fat con-
tent. Evidence of non-genetic effects was obtained
from a correlation between intra-pair differences of liver
fat and those of BMI (r = 0.47, 95% CI 0.07–0.74,
p = 0.009), which implied that BMI differences
explained 22% (0.47  0.47) of the differences in liver
fat within MZ pairs.
In the 13 obesity-discordant MZ twin pairs (BMI dif-
ference 5.0 ± 0.5 kg/m2), the obese MZ co-twins had sig-
nificantly higher (p = 0.002 for the difference between
obese MZ and non-obese MZ co-twins) liver fat content
(7.3 ± 2.1%) than the non-obese MZ co-twins
(2.0 ± 0.4%). The effects of acquired obesity on liver
fat content varied considerably between the twin pairs,
and this was not explained by BMI differences or by gen-
der (Fig. 3).
4. Discussion
In this study, we estimated the heritabilities of S-ALT
and fS-insulin concentrations as markers of liver fat
content in 313 young adult MZ and DZ twins. Heritabil-
ity was high and significant both for S-ALT (55%) and
for fS-insulin (61%). To validate the use of S-ALT as
marker of liver fat, we measured liver fat content by
1H MRS in a subgroup of 66 subjects. In keeping with
our previous findings [3,41], we found positive correla-
tions between liver fat content and S-ALT (r = 0.50–
0.70) and fS-insulin (0.59). The high intra-pair correla-
tion for liver fat content in MZ pairs (r = 0.70) was con-
sistent with these high heritability estimates for S-ALT
and fS-insulin.
The 313 subjects were recruited from a large popula-
tion-based twin cohort comprising of 4929 Finnish indi-
vidual twins. The study sample covers a wide range of
BMI comparable with the whole cohort and represents
healthy young adults who do not use regular medications.
Medical history and daily alcohol consumption were
carefully reviewed to exclude causes of steatosis and ele-
vated liver enzymes other than those associated with
obesity and insulin resistance. This enabled reliable esti-
mation of genetic causes in variation of S-ALT and fS-
insulin concentrations. Furthermore, MZ and same sex
DZ twins are perfectly matched for age, sex and ethnicity.
The heritability of liver function tests has previously
been estimated in two twin studies [42,43]. Bathum
et al. investigated 290 pairs of elderly (age range 73–
102 years) Danish same sex twins and found 35–61%
heritability for S-ALT, S-GGT, serum bilirubin, serum
albumin and serum lactate dehydrogenase [42]. The her-
itability for S-ALT was 35% and the best-fitting model
for S-ALT was DE (35% for dominant genetic and
65% for unique environmental effects). The results did
not change after adjusting for self-reported BMI and
alcohol consumption. Information regarding medical
history or medication status were not included in the
analyses. In the present study we found almost a twice
as great estimate of heritability of S-ALT concentration
than in the Danish study [42]. In contrast to this study,
the Danish twins were old, their disease records or med-
ications were not considered and BMI was self-reported.
Fig. 3. Effects of acquired obesity on liver fat content (measured using
1H MRS) in 13 obesity-discordant MZ twin pairs. 1H MRS, proton
magnetic resonance spectroscopy; MZ, monozygotic.
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These factors can introduce variability that tends to
decrease twin similarity and heritability estimations.
Notably, both the present and the Danish study sug-
gested that genetic effects due to dominance (i.e. the
interactions between alleles of the relevant genes rather
than simple additive effects alone) contribute to varia-
tion in S-ALT. However, the twin model without infor-
mation on other family relationships, has poor power to
distinguish between additive and dominant genetic
effects. Therefore both the present and the Danish stud-
ies provide evidence of substantial genetic influences,
but do not permit us to unequivocally distinguish
between additive and dominant effects.
Middelberg et al. studied 965 Australian families with
adolescent twins and their non-twin siblings to investigate
the contribution of genetic and environmental factors to
variation in S-ALT, S-AST, S-GGT and serum uric acid
concentrations [43]. Genetic and environmental factors
(e.g. diet, lifestyle) influencing these four parameters were
studied longitudinally at ages of 12, 14 and 16 years in the
same twins. The heritability of S-ALT was 40%. The con-
tribution of obesity, alcohol consumption, medications or
disease records to heritability of S-ALT was not reported
in the Australian study [43].
Previous studies have shown that fS-insulin is a good
marker for liver fat content, even independent of age,
gender and BMI [3]. The fatty liver is insulin resistant
[44–46] which impairs the ability of insulin to inhibit
hepatic glucose production resulting in mild hyperglyce-
mia and hyperinsulinemia. Impaired hepatic insulin
clearance also contributes to hyperinsulinemia in sub-
jects with a fatty liver [46,47]. Consistent with these data
we found close correlations between liver fat content
and fS-insulin concentration. The relationship was sim-
ilar in both men and women. The heritabilities for S-
ALT (55%) and fS-insulin (61%) concentrations were
of similar magnitude. These results suggest that genetic
factors underlying interindividual differences in liver
fat content may also regulate fS-insulin concentrations
e.g. by changing insulin clearance and action or vice
versa. Nonetheless only a small fraction (9%) of the
genetic effects underlying S-ALT were shared with those
genetic effects influencing fS-insulin concentration, indi-
cating that these two markers for liver fat content are
mainly determined by separate sets of genes.
Although liver fat content varies considerably at
any given BMI [4], it is also regulated by acquired fac-
tors, especially changes in body weight [31]. However,
whether there is interindividual variation in the
response of liver fat accumulation to changes in body
weight has not been examined. In this study we ana-
lyzed a rare subgroup of young MZ twin pairs discor-
dant for obesity. This analysis suggested that the
tendency to deposit fat in the liver in acquired obesity
is not simply explained by BMI. This result would be
consistent with the seminal work on MZ twins by
Bouchard et al., who showed that changes in the
amount and distribution of fat (subcutaneous/visceral)
in response to overfeeding and negative energy bal-
ance seem to be largely explained by genetic factors
[48]. However, since our subjects were young and
had relatively low liver fat contents, our conclusions
may not necessarily translate to older age groups with
higher liver fat contents. With advanced age, the con-
tribution of environmental and lifestyle factors may
become more evident.
In conclusion, our data in healthy young adult
twins suggest that genetic factors contribute to varia-
tion in S-ALT, a marker of liver fat content.
Detailed characteristics of these genetic factors will
help understand why some individuals, but not oth-
ers, accumulate fat in the liver and develop metabolic
syndrome.
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AM, Westerbacka J, et al. Acquired obesity is associated with
increased liver fat, intra-abdominal fat, and insulin resistance in
young adult monozygotic twins. Am J Physiol Endocrinol Metab
2005;288:E768–E774.
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